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Recent advances in the field of stem cell research have enabled the derivation of renal 
organoids from hiPSCs; these organoids might be a powerful tool with important 
implications for regenerative medicine, but meticulous assessment of the functional 
abilities of the induced nephrons is key to the use of these organoids in any 
application. Here, I show that hiPSC-derived renal organoids possess proximal tubular 
transporters and receptors; I present optimised techniques to assess the function of 
these receptors in-vitro and show that these organoids have anion and cation uptake 
capacities similar to what can be seen in foetal kidney tissue or isolated proximal 
tubules, implying tubular functional capacity, an aspect of renal physiology that has 
particular importance in the renal handling of drugs and toxins.  
Due to high blood flow and the primary role of the kidney in clearing toxins and 
metabolites, renal cells are highly vulnerable to drug toxicity. The lack of in-vitro high 
throughput models to screen pharmaceutical compounds for potential nephrotoxicity 
during drug development has always hindered the field of drug development and 
increased the cost of delivering drugs into the market; in this study, I demonstrate that 
hiPSCs-derived renal organoids are able to predict nephrotoxicity with reasonable 
accuracy. Combining this ability with the possibility of cryopreserving renal-
differentiated cells and to the use of HMOX1 reporter cell line, to detect oxidative 
stress, could streamline the use of these organoids in nephrotoxicity screening and 
could potentially flourish the field of drug development.  
While the current model of renal organoids could be used for drug screening without 
further manipulation, the use of such tissue for therapeutic purposes necessitates a 
higher degree of organisation and complexity. In-vivo kidney function is based on the 
complex interplay of a range of highly specialised cells together with their three-
dimensional structure and organisation. Scientists are adopting different strategies to 
build kidney tissue, from hiPSCs, that could be suitable for use in therapeutic 
applications. Common to any of these strategies is the need to generate the correct 
cell types in sufficient numbers and purity, and most important, in the right location. I 
aim in this study to isolate correctly differentiated ureteric bud (UB) structures from 
surrounding cells and to induce branching from single UB-like structure to recapitulate 
branching morphogenesis in-vitro. I conjugated GDNF protein to a fluorophore and 
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used it to label the UB structures and isolate them. I show that the combination of 
GDNF, FGF1, CHIR99021 and RA was able to induce branching in the isolated UB-
like structures. The ability to isolate pure differentiated UB structures from surrounding 
contaminant tissue and to induce them to branch forming contiguous collecting duct 
tree could be a step further towards engineering a more realistic kidney tissue with 
single continuous collecting duct system, yet optimising culture conditions and 
techniques to build such a tissue is still needed.  
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Lay abstract 
Current advances in stem cell research have had considerable impact on the field of 
regenerative medicine and raised the hope that obtaining lab-grown organs might be 
possible one day. Recent research has enabled the generation of miniature kidney-
like structure from stem cells, albeit with poor overall structural organisation. The 
function of these structures, has not, however, been evaluated; I have conducted 
experiments to examine some functional aspects of these structures to evaluate how 
similar they are compared to the normal organ; I show that the mini kidney-like tissue 
is not only structurally similar to the kidney tissue, but it can also perform some of the 
function of a kidney.  
Kidneys are normally at high risk of drug toxicity; due to the lack of proper models to 
test the toxic potential of pharmaceutical compounds before getting access to the 
market, the process of drug development becomes very expensive and slow; I 
demonstrate that these kidney-like structures, being structurally and functionally 
similar to the kidney, might be a useful high throughput in-vitro model for predicting 
nephrotoxicity and thus could enhance the process of drug development and help in 
protection against one of the major causes of renal failure; drug toxicity. 
Our kidneys are complex organs comprised of a variety of different types of cells, the 
intricate arrangement of which is crucial for the proper function of the organ in-vivo; 
for example for a kidney to function in a normal way, the excretory part of the kidney 
should be connected all through the organ and it should lead to a single exit path 
through which the urine comes out of the kidney. Despite showing structural and 
functional similarity to the kidney tissue, the miniature kidney-like structures that could 
be obtained from stem cells so far lack that intricate 3D macroscale organisation; one 
main pre-requisite for the use of these structures in therapeutic purposes is the ability 
to obtain pure cell types to arrange them in a realistic way. For that purpose, I 
developed a technique to isolate cells responsible for forming the excretory part of the 
kidney, the collecting duct system, and developed technique to evaluate the ability of 
the isolated cells to grow into single, branching and contiguous collecting duct tree, 
like what we see in a normal organ. These developed techniques could be one way to 
obtain pure collecting duct cells and thus might be a step toward organising the current 
model of stem cell derived kidney-like tissue.  
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End-stage renal disease is a serious medical problem that necessitates renal function 
replacement either by renal transplantation, from a donor, or dialysis. In the UK alone, 
patients on the donor waiting lists who are waiting for a kidney donor represent around 
80% of the total patients in the lists, and around 60% of death among patients while 
waiting for a donor occurs in kidney patients. These percentages are for kidney-only 
patients and the numbers are even higher if kidney plus another organ is considered 
(NHS, 2018). 
After receiving a transplant, except from a monozygotic twin, patients are kept under 
immunosuppressive drugs which puts them under high risk of infection and expose 
them to higher morbidity and mortality rates (Gupta and Lam, 2016). Furthermore, 
despite the current advance in allograft survival, the ten year graft survival estimate is 
68-86% (NHS, 2018), this especially becomes a problem in paediatric patients 
indicating that one-off kidney transplantation could be insufficient to last a normal 
lifetime in a considerable percentage of patients who experience transplant failure and 
are therefore either shifted to dialysis or considering re-transplantation. Dialysis 
remains as a life-saving solution for those who do not find a donor. Nonetheless, it is 
inefficient in filtering the blood from waste products with uremic retention solutes left 
behind predisposing to atherosclerosis (Masereeuw and Stamatialis, 2017a). In 
addition, dialysis does not compensate for the renal endocrinal function, namely 
Erythropoietin synthesis and Vitamin D activation; chronic kidney disease patients 
usually suffer from chronic anaemia and osteomalacia; generally, dialysis decreases 
the patient’s quality of life (Gupta and Lam, 2016; Moon et al., 2016).  
There is therefore an increasing need to find new therapeutic modalities for end stage 
renal disease. Researchers are adopting different strategies to tackle the problem, 
spanning regeneration of the damaged kidney in-situ, engineering a new organ in-vitro 
and then transplanting it to the patient, and engineering Bio-artificial kidneys that can 
replace kidney function. For researchers who are trying to regenerate the damaged 
kidney in-situ, choosing the type of cells used to induce regeneration has been a big 
question and different types of cells have been shown to induce regeneration, reverse 
inflammation and fibrosis, and/or induce new vessel formation (thus rescuing the 
remaining nephrons). Cells used for this purpose include: renal progenitors obtained 
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either by dissociation of embryonic kidneys, isolation from adult kidney (they are 
present in very low percentage in adult kidneys), differentiation from pluripotent cells, 
or by direct reprogramming from renal tubular cells (Kaminski et al., 2016; Lagies et 
al., 2018). Cells used for regeneration of the damaged kidney are not restricted to 
renal types of cell; endothelial progenitor cells have been shown to reverse the 
inflammation and fibrosis, induce new vessel formation, and improve the kidney 
(Chade et al., 2009). As well mesenchymal stem cells or their conditioned media (van 
Koppen et al., 2012) and bone marrow derived cells and their conditioned media (Golle 
et al., 2017) have also been demonstrated to induce regeneration. However, the 
engraftment efficiency in most of the studies so far was low and most of the effect is 
believed to be achieved by humoral factors.  
Techniques that work to engineer new transplantable kidney tissue are also diverse. 
One option is to repopulate a decellularized renal matrix (Gifford, 2015). Nevertheless, 
this approach still needs an adult kidney to use as a scaffold. 3D bioprinting of a kidney 
is another option (Murphy and Atala, 2014); however, bioprinting a complex structure, 
like the kidney, that has different types of cells performing different functions and has 
cortico-medullary zonation, could be very challenging and sophisticated. Another 
option aims at engineering foetal kidneys from human induced pluripotent stem cells 
(hiPSCs), using optimised differentiation protocol to obtain renal-differentiated cells 
and renal organoids from them, applying techniques previously developed in mouse 
to organise the structure and obtain a tissue that resembles foetal kidney with a ureter, 
and then allowing that tissue to mature and develop by grafting into a host thus ending 
by tissue that could be transplanted to the patient (Davies and Chang, 2014; Mills et 
al., 2017).   
Recent advances in optimising protocols to obtain renal cells and renal organoids from 
iPSCs could reshape the future of regenerative medicine and pave the way for patient-
tailored immune-competent therapy; one of the major advantages of hiPSCs is that 
they could be generated from any individual and thus they will evade the allogenic 
rejection that occurs upon transplanting from a donor and would eliminate the need 
for immunosuppressive drugs (Gupta and Lam, 2016).  
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hiPSC-derived renal cells hold remarkable promise not only for regenerative medicine 
but also for drug discovery and pharmaceutical purposes. Kidneys are highly 
vulnerable to drug toxicity due to their essential role in handling drugs and toxins 
(Pazhayattil and Shirali, 2014; Nigam et al., 2015). During the process of drug 
discovery, potentially therapeutic compounds have to go through a meticulous process 
of assessment to exclude toxic compounds, however, current models for 
nephrotoxicity screening are inefficient with some drugs show unexpected toxicity after 
their release into the market (Davies, 2018).  This hinders the process of drug 
discovery and increases its cost; hence there is an increasing need to develop new 
models for evaluating drug efficacy and toxicity and hiPSC-derived renal tissue 
represents a promising potential model. This thesis investigates different aspects of 
the current model of hiPSC-derived renal tissue and possible ways for improving it. 
 
 
1.1 Kidney structure and function: 
Exploring the constituting components of the renal tissue, their complex organisation 
within the organ, and the importance of that complexity for a proper function is a pre-
requisite to all engineering trials. 
Kidneys are paired retro-peritoneal organs that have excretory function. Together with 
the ureters, the urinary bladder and the urethra they constitute the urinary system. 
Each kidney has a collecting duct tree plumbing into the ureter that conveys urine from 
the kidney to the urinary bladder from where it is excreted out of the body through the 
urethra. 
The kidney is enclosed within a fibrous capsule; its medial concave surface contains 
the renal hilum which is the site of entry of the renal artery and nerves and also the 
site of exit of the renal vein, lymphatic vessels and the ureter. The renal parenchyma 
can be divided into an outer renal cortex and an inner medulla. There is no physical 
boundary between the cortex and medulla, but the difference in their appearance 
makes it possible to distinguish the cortico-medullary boundary visually (Hallgrimsson, 
Benediktsson and Vize, 2003). The human kidney medulla is formed of multiple 
conical pyramids, the tips of these pyramids are known as papillae. Urine flows out of 
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the papillae into the minor calyces which converge to form major calyces. In turn, the 
major calyces also converge to form the renal pelvis which continues as a narrower 
tube; the ureter (figure 1.1a). 
The nephron is the functional and structural unit of the kidney; it is composed of 
different domains and it is the part responsible for blood filtration and urine production. 
Each mouse kidney contains between 12,000 and 16,000 nephrons with the number 
of nephrons varying according to the mouse strain (Short et al., 2014). There is also a 
wide range of variability in human regarding the number of nephrons per kidney; 
studies suggest that the number ranges between 200,000 and 1,800,000 with an 
average of 1,000,000 nephron per kidney (Sariola and Philipson, 1999; Hughson et 
al., 2003; Bertram et al., 2011). Nephron endowment seems to be dependent on many 
factors and has a great impact on disease/health state with higher nephron number 
thought to be protective against renal diseases (Bertram et al., 2011; Walker et al., 
2012). 
The nephron can be divided into two main components; the renal corpuscle and the 
renal tubule, to which it connects (figure 1.1b). The renal corpuscle is the site where 
blood filtration takes place. It is at the proximal end of the nephron and is composed 
of Bowman’s capsule into which an afferent arteriole invades and forms a knot of leaky 
glomerular tuft capillary; the glomerulus, from the other side of which the blood exits 
through the efferent arteriole. The Bowman’s capsule is itself formed of a visceral 
layer, lined with specialized cells known as podocytes, a parietal layer, and a capsular 
space between them. The podocytes lining the visceral layer of Bowman’s capsule 
together with the glomerular basement membrane and the fenestrated endothelium 
lining the glomerular capillary form the three core constituents of the glomerular blood 
filtration barrier that separates between blood in the glomerular capillary and the filtrate 
in the capsular space of Bowman’s capsule and controls filtration into the renal 
corpuscle. Water and small sized molecules filter freely through this barrier, while it 
retains large molecules as proteins. It also exerts a charge selectivity with the 






Figure 1.1. a) Cross section in the kidney demonstrating the overall structure of the 
organ (adapted from https://airfreshener.club/quotes/kidney/-calyx-pelvis-renal.html).  




The vascular endothelial cells represent the first layer of the glomerular filtration 
barrier. These endothelial cells are characterized by having fenestrations of 50-100 
nm size. The endothelial surface is covered by a glycocalyx that functions to retain the 
cellular component of the blood and the large molecules (Hallgrimsson, Benediktsson 
and Vize, 2003; Satchell and Braet, 2009). 
The glomerular basement membrane is the middle layer of this barrier; it is an 
acellular, thick, highly specialized matrix. Both the endothelial cells and the epithelial 
podocytes contribute to its synthesis. Also, the mesangial cells have been shown to 
contribute to its turnover. Type Ⅳ collagen, β2-Laminin and sulphated proteoglycans 
are its main constituents. (Abrahamson, 1985; Abrahamson et al., 2009; Menon, 
Chuang and He, 2012; Miner, 2012). 
The podocytes are the mesenchymal-derived epithelial cells that line the visceral layer 
of Bowman’s capsule. They extend what is known as foot processes; these foot 
processes interact at their joining surfaces to form the slit diaphragm and the spaces 
between them are known as filtration slits. The slit diaphragm is composed of proteins 
which are known for their importance in tight junction and adherence junction (e.g. 
Zona occludens-1, Catenin and P-cadherin). Podocytes lie on top of the GBM and the 
interaction between β2-Laminin from the GBM and α3 β1 integrin on the basal surface 
of the podocytes plays an important role in anchoring podocytes to the GBM (Adler 
and Chen, 1992). The luminal surface of the podocytes is covered with anionic 
glycocalyx; the main constituent of which is Podocalyxin (Kerjaschki, 1984). Nephrin 
(NPHS1); a transmembrane protein that is found in the slit diaphragm, interacts with 
either Nephrin or Nephrin-like protein (NEPH1) from the adjacent podocyte and with 
other regulatory proteins through its intracellular domain facilitating actin 
polymerization which is key for foot process architecture. Mutations in its coding gene 
result in foot process abnormality and cause congenital Nephrotic syndrome which is 
characterized by massive proteinuria. Foot process effacement, a condition in which 
the foot processes are abnormally flattened and their architecture is distorted, is a 
leading cause to glomerular proteinuria (Ruotsalainen et al., 1999; Wartiovaara et al., 
2004; Menon, Chuang and He, 2012; Miner, 2012). 
The ultrafiltrate in the Bowman’s space then passes to the tubular epithelium which 
can be divided into four main segments: the proximal tubule, the loop of Henle, the 
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distal tubule and the connecting tubule. The proximal tubule is the tubular segment 
that connects to Bowman’s capsule and is marked by the transition of the epithelial 
lining from the simple squamous epithelium of Bowman’s capsule to the cuboidal type 
(Bulger, Cronin and Dobyan, 1979; Haensly et al., 1982). The proximal tubule itself 
can be further subdivided into three segments S1, S2 and S3. The renal corpuscle 
and the first two segments of the proximal tubule (S1, S2) lie in the renal cortex, while 
the S3 segment lies in the outer medulla (Mcmahon, 2016). The luminal surface of the 
proximal tubules stands by its brush border that is formed of densely packed microvilli 
which function to increase the surface area available for reabsorption (Heidrich et al., 
1972). Also, the cytoplasm of these cells is rich in mitochondria to supply energy 
needed for the active transport across the epithelial membranes. A myriad of apical 
and basolateral transmembrane channels and transporters within the proximal tubule 
function to reabsorb and recover salt, glucose, amino acids and vital molecules from 
the ultrafiltrate into the surrounding vascular capillaries (Sekine et al., 2012; Yin and 
Wang, 2016). (More details about the proximal tubular transporters and their functions 
will be detailed in a later section). 
The ultrafiltrate then passes to the loop of Henle which dips deep into the medulla 
before it loops and reverses its direction back to join the distal tubule in the cortex 
(Hallgrimsson, Benediktsson and Vize, 2003). The primary function of the loop of 
Henle is to concentrate the urine through maintaining high interstitial salt concentration 
in the medulla. The thick ascending limb does not have aquaporin proteins and is 
impermeable to water while it actively transports sodium. This increases the interstitial 
fluid osmolality which helps osmotic water reabsorption from the descending limb and 
the collecting ducts. The thin descending limb of the loop of Henle is highly permeable 
to water but has limited permeability to sodium and urea (Kokko, 1970, 1972). In 
contrast, the thin ascending limb has relatively high permeability to sodium and urea 
but is water-impermeable (Imai and Kokko, 1974, 1976). The Counter-current 
configuration of flow inside the loop of Henle is thought to multiply the osmolality 
difference between the fluid that flows in the ascending limb and the surrounding 
tubules and vessels establishing a cortico-medullary osmotic gradient that increases 
progressively from the cortico-medullary junction to the papillary tip in the inner 
medulla (Pallone et al., 2003; Sands and Layton, 2009, 2014). 
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The distal convoluted tubule (DCT) is the shortest segment of the nephron; it spans 
only 5 mm in human. Cells in the distal convoluted tubules are characterised by the 
positioning of their nuclei close to their apical sides and by the deep infoldings 
extending from their basolateral membrane. The DCT regulates sodium, potassium, 
calcium and magnesium reabsorption under the control of aldosterone and parathyroid 
hormones and shares in maintaining water balance under the control of vasopressin 
hormone (Subramanya and Ellison, 2014). The DCT and the connecting tubule are 
together referred to as the distal tubule; the DCT can be further subdivided into DCT1 
and DCT2. DCT2 together with the connecting tubule and the collecting ducts are 
known to be aldosterone-sensitive distal nephron, as it is inferred from the term, they 
represent the site of action of the aldosterone hormone.   
The distal tubules connect to the collecting ducts (CDs). The CDs form a highly 
arborized tree that derives from a distinct developmental origin than that of the 
contiguous nephron tubule (see details in section 1.2.4). The lining cells of the 
collecting ducts are divided into principal cells, the more abundant cell type that is 
mainly involved in sodium retention, and intercalated cells, a rarer type of cell that is 
involved in acid-base regulation through transporters that secrete hydrogen ions and 
bicarbonate (Al-Awqati, 2013; Pearce et al., 2015). The collecting ducts then drain the 
urine through the renal papillae into the minor calyces which in turn convey urine to 
the major calyces then down the ureter to the urinary bladder. 
This brief overview of kidney structure and function demonstrate how complex the 
kidney is; its function necessitates the integrative interaction between mesenchymal-
derived different specialised epithelial cells, a highly branched connected collecting 
duct tree that drains into a single ureter, a tightly regulated vascular system, and 
different types of interstitial cells, and makes it clear that building up a realistic 
organoid from stem cells that contains all these different types of cells interacting 
together in a correct way, crucial for producing and excreting urine, is an intricate 





1.2 Early stages of embryonic development: 
Differentiating iPSCs or ESCs into renal cells requires the recapitulation of natural 
developmental processes in-vitro. Therefore, understanding how a single totipotent 
cell (the zygote) undergoes different cell specification processes to end in a whole 
organism, consisting of different body systems and organs, is a pre-requisite. 
Embryonic development would need a whole literature review, so in this overview, 
early stages of embryonic development are summarized only within the context of 
renal specification. 
Mammals, in general, share common developmental processes with inter-species 
differences. I will focus on the human and mouse embryonic development and, 
wherever possible, I will try to highlight the inter-species differences between them. 
In the 3rd week of human embryonic development, a very major event takes place; 
gastrulation, that converts the embryo into a trilaminar disc formed of the three germ 
layers: ectoderm, mesoderm and endoderm (Solnica-Krezel and Sepich, 2012; Moore, 
Persaud and Torchia, 2015; Schoenwolf et al., 2015) (figure  1.2). 
Gastrulation starts by formation of the primitive streak in the midline of the caudal part 
of the epiblast. The primitive streak (PS) is formed of a thickening of cells with a central 
groove known as the primitive groove, the cranial end of the groove is continuous with 
the primitive pit which is a depression inside the expanded primitive node. After 
formation of the PS, the main embryo’s body axes will be defined: the cranio-caudal 
axis (the primitive streak develops on the caudal part of the epiblast), the medio-lateral 
axis (as the PS develops in the midline) and the dorso-ventral axis (the epiblast 
becomes dorsal) (Robb and Tam, 2004; Solnica-Krezel and Sepich, 2012). 
During gastrulation, cells undergo an epithelial-to-mesenchymal transition. In their 
epithelial state cells are regularly shaped and are tightly connected, while 
mesenchymal cells are irregular in shape and detach from each other as they extend 
pseudopodia, filopodia and lamellipodia. During epithelial-to-mesenchymal transition, 
the cells upregulate the transcription factor SNAIL and downregulate or even lose E-
cadherin (ECAD or CDH1) from their surfaces (Solnica-Krezel and Sepich, 2012; 




Figure 1.2. a) Section in the gastrulating embryo demonstrating the three embryonic germ layers 
(the ectoderm, the mesoderm and the endoderm). b) Schematic illustration of the metanephric 
kidney specification starting from the epiblast stage of the embryo (pluripotent cells). Cells from 
the epiblast migrate through the primitive streak to form embryonic endoderm and mesoderm. The 
intermediate mesoderm is the part of the embryo that gives rise to the two main renal progenitors, 
the UB and MM. IM: intermediate mesoderm; AIM: anterior intermediate mesoderm; PIM: posterior 
intermediate mesoderm; UB: ureteric bud; MM: metanephric mesenchyme. 
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Once the PS is formed, the epiblast cells migrate through it into the inside of the 
embryo. The first-migrating cells displace the hypoblast layer to form the endoderm 
layer of the embryo. The cells that remain in the epiblast and do not migrate through 
the primitive streak will form the ectodermal layer of the embryo. While the mesoderm 
layer is formed by cells that migrate through the primitive streak and reside between 
the epiblast and the endoderm layer (figure 1.2). The mesodermal cells divide into five 
main subdivisions: the cardiogenic mesoderm, the notochord (also known as the 
midline or axial mesoderm) and on both sides of the notochord from medial to lateral 
direction the mesoderm is divided into: para-axial mesoderm, intermediate mesoderm 
(IM; it is the part of the embryo that gives rise to all the nephrogenic structures and is 
therefore called the nephrotome) and the lateral plate mesoderm (Schoenwolf et al., 
2015).  
 
1.2.1 Mesoderm patterning: 
Here, I will focus on mesodermal medial-lateral specification and the morphogens that 
control the intermediate mesoderm specification, as these actions are responsible for 
generating renal structures. 
Fate mapping studies in animals reveal that cells in different regions of the epiblast 
migrate through different parts of the PS and take a different fate in the mesoderm. At 
the mid PS stage, cells of the notochord migrate through the most cranial end of the 
PS in the midline to form the notochordal process. Cells of the para-axial mesoderm, 
IM and the lateral plate mesoderm migrate in a cranial-to-caudal succession through 
the PS with the para-axial mesoderm cells migrating through the cranial part and the 
lateral plate mesoderm migrating through the caudal part (Smith, Gesteland and 
Schoenwolf, 1994; Parameswaran and Tam, 1995; Kinder, Loebel and Tam, 2001).  
With the definition of the dorsal-ventral axis of the embryo, the notochord becomes 
the most dorsal mesoderm and the lateral plate mesoderm becomes the most ventral 
mesoderm. Interaction between dorsalising factors and ventralising factors generates 
gradients of morphogens over the embryonic disc during gastrulation and promotes 
dorsal-ventral patterning of the mesoderm; low, intermediate or high concentrations of 
specific morphogens induce specification of particular mesodermal fate (De Robertis 
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and Kuroda, 2004). Studies in mice have shown that mutations affecting Fgfr1 can 
interfere with para-axial mesoderm formation (Yamaguchi et al., 1994). Similarly, loss 
of WNT3A signalling also leads to defects in the para-axial mesoderm (Yoshikawa et 
al., 1997). In contrast, Bmp4 is expressed in the posterior part of the primitive streak 
(the part from which the ventral mesoderm, IM and lateral plate mesoderm, emerges) 
and is known to be a ventralizing factor; loss of its function leads to defects in ventral 
mesoderm development (Winnier et al., 1995). Studies performed on chicken, 
zebrafish and xenopus embryos have provided evidence that BMP molecules are 
necessary for IM specification and gene expression. 
The IM is further patterned along its anterior-posterior axis. The definitive kidney 
develops from two main progenitors: the metanephric mesenchyme (MM) and the 
ureteric bud (UB), both of which have been shown to drive from the IM (Mugford et al., 
2008). It was first thought that the two progenitors originated from anterior (cranial) 
specified IM that extends posteriorly (caudally) and commits to the two different types 
of progenitors. However, fate-mapping studies using Osr1 (expressed in the IM) and 
Brachyury (T; a marker of gastrulation and transient mesodermal marker) genes have 
shown that these two progenitors arise from different parts of the IM. The anterior IM 
gives rise to the Wolffian duct (WD), the UB precursor, prior to E8.5 in mouse and they 
develop into T- state earlier. While the MM develops later from the posterior IM and is 
maintained in T+ state for a longer period (Attia et al., 2012; Atsuta et al., 2013; Taguchi 
et al., 2014). 
 
1.2.2 Wolffian Ducts: 
The Wolffian duct (WD) is so named after the German scientist Casper Friedrich Wolff 
who first described it in 1774; it is also known as the nephric duct. It is the first 
urogenital epithelial structure that develops from the IM. It develops as a cellular 
thickening arising from the most cranial part of the IM (the prospective pronephric 
region) that undergoes epithelisation and then elongates and extends caudally 
through mesenchymal-to-epithelial transition of their tip cells. While migrating, the WD 
induces the formation of three paired nephric structures from the nearby IM in a 
cranial-caudal sequence: the pronephros, the mesonephros and the metanephros (the 
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last one to develop and the progenitor for the definitive kidney) (Saxén, 1987; Saxén 
and Sariola, 1987; Costantini and Kopan, 2010). 
Molecular mechanisms underlying the specification of the WD within the IM and 
involved in its further development and elongation to reach the urogenital sinus have 
been investigated through mouse knock out models; the transcription factors PAX2, 
PAX8, LHX1 and GATA3 have been shown to be important players (Dressler et al., 
1990; Fujii et al., 1994; Bouchard et al., 2002; Grote et al., 2006). 
 
1.2.3 The Pronephros and the mesonephros: 
The pronephroi develop from the nephrogenic cord as small mesenchymal 
condensations. The pronephroi do not function in mammals including human; they 
degenerate by the fourth week of gestation (Vetter and Gibley, 1966; Dressler, 2006); 
however, they represent the primary filtering structures for lower vertebrates including 
Larva fish (Drummond et al., 1998) and Xenopus embryos (Vize et al., 1997). 
In contrast, the mesonephroi have been demonstrated to produce urine in mammals 
during embryogenesis (Torres et al., 1995). In mouse, the mesonephros is composed 
of around 18 pairs of tubules which could be subdivided into cranial tubules and caudal 
tubules (Vetter and Gibley, 1966; Sainio, 2003). The cranial tubules acquire 
connection to the WD at 4-6 sites through short connecting segments that develop 
from the WD, they have rudimentary glomeruli and some of them form branches from 
their distal segments (Croisille, Gumpel-Pinot and Martin, 1976; Sainio, Hellstedt, et 
al., 1997; Sainio, 2003). The caudal tubules, which represent most of the 
mesonephros, do not connect to the WD (Sainio, Hellstedt, et al., 1997; Davidson, 
2008). Like the pronephros, the mesonephros finally regresses except for some of the 
cranial tubules which become modified in males to form the rete testis (Vetter and 






1.2.4 Metanephric kidney development: 
Among the three pairs of kidneys that develop during the embryonic stage, the 
Metanephros represents the precursor for the adult functional kidney. It is the last pair 
that develops chronologically and is the most caudal (posterior) one (Bremer, 1916). 
The Metanephric kidney develops from two main progenitors; the ureteric bud (UB) 
and the metanephric mesenchyme (MM). While the MM and the UB are both 
derivatives of the IM, the two have distinct spatial origin (as mentioned earlier); the UB 
develops as an outgrowth of the Wolffian duct, which itself is a derivative of the anterior 
IM, and the MM develops from the posterior nephrogenic cord (Fraser, 1920; 
Grobstein, 1955; Vetter and Gibley, 1966; Taguchi et al., 2014) (figure 2b). 
The MM blastema first appears at around day E10.5 in mouse as an aggregate of 
mesenchymal cells derived from the IM adjacent to the caudal part of the WD. It is to 
be noted that once the MM blastema is specified from the IM, the cells already have a 
predetermined kidney-making determination and experiments showed that in no case 
will other embryonic cells at that stage of embryonic development be able to make 
metanephric nephrons or other specific metanephric structures (Saxén, 1970, 1999). 
At around day E10.5 in mouse (week 4 in human), the caudal end of the WD responds 
to inductive signals emanating from the adjacent MM by localized cellular outgrowth 
to form the UB. Early studies in which the MM and UB were separated and then 
cultured either isolated, recombined in-vitro, or combined with other kinds of tissues 
provided a strong evidence that there are reciprocal inductive signals between the two 
progenitors and that this interaction is crucial for the metanephric kidney development. 
The UB emits signals that induce the MM to condense around its tip and undergo 
mesenchymal-to-epithelial transition to start nephrogenesis; and on its turn, the MM 
induces the UB outgrowth and its subsequent branching (Grobstein, 1953; Grobstein, 
1955; Saxén, 1987). Studies showed that these inductive signals could also be 
provided, at least in part, by a number of other heterologous tissues, for example co-
culture of the isolated MM with the dorsal spinal cord decreases apoptosis and induces 
nephron formation (Grobstein, 1955; Lehtonen et al., 1983; Saxén and Lehtonen, 
1987). On the other hand, studies mixing the UB with different mesenchymal tissues 
also showed that UB arborisation could be seen upon mixing with lung mesenchyme; 
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however, the branching pattern was more like that of the lung than that of the kidney 
(showed more lateral branching) suggesting similarity in the signals inducing 
branching to the UB and the lung buds and also suggesting a mesenchymal influence 
on the pattern of branching (Kispert et al., 1996; Lin et al., 2001) .  
The nature of the inductive signals between the UB and the MM is now fairly 
understood thanks to experiments involving transgenic mice knock-outs and in-vitro 
culture and manipulation to embryonic kidney rudiments. Glial derived neurotropic 
factor (GDNF) produced from the MM and the co-receptor GFRα1 (expressed in both 
WD and MM) stimulate the tyrosine kinase receptor c-RET (expressed in the WD) to 
induce localized cellular proliferation and migration to form the UB. GDNF-soaked 
beads are able to induce the formation of multiple buds from the WD projecting 
towards the beads (Sainio, Suvanto, et al., 1997; Tang et al., 1998). The signal 
produced from the UB to induce differentiation and maturation of the MM was also a 
subject for meticulous investigations. In 1995, Davies and Garrod observed that 
treatment with lithium chloride, a WNT agonist, was able to induce tubulogenesis in 
cultured isolated mouse MM (Davies and Garrod, 1995). Later, it was proved that 
WNT9B, secreted from the UB, acting through the canonical WNT/β-Catenin pathway, 
induces MM condensation and initiates mesenchymal to epithelial transition (Carroll 
et al., 2005).  
The advances that have been made to understand the signalling pathways involved 
in metanephric kidney development and morphogenesis not only widen our 
understanding of kidney organogenesis, but also provide developmental cues that 
could be used to direct cells in a progenitor state towards more specialised cells 
forming highly specialised structures and participating in a complex way to perform 
different kidney functions (more details about important molecular mechanisms 





1.2.4.1 Ureteric bud outgrowth and branching 
Once inside the MM, the UB: grows and differentiates into tip cells and stalk cells, 
undergoes a process of repeated branching and patterning morphogenesis, and 
continues to induce the MM to condense around its tips and form nephrons (Michos, 
2010). 
The branching process implies a repeated process of: proliferation of the UB tip cells 
to form expanded ampulla, splitting of the ampulla forming new branches and then 
elongation of these branches (Lin et al., 2003; Watanabe and Costantini, 2004). 
In mouse, the UB undergoes ten generations of iterative branching after which the 
branching slows down and the collecting ducts elongate before giving one to two 
rounds of branching before birth (Srinivas et al., 1999; Cebrián et al., 2004). Terminal 
bifurcation is believed to be the main way of branching (Saxen et al., 1965; Saxen and 
Wartiovaara, 1966) with the first branching described to be occurring at an angle of 
180 to give a T-shaped structure and the following ones at more acute angle to give 
Y-shaped bifurcations (Saxen et al., 1965) less commonly trifurcations are also 
described. A time-lapse study performed on transgenic mice expressing green 
fluorescent protein marking their UB branches (under the control of Hoxb7 gene; the 
expression of which is restricted in the kidney to the UB and its branches) concluded 
that lateral branching also takes place in UB branching and it could be a way to fill the 
gaps left by terminal bifurcations (Srinivas et al., 1999). 
In human, consistent with earlier studies, a recent study on human kidney 
organogenesis describes the first appearance of the UB as a globular outgrowth from 
the WD at around Carnegie stage (CS) 13. According to the same study, the first one 
to two branches are observed by CS16 with the first branch most likely to be 
trifurcation. Between CS16-CS22 the branching tips have either T or Y-shape; CS23 
- week16 the tips adopt a V-shaped morphology. They also describe an expanded tip 
morphology with a prominent lumen between CS23 and week9, the expansion 
extends to the stalk region and that morphology is distinct from the other stages 
examined in their study. Matching this morphology with their findings that predict the 
glomerular filtration to start at CS23, they suggested that this could be because of 
active glomerular filtration occurring before the ureter connects to the urinary bladder. 
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Unlike the mouse UB, they described the first branches of the human UB between 
CS13 and CS19 to have a pseudo-stratified tip epithelium (Potter, 1972; Lindström et 
al., 2018). 
1.2.4.2 Mesenchyme condensation and nephron formation 
After penetration of the UB, the loose mesenchymal cells condense around the tip 
forming densely packed cap mesenchyme (CM). As the UB grows and undergoes 
branching, the MM continues to form new caps around each newly formed tip and the 
process of nephron formation undergoes different steps of growth, differentiation and 
patterning. The CM forms pretubular aggregates from which the first epithelial 
structure, the renal vesicle, develops. The renal vesicle is a polarized structure that 
remains in contact with the UB tip at one side (Saxén, 1987; Georgas et al., 2009). 
Morphological changes then take place; a single cleft forms at one end of the vesicle 
changing its morphology into a comma-shaped body which then changes into an S-
shaped body after a second cleft is formed at the other end (Jokelainen, 1963). The 
S-shaped body has a distinct proximal-distal pattern, with its distal end joining the UB 
and finally forming a continuous lumen between the CD and the nephron (Georgas et 
al., 2009) (figure 3c). 
The S-shaped body further elongates and differentiate; ultimately giving rise to various 
specialised cell types arranged in distinct specialised domains of the mature nephron 
each with a unique expression pattern: 
Bowman’s capsule: which is the most proximal part of the nephron. It has a parietal 
layer and a visceral layer; the visceral layer is lined with podocytes which express the 
characteristic transcription factors Wilms tumour1 (WT1) and PODXL1; the specific 
transmembrane protein NPHS1, and secrete the Vascular endothelial growth factor 
(VEGF) that recruits the vascular endothelial cells to invade the capsule and form the 
glomerular capillary loop (Kreidberg et al., 1993; Kitamoto, Tokunaga and Tomita, 
1997; Ruotsalainen et al., 1999). 
Proximal convoluted tubules: which express Aquaporin1 (AQP1) and Jagged1 and 
bind Lotus tetragonolobus lectin (LTL) (Hennigar, Schulte and Spicer, 1985; Barresi, 
Tuccari and Arena, 1988; Cheng et al., 2003; Bauchet et al., 2011). 
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Loop of Henle: it has a thin descending limb that expresses AQP1 and a thick 
ascending limb which expresses Uromodulin (Bauchet et al., 2011).  
Distal convoluted tubules: the distal most part of the nephron which connects to the 
CD and is expressing the adhesion molecule ECAD (Lee et al., 2013). 
At E10.5 the mouse MM is already divided into 2 main sub-populations: central SIX2+ 
nephron progenitor cells that condense around the invading UB forming CM and outer 
stromal FOXD1+ cells (Kobayashi et al., 2008). Lineage tracing studies have shown 
that cells expressing Six2 are multipotent self-renewing cells that give rise to all cell 
types incorporated in the nephron epithelium (Kobayashi et al., 2008). 
Nephrogenesis does not occur as a single burst where all the MM undergoes 
mesenchymal-to-epithelial transition (MET) and forms nephron tubules, but rather 
proceeds in a repeated radial pattern around the dividing UB tips. For this to happen, 
there should be a balance between differentiation and self-renewal of the progenitor 
cells. Studies have shown that the transcription factor SIX2 plays a key role in 
maintaining this balance (Self et al., 2006). More details about SIX2 function and its 
interaction with other signalling pathways to maintain the balance between 
differentiation and self-renewal will be discussed in the following section.  
Signals emanating from renal stromal cells have also been demonstrated to fine-tune 
this balance; destroying stroma with diphtheria toxin disrupts WNT9B signalling and 
leads to thickened mesenchymal caps and reduced nephron formation (Das et al., 
2014). Mutations affecting Foxd1 are also associated with arrest of differentiation and 
expansion of the nephron progenitors caused by the high level of proteoglycan 
decorin, its level is normally high in the medullary interstitium but not in the cortical 
interstitium (where nephrogenesis takes place), which antagonizes the effect of BMP7 
(Fetting et al., 2014). 
1.2.5 Important genes involved in embryonic kidney development: 
Detailed information about molecular mechanisms and the important genes implicated 
in kidney development would need many more pages to be fully covered, however, I 
would like to highlight the importance of the following genes in kidney development 
with three main aims: 
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1- To understand basic pathways and mechanisms underlying metanephric 
kidney development and branching morphogenesis. 
2- Growth factors encoded by some of these genes will be used throughout the 
thesis either to induce renal differentiation or UB branching. 
3- The expression of these genes will be used to verify the differentiation of the 
cells to a specified renal fate.  
Paired-box transcription factors PAX2 and PAX8 
PAX2 and PAX8 are 2 important interconnected transcription factors the function of 
which is important for the specification and development of the kidney. The two 
transcription factors have an important role in IM specification. Their expression is 
restricted to the IM, unlike LHX1 or OSR1 which extend to the lateral plate mesoderm 
(Bouchard et al., 2002). They are also co-expressed in the WD, the UB and later in 
the CD (Dressler et al., 1990). 
Their function seems to be inter-connected and partially redundant as Pax8 mutants 
do not exhibit any renal abnormalities; Pax2 mutants can still develop WD but they 
degenerate before reaching the urogenital sinus and, consequently, the UB does not 
develop (Torres et al., 1995; Brophy et al., 2001; Soofi, Levitan and Dressler, 2012). 
The initial development of the WD in Pax2 deficient mice is probably due to 
overlapping function of Pax8 during the early stage of development (Torres et al., 
1995). Nonetheless, Pax2/Pax8 double mutants fail to develop WD from the IM and 
fail to express the WD markers LHX1, c-RET (Bouchard et al., 2002) and GATA3 
(Grote et al., 2006). As a consequence, the double mutant embryos do not develop 
pronephroi or any other nephric structures and the IM undergoes apoptosis (Bouchard 
et al., 2002). 
In addition, Pax2 is also expressed in the nephrogenic cord, the MM and the 
differentiating nephrons (Dressler et al., 1990). In the MM, it stimulates the expression 
of important kidney development regulators including: LHX1, SIX2 and GDNF 
(Ranghini and Dressler, 2015). PAX2 stimulates the UB outgrowth into the MM by 
stimulating the expression of the GDNF (Brophy et al., 2001; Ranghini and Dressler, 
2015). It has also been shown that PAX2 plays an important role in segregating the 
nephron progenitor cells from the surrounding renal interstitial cells; the conditional 
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inactivation of Pax2 in nephron progenitors leads to their trans-differentiation into renal 
stromal-like cells (Naiman et al., 2017).  
As the CM undergoes mesenchymal to epithelial transition, the maturing nephrons 
downregulate Pax2 expression (Ryan et al., 1995). Reactivation of its expression is 
demonstrated in adult kidneys after exposure to injury, suggesting a role in kidney 
regeneration (Villanueva, Céspedes and Vio, 2006; Kusaba et al., 2014). 
LHX1: 
LHX1 belongs to the LIM family of transcription factors. It plays important roles in 
different stages of kidney development and is expressed in different nephric structures 
including the WD, UB, pretubular aggregates, renal vesicles, comma-shaped and S-
shaped developing nephrons; and also, in the maturing podocytes (Karavanov et al., 
1998; Sariola, 2002; Kobayashi, 2005).  
In earlier stages of embryonic development, it is expressed all-over the IM and lateral 
plate mesoderm while by E9.5 the expression becomes restricted to the WD that 
develops within the IM and then it becomes expressed in the mesonephric tubules and 
the developing metanephros (Barnes et al., 1994; Carroll and Vize, 1999; Kobayashi, 
2005). LHX1 is involved in the specification of different renal progenitors from the IM 
and its over expression during the early stage of kidney specification leads to 
expansion of the kidney field (Cirio et al., 2011). Loss of function mutations of Lhx1 
lead to necrotic degeneration of caudal part of the WD and renal agenesis as a 
consequence (Tsang et al., 2000; Pedersen, Skjong and Shawlot, 2005). 
During metanephric kidney development it plays a key role in regulating ureteric bud 
growth and morphogenesis (Kobayashi, 2005; Pedersen, Skjong and Shawlot, 2005), 
and in renal vesicle patterning (Kobayashi, 2005). PAX2/8 are important to maintain 
LHX1 expression, which is downregulated in Pax2/8 double mutant (Bouchard et al., 
2002). 
GDNF/RET: 
As briefly mentioned before, the GDNF-RET-GFRα1 pathway plays an important role 
in inducing UB formation. Early events of the metanephric kidney development 
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involves signalling of the GDNF protein via GFRA/RET receptor complex to induce 
localised outgrowth from the caudal end of the WD forming the UB. The GDNF protein 
is initially, before induction by the UB, expressed all over the specified metanephric 
mesenchyme then the expression undergoes progressive restriction to the caudal 
part, correlated to the precise site where the UB forms, after the outgrowth of the UB 
the expression becomes more restricted to the CM surrounding the growing ureteric 
tips. Similarly, RET expression is initially found all-over the WD and later it becomes 
localised to the growing tips (Marose et al., 2008).  
Cells of the growing UB could be divided into tip cells expressing RET and stalk cells 
which are RET negative (Shakya et al., 2005; Costantini and Shakya, 2006). The 
undifferentiated MM around the tip cells are thought to produce factors that promote 
growth and branching while the growing nephron epithelia around the stalk cells 
induce elongation and stop branching (Sweeney, Lindstrom and Davies, 2008). As the 
GDNF has a chemo-attractive property it is suggested that attraction of the tip cells 
towards sources of GDNF induces branching (Sariola and Saarma, 2003). Blocking of 
the GDNF activity in in-vitro cultures using anti-GDNF antibodies yields smaller 
kidneys with fewer UB tips (Vega et al., 1996).  
GDNF stimulation of the RET receptors further upregulates Ret expression at the tip 
cells (Pepicelli et al., 1997; Costantini, 2012). In addition, GDNF stimulates Wnt11 
expression in the UB tips which in turn acts, through a paracrine action, to maintain 
Gdnf expression in the CM (Majumdar et al., 2003; Mcmahon, 2016). 
The fact that the WDs in response to GDNF beads would form multiple ectopic buds 
shows that tight regulation of the GDNF expression is essential for proper positioning 
of the ureter and for preventing supernumerary ureters. FOXC1 and FOXC2 are two 
closely related transcriptional factors; they have an overlapping pattern of expression 
in different types of embryonic tissue, and they were shown to be important in 
regulating GDNF expression. Mouse embryos with Foxc1 homozygous mutations 
show anterior expansion of Gdnf expression which leads to double ureters and double 
kidneys with the ectopic ureters anteriorly located to the normal position (Kume, Deng 
and Hogan, 2000). Likewise, Greishammer and colleagues showed that mutations 
affecting the signalling pathway SLIT2/ROBO2 lead to anterior expansion of Gdnf 
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expression in the MM and cause supernumerary anterior located ureters 
(Grieshammer et al., 2004) (figure 1.3a). 
Michos and colleagues showed that UB can grow and branch in absence of the 
GDNF/RET pathway when its negative regulator SPRY1 is also absent. Gdnf-/-; 
Spry1-/- or Ret-/-; Spry1-/- mice developed normal sized kidneys with branching UBs 
and normal nephrogenesis; the pattern of branching however was altered suggesting 
important role of the GDNF in branch patterning and revealing that beside GDNF there 
are other factors participating in inducing UB branching (Michos, 2010). Consistent 
with this, GDNF alone is not sufficient to support growth and branching in isolated 
cultured UB, addition of extracellular matrix and either MM conditioned medium or 
combination of other growth factors is necessary (Sakurai, Bush and Nigam, 2005; 





Figure 1.3. Illustration of the metanephric kidney development. a) The specified MM expresses 
GDNF protein and the transcriptional factors EYA1, SIX1, PAX2, SALL1, HOX11 and WT1. The 
Wolffian duct express the tyrosine kinase receptor RET, which respond to the GDNF protein 
secreted from the metanephric mesenchyme by localized cellular proliferation and migration to 
form the ureteric bud (UB). The GDNF/RET pathway is tightly regulated along the anterior-posterior 
axis to prevent supernumerary and ectopic ureters. Enhancers of the GDNF/RET pathway are 
shown in brown and inhibitors are shown in blue. b) The UB penetrates the MM and starts 
bifurcation. WNT9B, secreted from the UB, stimulates the MM to condense and form the cap 
mesenchyme which forms aggregates close the ureteric stalk (the pre-tubular aggregates). C) 
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Different stages of nephron formation and the particular pattern of expression of the different 
segments of the nephron and the collecting duct. The embryonic age at which the presented 
markers is detected is shown in red. m: for indicating the mouse embryonic age; h: for indicating 
the human embryonic age. CM: cap mesenchyme; UB: ureteric bud; CD: collecting duct. Adapted 
from (Elhendawi and Liu, 2018; for references see section 1.2.4 , 1.2.5, and table 2.1). 
Retinoic acid (RA) signalling through Retinoic acid receptors (RARs): 
Similar to the paracrine signalling between the nephrogenic mesenchyme and the UB, 
through the GDNF/RET pathway, an important interplay between the renal stroma and 
UB also exist. Renal stromal cells produce RA which acts on RARs in UB cells to 
regulate Ret expression, UB growth and further branching (Rosselot et al., 2010). 
RA is the active form of vitamin A; deficiency of vitamin A has been linked to renal 
abnormalities, in the form of fewer nephrons and abnormal UB branches, of varying 
degrees related to the degree of deficiency (Bhat and Manolescu, 2008). RARs belong 
to a family of transcription factors that regulates the expression of different genes. 
Three genes, Rara, Rarb and Rarg, are responsible for encoding members of the RAR 
family. Rara and Rarb2 double homozygous mutants were demonstrated to have 
abnormally small kidneys, low nephron no and abnormal few UB branches. Further 
analysis of the developing embryos showed downregulation of RET receptors in the 
UB and the developing CD system (Mendelsohn et al., 1999). Forced expression of 
Ret in Rara/Rarb2 double mutants reverses the effect of the mutation and rescues the 
kidney which confirms the role of RA in regulating Ret expression (Batourina et al., 
2001).  
It was first thought that RA, secreted from stromal cells, bind to RARS present in 
stromal cells, in an autocrine pathway, to stimulate retinoid response elements that on 
turn regulate Ret expression in the UB (Mendelsohn et al., 1999). Later, it has been 
shown that RARs are also expressed in the UB and experiments on isolated UBs 
(cultured in gel; in absence of the surrounding MM) showed that when GDNF or RA 
was added alone to the culturing media, the cultured UBs downregulate Ret 
expression and do not show branching, while adding RA with GDNF induces 
branching (Rosselot et al., 2010). That experiment has shown that RA works on RARs 
expressed in the UB, in a paracrine pathway, and that both GDNF and RA both act 
independently to induce branching; while RA induces the expression RET receptors, 
GDNF is important for their activation. Furthermore, conditional expression of 
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homozygous mutant form of Rara in the ureteric bud leads to severe renal hypoplasia 
and agenesis in some conditions which were attributed to the loss of Ret expression 
(Rosselot et al., 2010). 
GATA3: 
One of the members of the GATA family of transcription factors; members of this family 
have high similarity in their zinc finger DNA binding domain (Ko and Engel, 1993). In 
the human kidney GATA3 expression is demonstrated in the WD, collecting ducts of 
the mesonephros until their involution, the UB, CDs and mesangial cells of both 
mesonephros and metanephros (Labastie et al., 1995). 
Haploinsufficiency of the GATA3 gene in human leads to hypoparathyroidism, 
deafness and renal anomalies; a condition known as HDR, indicating its importance 
in the development of the parathyroid, inner ear and kidney (Van Esch et al., 2000). 
The renal anomalies in HDR vary between renal dysplasia, hypoplasia, vesico-ureteric 
reflux, glomeruloneprhritis and renal aplasia; these renal anomalies are sometimes 
accompanied by female genital malformations (Van Esch and Devriendt, 2001; 
Hernández et al., 2007). 
Likewise, conditional inactivation of the Gata3 gene in mouse, in the developing ND, 
has been linked to a variety of renal anomalies including renal agenesis, aplasia and 
severe renal dysplasia; it was also associated with genital anomalies. Gata3 is a direct 
target of PAX2/8 working downstream to them (Grote et al., 2006). It has also been 
demonstrated that WNT/β-catenin pathway activates the expression of Gata3 which 
on turn activates Ret expression in the ND and UB (Grote et al., 2008). I tried in this 
work to construct a GATA3-reporting hiPSC line to track the expression of GATA3 in 
renal organoids and isolate the induced UBs (details about this work are described in 
chapter 6)  
Wingless signalling pathway (WNT): 
WNT proteins belong to a family of lipid-modified signalling proteins that are implicated 
in several developmental events throughout embryogenesis. Binding of WNT protein 
to its receptor complex FRZ/LRP inhibits the destruction complex GSK3/APC/Annexin 
(in absence of WNT, that complex destructs the transcription factor β-Catenin and 
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keeps its cytoplasmic level low) and increases the concentration of β-Catenin (Logan 
and Nusse, 2004). WNT signalling through the canonical β-Catenin pathway has been 
shown to regulate crucial steps in kidney development and is involved both in UB 
branching (Bridgewater et al., 2008) and MM condensation and nephrogenesis (Park, 
Valerius and McMahon, 2007). 
Several WNT proteins have been shown to be expressed in the metanephric kidney 
including WNT4, WNT2B and WNT5A in the metanephric mesenchyme and WNT9, 
WNT11, WNT6, WNT7B, WNT5A and WNT5B in the UB and the developing CD 
system. WNT4 was shown to have role in nephrogenesis (Stark et al., 1994; Kispert, 
Vainio and McMahon, 1998); at E11.5 it is expressed in the mesenchyme condensing 
around the T-bud; that pattern of expression is maintained in every newly formed CM 
afterwards, and then it continues to be expressed in pre-tubular aggregates, the renal 
vesicle and the comma-shaped body, while its expression starts to regress in the S-
shaped body where it is restricted to its distal limb before the expression is lost after 
fusion with the CD. Homozygous targeting of Wnt4 results in embryos with small 
agenic kidneys in which the MM forms CM but it fails to differentiate further and does 
not develop pretubular aggregates, thus WNT4 was identified as an auto inducer that 
is expressed in the CM to induce nephrogenesis (Stark et al., 1994).  
It has long been known that inductive signal from the UB is crucial for inducing 
nephrogenesis and, as WNT4 is expressed in the MM itself, it has been proposed that 
its nephron-inducing effect works downstream of another inducer from the UB. 
Eventually,  WNT9B was identified as the UB-derived nephrogenesis inducer (Carroll 
et al., 2005). Wnt9b is expressed in the WD and continues to be expressed in its 
derivative; the UB. Within the UB, Wnt9b is strongly expressed in the stalk and 
downregulated in the tip cells, unlike Wnt11 which is mainly expressed in the tip cells. 
This pattern of expression, which does not extend to the tips, is maintained within the 
UB as it branches to form CD tree. Renal vesicles appear correlated to and preceded 
by the wnt9b expression below the tips of the UBs. 
Moreover, WNT9B secreting cells can induce nephrogenesis in isolated MM. 
Knockout of Wnt9b results in downregulation of Wnt11 in the UB tips and Gdnf in the 
MM, as a consequence, the UB branching is disturbed after the T-bud stage; in 
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addition, the expression of WNT4, FGF8, PAX2 and LHX1 (which represent early 
markers of tubulogenesis) is not detected in the mesenchyme (Carroll et al., 2005).  
More recently, the importance of the β-Catenin pathway in renal stromal cells was 
demonstrated through conditional knock-out of β-Catenin in stromal cells, which 
caused marked renal defects including reduction in the condensing cap mesenchyme 
with decreased cell proliferation and loss of Cited1 expression; the expression of 
Wnt9b in UB cells was also downregulated. In contrast, overexpression of β-Catenin 
in stromal cells upregulates Wnt9b expression and increases the CM population 
(Boivin et al., 2015).  
Fibroblast growth factors (FGFs): 
Another family of proteins with essential role in kidney development is the FGF family 
signalling through FGF receptors (FGFRs) which belong to the receptor tyrosine 
kinase family. Among the members of FGFRs FGFR1 and FGFR2 have been 
demonstrated to be expressed in both the UB and MM. 
Signalling through this pathway was shown to induce UB branching (Qiao et al., 1999, 
2001). Zhao et al showed that conditional deletion of Fgfr2 in the UB leads to abnormal 
thin stalks, aberrant few branches, and smaller abnormal shaped kidneys (Zhao et al., 
2004). Similar branching defects are also seen in mutants of Fgf7 and of Fgf10 (Qiao 
et al., 1999; Ohuchi et al., 2000; Revest et al., 2001); FGF7 and FGF10 are expressed 
by the CM cells to induce the FGFR2B expressed in the ureteric epithelial cells and 
stimulate branching. Knock out of Fgf7 leads to reduced branches and as a result, 
fewer nephrons (Walker, Sims-Lucas and Bates, 2016).  
Furthermore, it was shown that FGFR signalling could compensate for the loss of 
GDNF/RET signalling; the key RTK pathway involved in UB budding and branching, 
when combined with inactivation of BMP/Activin signalling (Maeshima et al., 2007; 
Michos, 2010). A more recent study has shown that Fgfr2 is expressed all-over the 
WD where it plays an important role in its maintenance in the caudal mesonephros. 
Upon specific inactivation of the receptor in the WD, the study showed WD regression 
and obstruction of the WD in the area of caudal mesonephros (Okazawa et al., 2015).  
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On the other hand, the importance of FGFs signalling in MM development was also 
investigated. FGF2 has been demonstrated to prevent apoptosis in the isolated MM  
and induce mesenchymal condensation (Perantoni, Dove and Karavanova, 1995; 
Barasch et al., 1997). Conditional deletion of either fgfr1 or fgfr2 in the MM does not 
lead to any renal abnormalities but simultaneous deletion of the two receptors causes 
renal aplasia suggesting redundancy in the function of the two receptors; the MM fails 
to condense and analysis of the MM rudiments shows preserved expression of Eya1 
and Six1 but absence of SIX2, SALL1 and PAX2. The UB does form in these mutants 
but fails to elongate or undergo branching, consistence with this Gdnf is expressed at 
E10.5 but falls dramatically afterwards (Poladia et al., 2006).  
FGF9 and FGF20 have also been demonstrated to promote survival, induce 
proliferation while maintaining stemness of nephron progenitors in the CM; this finding 
was demonstrated in-vivo either through knock-out studies of both Fgf9 and Fgf20 in 
mice or by demonstrating that mutation in FGF20 in human leads to renal agenesis. 
In addition, FGF9 or FGF20 is able to maintain isolated MM cell in in-vitro cultures and 
retain their ability to form nephrons in response to WNT agonist for up to 5 days (Barak 
et al., 2012). 
In contrast, FGF8 is expressed in pretubular aggregates and induces the 
differentiation to renal vesicles; it works in conjunction with WNT4 in response to 
WNT9B signals from the UB. Its function is upstream to WNT4, however, WNT4, 
through a positive feedback effect, maintains its expression (Grieshammer et al., 
2005; Perantoni et al., 2005). 
WT1: 
Wilms Tumour1 (WT1) is a zinc finger transcription factor; mutation in its encoding 
gene was identified as the leading cause of the paediatric Wilm’s tumour, after which 
the gene was named, that affects the renal progenitor cells resulting in uncontrolled 
proliferation and abnormal differentiation (Mierau, Beckwith and Weeks, 1987; Cowell 
et al., 1991; Hohenstein and Hastie, 2006).  
Wt1 is expressed in the early mesonephric tubules and then in the specified uninduced 
MM; after induction from the UB its expression increases in the MM and becomes 
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specifically higher in the CM. It continues to be expressed in the proximal part of the 
developing nephrons and the podocytes. It is widely expressed by other mesoderm-
derived tissues; however, its expression becomes restricted to renal podocytes by E20 
in mouse (Armstrong et al., 1993). That pattern of expression, which is restricted to 
the podocytes, is maintained afterwards and is seen in normal adults suggesting a role 
of WT1 in maintaining normal podocyte phenotype. Wt1 mutations cause Wilm’s 
tumour, genitourinary defects, and immature podocyte phenotypes which are involved 
in genetic causes of glomerulosclerosis including Denys Drash and Fraiser syndromes 
(McTaggart et al., 2001; Patek et al., 2003; Srichai et al., 2004). 
Wt1 mutants maintain the expression of Gdnf (Donovan et al., 1999) but fail to recruit 
UBs (Kreidberg et al., 1993) or start nephrogenesis upon recombination with normal 
UB. The block of nephrogenesis could be explained by the finding that Wnt4 is 
controlled by WT1 (Essafi et al., 2011). WT1 is also required for the survival of the 
progenitor cells; Wt1 mutants undergo spontaneous apoptosis. This has been shown 
to be mediated through regulating a balance between FGF and BMP/pSMAD 
signalling; Inhibiting pSMAD or inducing FGF stops apoptosis in nephron progenitors 
in Wt1 mutants (Motamedi et al., 2014). Another recent study has investigated the 
effect of conditional Wt1 knockout in different developmental stages, before and after 
MET. According to that study, loss of Wt1 function before the MET leads to expansion 
of the MM and severe disruption of mesenchymal condensation and subsequent 
epithelization, while loss of Wt1 function after MET disturbs glomerulogenesis and 
tubular maturation. They also compared the genome-wide pattern of expression of the 
mutant mouse models to that of human Wilm’s tumour cases carrying either wild-type 
or mutant WT1. Interestingly, they found that the expression pattern of the mutant 
mouse kidneys in which Wt1 loss of function occurs after MET closely resembles 
human wild-type WT1 cases, while kidneys in which loss of function occurs after MET 
resemble in their expression pattern human mutant WT1 cases (Berry et al., 2015). 
SIX1/SIX2: 
In mouse metanephros Six1 is expressed early and has a role in the specification of 
MM within the IM at E10.5 before UB induction and its expression is transient; it 
supports the survival of MM cells and in its absence the MM undergoes apoptosis and 
the formed UB fails to branch (Xu et al., 2003; Nie et al., 2011; Xu and Xu, 2015).  
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SIX2 plays a key role in the maintenance and renewal of nephron progenitor cells. It 
is expressed in the CM cells and its deletion leads to abrupt premature epithelisation 
of CM and early cessation of nephrogenesis which ultimately causes severe reduction 
in nephron number (Self et al., 2006; Kobayashi et al., 2008). In response to WNt9B 
induction from the UB, a subset of SIX2+ve cells relatively lower their Six2 expression 
and express Wnt4 together with other nephrogenesis markers including FGF8, PAX8 
and BMP7 (Kobayashi et al., 2008; Mugford et al., 2009; Park et al., 2012). On the 
opposite side, a separate population of SIX2 positive cells, which is co-expressing 
CITED1 (Cited1+/Six2+), is refractory to WNT9B induction and does not participate in 
nephrogenesis, but rather, engages in self renewal of the nephron progenitor cells 
(Mugford et al., 2009; Park et al., 2012; Brown et al., 2013). BMP7 signalling through 
the SMAD pathway has been demonstrated to drive the cells from the refractory 
CITED1+/SIX2+ state into a CITED1-/SIX2+ state that is responsive to induction to 
start nephrogenesis (Brown et al., 2013). 
The function of SIX2 comes downstream to SIX1 as demonstrated by reduced SIX2 
levels in Six1 mouse mutants (Xu, 2003; Xu et al., 2003). The expression pattern, 
transcriptional targets and function of SIX2 is highly conserved between human and 
mouse (O’Brien et al., 2016). While the expression and function of Six1 and Six2 seem 
to be well separated in mouse, Six1 is expressed earlier and function to support the 
MM cell survival whereas Six2 expression follows and is maintained throughout 
nephrogenesis in the CM to support self-renewal of the progenitor cells, a recent study 
showed that there is an overlap between them in human; and surprisingly SIX1 was 
demonstrated as a target gene for SIX2. Six1 expression disappears in mouse after 
the first round of UB branching while in human SIX1 continues to be expressed in 
overlap with SIX2 in CM (O’Brien et al., 2016). 
Calbindin28KD: 
Calbindin28KD is a cytoplasmic, vitamin D-dependent calcium-binding protein. In adult 
kidney Calbindin is mainly expressed in the distal convoluted tubules where it plays a 
key role in active calcium transport. It interacts with the apical calcium transporting 
channel TRPV5 and buffers any free calcium released to the inside of the cell to 
prevent negative feedback effect of the free intracellular calcium on the channel 
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(Lambers et al., 2006), it has also recently been shown that it regulates the expression 
of DCT calcium transport molecules including TRPV5 and TRPV6 (Lee et al., 2016). 
During kidney development however, Calbindin expression is quite different; 
Calbindin28KD is detected in the mesonephric WD and the mesonephric connecting 
tubules but not in mesonephric nephrons. In the developing metanephros it is 
expressed in the UB and the collecting ducts; it is also expressed in the most distal 
part of the nephron. In-vitro culture models have shown that the expression in the UB/ 
collecting ducts is constitutive and is detected from the point the UB outgrows from 
the WD. The expression extends to the UB branches and the collecting ducts. 
Calbindin28KD expression in distal tubules is however dependent on the presence of 
vitamin D and on the developmental age. In absence of vitamin D, Calbindin28KD 
expression remains confined to the UB/CD system and is considered as a reliable CD 
marker in standard culture conditions (Davies, 1994). 
 
ECAD: 
ECAD is a cellular adhesion molecule, belongs to the cadherin family, that functions 
to maintain the integrity and polarity of renal epithelial cells. The transmembrane 
proteins of the Cadherin family belong to adherens junction and desmosome proteins. 
Disturbance in adhesion proteins has been linked to different renal diseases (Molitoris 
and Nelson, 1990; Prozialeck and Edwards, 2007). Various members of the cadherin 
family are expressed in the kidney; the most abundant are ECAD and N-cadherin (Lee 
et al., 2013). The renal expression of ECAD is subject to inter-species difference; 
being expressed in mouse and rabbit in all tubular segments (Piepenhagen et al., 
1995; Thomson and Aronson, 1999), while in human, monkey, rat and pig the 
expression of ECAD is mainly in the distal convoluted tubules and the collecting ducts, 
it is also expressed in the thick ascending limb of loop of Henle in both human (Kirk et 
al., 2010) and rat but not in pigs (Lee et al., 2013). N-cadherin is the main expressed 
cadherin in the proximal tubules in human, rat and pig, and ECAD is not expressed 
(or expressed in very low levels) in that segment (Nouwen et al., 1993; Prozialeck, 
Lamar and Appelt, 2004; Lee et al., 2013).  
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1.3 Renal Organoids: 
An organoid is an in-vitro grown tissue-like structure in which cells of different types 
are organised in a 3-D way that yields histology similar to that of the natural tissue. 
Techniques upon which organoid construction is based have their origin long ago. The 
experiment done by H.V Wilson was the first to show that single cells in an organism 
have all the information needed to re-construct a multicellular structure when he 
dissociated a sponge into single cells and then was able to reconstruct a viable sponge 
from the dissociated cells after re-aggregating them (Wilson, 1910). Decades after, 
several studies were performed to investigate the self-organisation ability of the more 
complex vertebrates and mammals. In 1952 Moscona and Moscona demonstrated the 
ability of dissociated chick mesonephroi to self-organise, after re-aggregation and 
incubation, into epithelial tubules surrounded by mesenchymal derived stroma 
(Moscona and Moscona, 1952). Similar work was conducted on metanephric kidney 
Aurbach and Grobstein dissociated metanephric kidney mesenchyme into single cells, 
re-aggregated the cells and cultured them either alone or in the presence of inducer. 
While the cells died when cultured alone, they formed nephrons when cultured with 
inducer which was in that experiment embryonic spinal cord as the natural inducer; 
the UB cells died upon dissociation (Auerbach and Grobstein, 1958). 
In 2010, Unbekandt and Davies showed that a single cell suspension of renal 
progenitors, obtained at that time by dissociating mouse embryonic kidneys, have the 
ability to self-organise and could be used to re-construct renal tissue. The re-
constructed tissue contained all the correct components of the normal renal tissue: 
nephrons, stromal cells and collecting ducts. That was the first production of what we 
call today renal organoids (Unbekandt & Davies 2010) (more details about this 
technique and the steps that were developed to improve it are discussed in chapter 
6). Those renal organoids were obtained from dissociated embryonic kidneys as there 
were no defined protocols, at that time, for obtaining renal progenitors from pluripotent 
stem cells and embryonic kidneys were the only reliable source for renal progenitors. 
Recent studies have succeeded in differentiating human pluripotent stem cells 
towards renal progenitors which provided the suitable starting cells to make human 
renal organoids using the self-organising ability of renal progenitors (Taguchi et al., 
2014; Morizane et al., 2015; Takasato et al., 2015).  
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1.4 Development of pluripotent cells: 
Embryonal Carcinoma Cells: 
The first described pluripotent cells that could be propagated in culture were 
embryonal carcinoma (EC) cells, proliferative undifferentiated cells that were isolated 
from teratocarcinoma; a multilineage tumour that contains different tissues, commonly 
including teeth and hair. Kleismith and Pierce demonstrated that single EC cells when 
injected into mouse brain were able to regenerate the multilineage teratocarcinoma, 
which means that these cells have, individually, the ability to differentiate into all cell 
types constituting the tumour (Kleinsmith and Pierce, 1964). Indeed, EC cell lines 
retained the capacity to differentiate into derivatives of all three germ layers; 
pluripotent (Kleinsmith and Pierce, 1964; Martin and Evans, 1975). Nevertheless, 
differentiated cells within the teratocarcinoma were not able to do the same (Martin, 
1980). Transplanting foetal germ cells into adult tissues effectively induced the 
production of these cells. However, their characteristics differed from those of germ 
cells, they rather resembled the early embryonic cell stages prior to gastrulation. 
Consequently, cells from the early embryonic stages were isolated and transplanted 
into extra-uterine tissue, similarly, they formed teratocracinoma (Diwan and Stevens, 
1976).  
The EC cells were able to produce chimeric embryos when injected to developing 
blastocysts, although with poor efficiency and poor contribution, with the EC-derived 
cells detected in different tissues of the embryo (Papaioannou, Waters and Rossant, 
1984; Rossant and Papaioannou, 1985). 
Embryonic Stem Cells: 
Two studies performed independently at almost the same time by Evans and Kaufman 
(University of Cambridge), and Martin (University of California) reported the first 
successful derivation of mouse embryonic stem cell lines from the inner cell mass of 
blastocyst stage embryos. Evans and Kaufman used the term EK cells to describe 
these cells while Martin gave the name Embryonic stem cells (ESCs) (Evans and 
Kaufman, 1981; Martin, 1981). ESCs show similar morphology and gene expression 
pattern to EC cells, also they form teratocarcinoma when injected in-vivo. 
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Mouse ESCs are derived from the inner cell mass of the blastocyst stage of embryonic 
development and they have some defining criteria: they have the ability of self-renewal 
and can proliferate indefinitely in-vitro, they can differentiate into cells corresponding 
to all the three germ layers thus generating all body cell types, they form teratoma 
when injected in-vivo, XX-lines do not show X-inactivation, they could be clonally 
selected and expanded, and they can form chimera (in which they highly contribute to 
all germ layers) capable of germline transmission (Bradley et al., 1984; Smith, 2001). 
Germ line transmission means that ESCs could be used as a tool for genetic 
manipulation in mice; knock-out mutation carrying mice, generated by gene targeting 
of ESCs, was first reported in 1989 (Thompson et al., 1989).  
ESCs are best described as pluripotent cells as they can integrate with blastocysts to 
form either chimera (in diploid complementation) or purely ESCs-derived embryos (in 
tetraploid complementation), however, they do not form de novo blastocysts neither 
do they produce trophoblast. Therefore, the term totipotent is restricted for the zygote 
and the blastomeres of the early developing embryo (Smith, 2001). 
Ten years after the first report of developing ESCs, it was found that a proliferative 
stem cell state could be obtained under specific culture conditions from primordial 
germ cells, these cells were called embryonal germ (EG) cells. Apart from their origin, 
from the primordial germ cells rather than the ICM, these cells were indistinguishable 
from ES cells (Matsui, Zsebo and Hogan, 1992; Resnick et al., 1992).  
For years later, researchers tried to isolate the equivalent human cells to mESCs. It 
was not until 1998 that Thomson and his colleagues succeeded in the isolation and 
maintenance of the first hESCs line (Thomson et al., 1998). Because of their 
properties, scientists had expectations that hESCs would be a useful tool for studying 
pathogenesis of different diseases, drug and toxicity screening, and most ambitious, 
providing replacement therapies for various diseases. Nonetheless, the use of hESCs 
faced ethical debate. The debate arose from the fact that ESCs are obtained from the 
ICM of an embryo, which leads to the destruction of the embryo. Furthermore, they 




Induced Pluripotent Cells: 
An early experiment done by John Gurdon demonstrated that transferring the nucleus 
of somatic fully differentiated frog cells into the cytoplasm of unfertilized eggs 
reprogrammed the somatic cells back to an embryonic state and generated tadpoles 
(Gurdon, 1962). A few decades later, Ian Wilmut and colleagues used the nuclear 
transfer technique to report the first somatic cloning of a mammal, generating the well-
known Dolly the sheep (Wilmut et al., 1997). The group of Takashi Tada showed that 
ESCs, like the oocyte, also can reprogram the nuclei of somatic cells (Tada et al., 
2001). These experiments clearly showed that the terminally differentiated somatic 
cell nuclei still enclosed all the genetic information needed to derive a whole organism 
and that there are factors, provided by the oocyte or the ESCs, that can reprogram 
them back to a pluripotent state (Yamanaka, 2012). 
In 2006, a breakthrough happened when Yamanaka and Takahashi succeeded in 
reprogramming mouse skin fibroblasts into a pluripotent state by the forced expression 
of four transcriptional factors (OCT3/4, SOX2, KLF4 and C-MYC). This achievement 
was a great leap forward in the field of regenerative medicine (Takahashi and 
Yamanaka, 2006a). These cells were designated as induced pluripotent stem cells 
(iPSCs) and were described as being indistinguishable from ESCs. 
The ability to generate viable fertile mouse from iPSCs, using the tetraploid 
complementation technique, reprogrammed from adult somatic cells was the most 
rigorous test of pluripotency and the best proof for the principle that iPSCs can be 
differentiated into all cell types, tissues, organs and even a whole viable organism 
(Zhao et al., 2010; Boland et al., 2012). 
The introduction of strategies to reprogram human somatic cells into induced 
pluripotent stem cells (iPSCs) (Takahashi, Okita, et al., 2007; Yu et al., 2007) has 
strongly encouraged the field of regenerative research and created a second surge of 
interest after the field had been slowed by the ethical restrictions on the use of 





1.4.1 Maintenance of mouse pluripotent cells: 
The ability of ES cells to self-renew indefinitely in culture together with their potency 
to differentiate into all germ layers are what make these cells unique. At the beginning 
of ESCs research, the exact factors that enable them to self-renew without 
differentiation (i.e. maintain pluripotency) were not known. Culture on a feeder layer of 
fibroblasts in the presence of serum was considered essential for the maintenance of 
pluripotency and self-renewal. The putative interaction of the feeder cells and serum 
with the ESCs to maintain pluripotency was unobscured by a group of studies. 
Culturing ESCs on gelatine coat in absence of feeder cells leads to its differentiation; 
adding feeder cells conditioned medium was able to delay the onset of differentiation 
(Koopman and Cotton, 1984). Smith and Hooper then demonstrated that conditioned 
medium obtained from buffalo rat liver cells allowed long term maintenance of ES cells 
without differentiation in absence of feeder cells (Smith and Hooper, 1987).  
The cytokine Leukemia inhibitory factor (LIF) was identified as the differentiation 
inhibitory factor secreted from these cells (Williams et al. 1988, Smith et al. 1988). 
Consistent with that, fibroblast feeder cells that lack functioning Lif gene are not able 
to maintain the undifferentiated state of ESCs (Stewart et al., 1992). However, ESCs 
cultured in LIF and serum, unlike those cultured on feeder cells, look morphologically 
heterogeneous and usually show some differentiated cells which probably means that 
feeder cells supply factors other than LIF to support pluripotency (Martello and Smith, 
2014). LIF binding to its receptors activates JAK which in turn recruits STAT3 to the 
LIF/receptor binding site and activates it through phosphorylation (Boeuf et al., 1997; 
Niwa et al., 1998; Matsuda et al., 1999).  
When ESCs are cultured without serum, they tend to differentiate after a short period 
of time, despite the presence of LIF, which infers that LIF/STAT3 is not sufficient to 
maintain self-renewal and that serum contains other undefined factor/s essential for 
maintaining the undifferentiated state. As the auto-differentiation tends to be towards 
neural precursors, Ying et al used a neuronal differentiation antagonist, BMP, in ES 
cultures and concluded that combining BMP with LIF could replace serum and 
maintain the self-renewal undifferentiated state of the ESCs (Ying et al., 2003). 
However, BMP alone is not enough to maintain self-renewal, instead it induces 
differentiation to non-neuronal fate (Wiles and Johansson, 1999; Malaguti et al., 2013). 
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On the other hand, a group of other factors is implicated in ESCs differentiation. As 
described above, LIF acts through activation of JAKs; ERK is a downstream effector 
of JAK. Activation of ERK, however, seems to oppose self-renewal as it has been 
shown that mutant LIF receptors that do not activate the ERK pathway show promoted 
self-renewal ability (Burdon et al., 1999). FGF4 is actively expressed in ESCs together 
with its receptor FGFR2. It was first thought that FGF4 acts as an autocrine factor to 
support self-renewal, nonetheless, Fgf4 deletion (Fgf4-/-) suggested a role in growth 
and survival of differentiated cells (Wilder et al., 1997). FGF4 is a major activator of 
ERK; consistent with the previous studies, Kunath et al demonstrated that FGFF4 
stimulates ERK1/2 which stimulates ESCs to stop self-renewing and start lineage 
commitment. Furthermore, ERK2 mutant cells resisted differentiation and LIF was 
sufficient to maintain their self-renewal (Kunath et al., 2007). 
The WNT antagonist, GSK3 has also been shown to induce ESCs differentiation (Sato 
et al., 2004; Doble and Woodgett, 2007). Using FGFR/ERK specific inhibitors or GSK3 
specific inhibitors in combination with LIF allows long term maintenance of ES cells 
without differentiation. Moreover, the combination of the two inhibitors (2i) PD0325901 
and CH99021 that specifically inhibit ERK and GSK3 pathways respectively inhibited 
differentiation and supported self-renewal in absence of LIF and serum.  Upon that, it 
was proposed that ESCs are in a “ground state” of pluripotency that they will maintain 
as long as they are properly shielded from differentiation inducing stimuli (Silva and 
Smith, 2008; Silva et al., 2008; Ying et al., 2008). 
1.4.2 Culture conditions for maintaining human pluripotent cells:  
Human pluripotent cells (hPSCs: hESCs and hiPSCs) need quite different conditions 
from those needed to maintain the murine pluripotency. While the mESCs are known 
to be naive pluripotent cells, the human pluripotent cells are described as primed 
pluripotent cells (Ying et al., 2008; Nichols and Smith, 2009). One important difference 
between mESCs and hPSCs is that it is possible to passage mESCs as single cells 
effectively without affecting their growth, whereas hPSCs tend to die progressively 
when dissociated into single cells and prefer to stay in clumps. The specified factors 
that have been proved to support the maintenance of mESCs, LIF and BMP, were not 
enough to maintain hESCs (Xu et al., 2002). Studies demonstrated that interaction 
between different signalling pathways is important to maintain self-renewal and 
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pluripotency in human cells including Activin/Nodal, FGF2, TGF-β, and Noggin (Chen 
et al., 2014). So, the different nature of hPSCs necessitates different culture conditions 
to support their growth.  
Feeder cells: 
Feeder cells provide suitable adhesion surface to hPSCs as well as secrete some 
growth factors that contribute to their growth and maintenance. MEFs have classically 
been the feeder cells used to culture hPSCs (Thomson et al., 1998; Mallon et al., 
2006). Different human alternatives have been tested to replace the xenogenic 
contaminants in the culture system. Fibroblast feeder cells from human foetal or adult 
sources proved to be suitable for supporting long-term maintenance of hPSCs 
(Richards et al., 2002, 2003). Different other types of cells from foetal, neonatal and 
adult sources including foreskin, endometrium cells and Fallopian tube cells were also 
used to expand and maintain hPSCs (Richards et al., 2003). However, feeder-
dependent culture adds to the workload and is a time-consuming way of maintaining 
hPSCs and even the use of human feeder cells still has the risk of immunogenicity. 
Besides, it adds undefined culture conditions which lead to variability in results (Mallon 
et al., 2006). 
Feeder free conditions: 
Several extracellular surfaces have been used to provide adhesion surface to hPSCs 
including: 
Matrigel: Matrigel is a widely used extracellular matrix to support hPSCs cultured in a 
feeder-free condition. It is composed of solubilized basement membrane components 
extracted from Engelbreth-Holm-Swarm sarcoma cells. It includes Laminin, Collagen, 
Heparin sulfate proteoglycans and growth factors (Kleinman et al., 1982; Mackay et 
al., 1993). 
Recombinant Vitronectin and recombinant Laminin-511 both are defined xeno-
free extracellular matrix surfaces that are suitable for long-term maintenance of hPSCs 
(Braam et al., 2008; Rodin et al., 2010). 
Synthetic surfaces: some synthetic surfaces can support the maintenance of hPSCs 
(Kolhar et al., 2010; Melkoumian et al., 2010; Villa-Diaz et al., 2010). Most interesting, 
however, was the use of UV/Ozone radiation to modify the cell culture plastic making 
it convenient surface for hPSCs culture without the need of any matrices, peptides or 
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polymer coat (Saha et al., 2011). Compared to feeder-based cultures, this study 
showed 3 times increase in cell number.  
Suitable maintenance media for hPSCs 
The first attempts for culture and propagation of hESCs usually used a feeder layer of 
MEFs and added foetal bovine serum (FBS) to the media. Since the first isolation and 
culture of hESCs the components of the growth media used for their culture has 
changed a lot. The goal of such continuous dynamic adjustment and changing was to 
set conditions to suit their use for therapeutic purposes later on. The aim was to 
achieve a chemically defined condition that is free of animal products and serum, still 
suitable for supporting pluripotency. 
A group of studies have been performed to find replacements for the animal products 
in the culture system (Genbacev et al., 2005; Li et al., 2005; Vallier, Alexander and 
Pedersen, 2005). 
Ludwig and colleagues developed TeSR1; a chemically defined medium that 
contained a combination of amino acids, trace elements, inorganic salts, lipids, 
vitamins, 2-mercaptoethanol and some growth factors and proteins including: FGF2, 
TGF beta and human serum albumin. This media was able to support maintenance of 
hPSCs in a feeder free condition (Ludwig et al., 2006). Although TeSR1 originally 
depended on cloned human albumin as an albumin source, its relative high cost made 
most of the labs replace it with bovine serum albumin (BSA) which means that the 
source of albumin in the media is still derived from animal source, besides, the 
variation between albumin batches has led to inconsistency of results using TeSR1 
media. A modified version of that media, Essential 8 (E8) media, was then developed 
in the same lab. A major advantage for the E8 media over TeSR1 media is that it did 
not have serum albumin in its components. Initial removal of albumin from TeSR1 
media caused toxicity to the cells but when they removed 2-mercaptoethanol together 
with albumin they found that albumin became no longer essential (Chen et al., 2011). 
In comparison to TeSR1 media that contained 18 components added to the 
DMEM/F12 basal media, the E8 media has only 8 components described as being 
essential for the maintenance of hPSCs. 
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More recently however, a study reported that cells cultured in either E8 or TeSR1 
media show changes in nucleolar morphology and number, higher levels of radical 
oxygen species (ROS) and higher mitochondrial potential compared to cells cultured 
in KSR medium. According to that study, maintaining cells in E8 or mTeSR media 
induces double-stranded DNA breaks, higher sensitivity to gamma-irradiation and 
increases the expression of P53, a transcription factor that increases in response to 
DNA damage. Furthermore, cells cultured in these media have a higher potential of 
single nucleotide variations in their genomic DNA; having a normal karyotype is not 
enough to judge the genomic integrity of the cells. They concluded that the currently 
used parameters to evaluate different media rely only on pluripotency markers and the 
functional ability of the cells to differentiate into all three germ layers, however, these 
criteria do not measure the cellular stress or the genotoxic effect of the media (Prakash 
Bangalore et al., 2017). 
Improving hPSCs survival after passaging and cryopreservation: 
The addition of the Rho-associated kinase (ROCK) inhibitor Y-17632 has been shown 
to protect cells from dissociation-induced apoptosis and enhance the survival of 
hPSCs after dissociation into single cells both in feeder cultured cells and in feeder-
free culture condition using Matrigel-coated plates and MEF-conditioned medium. 
Using ROCK inhibitor increased the cloning efficiency and enabled subcloning of 
hPSCs after genetic manipulation (Watanabe et al., 2007). The use of ROCK inhibitor 
also proved to enhance the revival of hPSCs after cryopreservation and increased 
single cells cloning after thawing (Li et al., 2008). 
1.4.3 iPSC genomic instability: 
Reports on chromosomal abnormalities and genetic mutations in different iPSC lines 
have raised concerns regarding the use of these cells in therapeutic applications 
(Yoshihara et al, 2017; Henry et al, 2019). A clinical trial to implant hiPSC-derived 
retinal cells was halted in 2015 after detecting genetic mutations in three different 




Methods for detecting genomic instability: 
G-banded karyotyping is one of the commonly used methods to detect numerical 
aberrations, including aneuploidy and polyploidy, and large structural aberrations that 
are few megabases in size (Meisner and Johnson, 2008). Array-based technologies 
such as comparative genomic hybridization and single nucleotide arrays investigate 
chromosomal copy number variations at higher resolution and can detect genomic 
abnormalities at the level of individual genes, however, they do not detect balanced 
translocation or inversion (Le Scouarnec and Gribble, 2012). More recently, the 
development of next-generation sequencing (such as whole-genome sequencing and 
whole-exome sequencing) has enabled genome-wide detection of mutations at single-
nucleotide resolution. Several studies reported a considerable load of single-
nucleotide variants in different iPSC lines using whole genome sequencing or whole-
exome sequencing (Bahutani et al, 2016; Abyzov et al, 2017; Kown et al, 2017). 
Origin of iPSC genomic variations: 
Genomic instability in iPSCs has different causes. Studies that performed sequencing 
analysis for iPSCs and compared the result to that of their parental fibroblast cells 
have shown that some of the mutations had their origin in the fibroblasts (Abyzov et 
al, 2012; Gore et al, 2011). In this case, low frequency somatic variants in fibroblasts 
become selected and expanded as a result of clonal selection during iPSC generation 
(Yoshihara et al, 2017). 
Another fraction of genetic variations in iPSCs is caused by reprogramming-induced 
mutations. Using whole genome sequencing, Sugiura et al assessed mouse iPSC 
lines and ESC lines against their corresponding parental cells. They found a 
remarkably higher number of point mutations, that were not detected in the parental 
cells, in iPSCs compared to ESCs. In addition, they investigated the variant allele 
frequencies and investigated the heterogenicity of point mutation profiles within a one 
iPSC clone through subcloning. They concluded that a considerable number of point 
mutations occur during the generation of the iPSCs, particularly at the initiation steps 
(Sugiura et al, 2014).   
iPSCs could also acquire mutations as a result of prolonged culture (i.e., passage-
induced mutations). A study that compared the sequencing analysis of one iPSC line 
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at early and late passages found four passage-induced point mutations in the late 
passages (Gore et al, 2011).  
 
1.4.4 iPSCs and ESCs differentiation: 
Removal of the essential factors that maintain the pluripotent state of the ESCs or 
iPSCs results in their spontaneous differentiation. If no specific factors were used to 
purposely direct the cells toward a particular cell fate, the pluripotent cells would 
differentiate to form Embryoid bodies (EB) in in-vitro cultures or result in teratoma 
formation if injected in-vivo. Both teratoma and EB contain heterogenous types of 
differentiated cells (obtained from the three different germ layers) including neuronal, 
heart, kidney, skin etc. In contrast to that type of differentiation, directed differentiation 
uses information obtained from developmental studies to purposely direct the cells to 
a particular cell fate, i.e. recapitulating the natural signalling events that specifically 
occur during the development of the organ of interest in-vitro. Directed differentiation 
usually implies sequential multi-step protocols. While the efficiency of obtaining any 
particular cell fate through spontaneous differentiation is low, the directed 
differentiation aims at increasing the efficiency and the yield of the cells of interest. 
1.4.4.1 Differentiation towards renal progenitors and renal organoids: 
Early studies to differentiate pluripotent cells into renal progenitors were also based 
on murine cells. Injecting tagged mESCs into the metanephric kidney of E12 and E13 
embryos demonstrated that ESCs, in response to the embryonic developmental 
signals, were integrated into tubular structures that showed positive reaction to lotus 
tetragonolobus lectin (LTL) and expressed Na/K ATPase. The same study also 
showed seldom integration of individual cells into the glomerular tufts (Steenhard et 
al., 2005). Yamamoto et al showed the expression of WD and UB markers: PAX2, 
LHX1, RET and EMX2; and the MM markers: WT1, SALL1, WNT4 and GDNF in EB 
outgrowths; when cells taken from EB outgrowths were injected retroperitoneal, they 
resulted in teratoma formation. These teratomas were excised and analysed to show 
the expression of the same genes by RT-PCR. Nevertheless, histochemical analysis 
showed that the majority of the teratoma components were either neuronal tissue, 
skeletal muscle or smooth muscle; structures with positive renal progenitor markers 
were limited and the found nephrons resembled the mesonephric nephrons more than 
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the metanephric ones (Yamamoto et al., 2006). These early studies demonstrated the 
potential of mESCs to yield renal progenitors. That pattern of differentiation, however, 
was a spontaneous or stochastic differentiation with limited efficiency to produce renal 
progenitors. 
A group of studies tried to recapitulate the sequence of molecular events that drives 
the differentiation of renal progenitors from pluripotent cells in-vitro, using kidney 
development as paradigm, to achieve directed differentiation towards renal structures 
with higher efficiency. RA, BMP, WNT signalling, FGF, and Activin are all factors that 
have been demonstrated to be essential for mesodermal specification, IM 
differentiation and metanephric kidney development. Using different combinations and 
concentrations of these factors different studies have succeeded in step-wise 
differentiation of mESCs and/or miPSCs into renal progenitors (Kim and Dressler, 
2005; Bruce et al., 2007; Morizane, Monkawa and Itoh, 2009; Nishikawa et al., 2012).  
The study performed by Batchelder et al was the first to extrapolate data from mouse 
to human; they used RA, Activin-A and BMP4 or BMP7 to direct the differentiation of 
hESCs towards renal progenitors (Batchelder et al., 2009). Recently, there have been 
some published protocols using different growth factors for stepwise directed 
differentiation of human induced pluripotent stem cells (hiPSCs) toward UB and/or 
MM, then using the obtained renal progenitors to make renal organoids.  
In 2013, Xia et al showed that mesodermal cells and subsequently UB progenitors 
could be obtained from human ESCs and hiPS cells by using BMP4 and FGF2 to 
differentiate the pluripotent cells to mesodermal cells followed by treatment with 
retinoic acid, activin A and BMP2 to drive the cells toward IM and UB renal progenitors. 
The researchers then mixed the obtained cells with dissociated mouse embryonic 
kidney cells, reaggregated the cells, cultured the pellet in 3D, and showed the 
integration of their UB differentiated cells into the collecting ducts of the self-organised 
formed organoid (Xia et al., 2013). 
Using a 9-day differentiation protocol, Morizane et al, were able to obtain MM nephron 
progenitors expressing SALL1, SIX2, PAX2 and WT1. Those nephron progenitors 
were able to form renal vesicles that matured to give different parts of the nephron 
(Morizane and Lam, 2015).  
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Takasato et al. (2014); published a protocol for simultaneous generation of both UB 
and MM cell types from PSCs in 18-day differentiation protocol using CHIR99021 
followed by FGF9 and heparin (Takasato et al., 2014). This protocol was striking as 
the UB and the MM have different developmental origin; the MM originates from the 
posterior IM while the UB originates from the anterior IM (Taguchi et al., 2014).  
A year later, the same group modified their published protocol and proposed a theory 
that shorter period of initial CHIR99021 treatment (3 days) would lead to anterior IM 
fate and would end by more UB directed fate and longer period of initial CHIR99021 
treatment (5 days) differentiates cells toward posterior IM fate and would end by more 
MM directed fate while midway between both directions using 4 days of initial 
CHIR99021 would differentiate iPSCs into both renal progenitors simultaneously. The 
CHIR99021 treatment was followed by a period of FGF9 treatment which ends by the 
simultaneous induction of UB and MM progenitors. The differentiated renal progenitors 
when dissociated and cultured in a 3D environment were able to form renal organoids 
showing positivity to different renal structures including nephrons with positive markers 
to Podocytes: WT1 and NPHS1, Proximal tubules: LTL and AQP1, Loop of Henle: 
UMOD, and distal tubules: ECAD; CDs positive to PAX2, ECAD and GATA3; renal 
stromal cells and renal vascular progenitors (Takasato et al., 2015).  
Taguchi and colleagues used a backward developmental approach in which they 
isolated T+ posterior IM cells from mouse embryos and defined the growth factors that 
induce their differentiation into MM. They used their findings to define factors to 
differentiate mESCs and hiPSCs, in a five steps protocol, into MM cells expressing 
OSR1, WT1, SIX2, HOX11, PAX2.  Apart from the length of the differentiation 
protocols (14 days for human cells and 8.5 days for mouse cells), the protocols for 
driving renal progenitors from hiPSCs and mESCs were similar. The induced nephron 
progenitors from mESCs upon culture with mouse spinal cord showed stimulation of 
nephrogenesis and formation of 3-D renal tubular structures (Taguchi et al., 2014). 
More recently, using the same backward developmental study, Taguchi and 
Nishinakamura developed a 7-step differentiation protocol to obtain UBs from both 
mESCs and hiPSCs. The backward developmental study means that they started by 
identifying factors that induce maturation in a specified developmental stage, used 
these identified factors to recapitulate that stage of maturation from an earlier one, and 
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then they moved to earlier then earlier stages to repeat the same process. After that, 
they use the defined factors to establish a step-wise differentiation protocol to obtain 
UB (or NP) from mESCs and then applied the protocol to hiPSCs (after adjusting the 
timing of each stage to suit the longer developmental periods for human embryos) 
(Taguchi and Nishinakamura, 2017).  
The establishment of directed differentiation protocols to obtain renal progenitors from 
hiPSCs has enabled the formation of renal organoids (figure 1.4). Yet, meticulous 
assessment of the functional capacity of the induced nephrons is still needed. In 
addition, the obtained renal organoids lack the organisation and complexity of the 
normal organ and there is an obvious anatomical difference between organoids and 
the native kidney; rather than having nephrons arranged around a single collecting 
duct tree with a clear exit, the organoid consists of dispersed multiple non-connected 
collecting ducts. There is an increasing interest in organising the organoid structure 

















Figure 1.4. Schematic summary of the main protocols and techniques that enabled 
the generation of renal organoids. The main achievement of each protocol or 
technique is shown in black and the limitations are shown in red.   
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1.5 Aims:  
This project builds on the current advances in stem cell research which allowed the 
generation of renal organoids from hiPSCs and has two main areas of focus: 
First, to evaluate the currently available model of hiPSC-derived renal organoids by  
- Investigating the efficiency of some of the available protocols at differentiating 
hiPSCs into nephron progenitors and ureteric bud progenitors.  
- Exploring the ability of hiPSC-derived renal organoids to perform renal tubular 
function; an aspect of renal function which is involved in eliminating uremic toxins and 
of particular importance in renal drug handling.  
- Assessing their suitability as a platform to predict nephrotoxicity. This is important as 
nephrotoxicity screening is commonly performed on animal models and monolayer 
cultures both of which have disadvantages and are not really predictive, hence it will 
be extremely useful if renal organoids could be employed for that purpose. 
The second main focus is trying to improve that model and increase its complexity and 
anatomical realism, which is important for improving the functional capacity of these 
organoids, through: 
- Developing and optimising techniques for isolating correctly differentiated UBs; this 
is an essential step towards in-vitro engineering strategies which necessitate obtaining 
pure cell populations to be used in a controlled way to build an organised structure.  
- Studying signals involved in stimulating proliferation and inducing branching in 
embryonic UBs to use the obtained information to optimise a technique to test the 









2 Materials and Methods 
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2.1 hiPSC cultures 
2.1.1 Coating culture plates with Matrigel: 
Before thawing a vial of hiPSCs, culture plates were first coated with Matrigel (Corning, 
354277). Matrigel was always handled on ice and was aliquoted using chilled pipettes 
and tips to avoid its solidification. When receiving a new bottle of Matrigel, it was 
thawed on ice in a 4C fridge overnight. The Matrigel was then aliquoted into 15 mL 
Falcon tubes according to the batch dilution factor; the dilution factor is lot specific and 
is provided in the certificate of analysis. The dilution factor typically ranges between 
270-350 μL and is used to prepare 25 mL of working Matrigel solution. As I never used 
25 mL of Matrigel working solution at a time, I usually prepared aliquots of 67.5-87.5 
μL (quarter of the recommended dilution factor; to avoid repeated freezing and thawing 
of the Matrigel aliquots). The Matrigel aliquots were kept in -20C. To prepare Matrigel 
working solution, an aliquot of Matrigel was thawed on ice, then 6.25 mL of cold 
Kockout DMEM medium (KO-DMEM; Thermofisher, 10829018) were transferred to 
the Matrigel-containing tube and the solution was pipetted up and down gently. To 
coat culture plates, 1 mL of working solution was used per 1 well of a 6-well plate. 
Coated plates were either used immediately or sealed and stored at 4C for up to one 
week. 
2.1.2 Thawing of cells: 
hiPSCs were obtained from Lonza Walkersville inc (clone SFC-AD3-01). They had 
been reprogrammed from human adult fibroblasts using Sendai virus to force the cells 
to express the four reprogramming factors, OCT3/4, SOX2, KLF4, c- MYC (Fusaki et 
al., 2009).  
A 6-well Matrigel-coated plate was allowed to warm at room temperature for 1 hr to 
allow solidification of the Matrigel. A cryo-vial of hiPSC was taken from the liquid 
nitrogen and was thawed rapidly in a 37C water bath. The cell suspension was 
transferred to a 15 mL falcon tube containing 5 mL of pre-warmed KO-DMEM medium. 
The cell suspension was dispensed gently drop by drop to the wall of the tube to avoid 
osmotic shock. Cells were then centrifuged at 180 x g for 5 minutes. The supernatant 
was discarded, and the cells were re-suspended in 2 mL of Essential 8 (E8) medium 
(life Technologies, cat. A1517001) (Chen et al., 2011) containing 10 μM ROCK 
inhibitor Y-27632 (Tocris cat. 1254; to improve the recovery of the cryopreserved cells) 
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(Claassen, Desler and Rizzino, 2009). Excess medium was aspirated from the 
Matrigel-coated well. The cell suspension was mixed gently and then transferred to 
the Matrigel-coated well. Cells were cultured at 37C in a humified incubator with 5% 
CO2. 
2.1.3 hiPSCs culture and maintenance:  
hiPSCs were maintained by daily change of the spent medium with fresh E8 medium. 
When cells reached about 85% confluency, dissociation and passaging into new 
plates was performed. 1 hour before passaging, ROCKI Y-27632 was added to the 
cells in a concentration of 10 μM to prevent dissociation induced apoptosis (Kurosawa, 
2012). After that, spent medium was removed and cells were washed in pre-warmed 
Dulbecco’s PBS (DPBS). EDTA, 0.5 mM in DPBS, was then added to the cells to 
release them from the Matrigel and the cells were incubated for 5 min at 37C. After 
removal of the EDTA, E8 medium + ROCKI was pipetted up and down to dissociate 
colonies. Cells were then re-plated on the surface of new Matrigel coated plates at a 
seeding density ranging from 1:5 to 1:10 (cells from one well were split into 5- to 10-
wells); the split ratio depended on the passage number of the cells. Higher seeding 
density was required for lower passages and lower seeding density was required for 
higher passages (cells proliferate faster with higher passages). Next morning, medium 
was changed with E8 complete medium (and ROCKI was removed) with daily 
changing of the medium thereafter.  
2.1.4 Cryopreserving hiPSCs: 
hiPSCs were expanded and a stock of cells was cryopreserved in liquid nitrogen. For 
cryopreservation, cells were dissociated as with regular passaging. Cells from 1 well 
of a 6-well plate were re-suspend in 1.8 mL of E8 medium plus ROCK inhibitor and 
were transferred to two cryovials, 0.9 mL/1 cryovial. 0.1 mL of DMSO was then added 
to each cryovial. Cryovials were then placed in an isopropanol box (Mr. Frosty) and 




2.2 hiPSCs differentiation using the Takasato protocol:  
 
To start differentiation, iPSCs were dissociated using EDTA, as described with regular 
passaging. They were then further split into a single cell suspension (through pipetting 
the cell suspension up and down 10-15 times using 5 mL pipette) then seeded on the 
surface of Matrigel coated 6, 24 or 96 well plates at a seeding density of approximately 
15,000 cells/cm2 and were kept in E8 complete medium + ROCKI for overnight. Next 
morning, differentiation was started using the published protocol of Takasato et al., 
2015. APEL medium (STEMCELL Technologies; 05210) containing 8 μM CHIR99021 
was used for three days without changing the culture media during those three days 
(as the cells tended to detach with changing media; for details see chapter 3). After 
the period of CHIR treatment, cells were treated with FGF9 (in a concentration of 200 
ng/mL) and heparin (in a concentration of 1μg/mL) until day 12 of differentiation. After 
that, all growth factors were withdrawn, and cells were kept in APEL medium without 
any growth factors until day 20-25. From the point of shifting the media to APEL + 
FGF9+ Heparin until the end of the differentiation, the medium was changed every 
other day (figure 2.1). For the experiments that were set to compare between the three 
different timings of initial CHIR99021 treatment, the same described method was 
followed with the difference that CHIR treatment was added for 3, 4, or 5 days. For the 
4- and 5-days treatment, 50% of the media was replaced with fresh media on day 
three. Changing the media during CHIR treatment and the first 3-4 days of FGF9+ 




Figure 2.1. Schematic of the Takasato differentiation protocol 
 
2.2.1 Monolayer immunostaining:  
Immunostaining was performed on samples from different stages of the differentiation 
protocol to detect the stepwise direction of differentiation from pluripotency through 
the primitive streak, IM stage and renal differentiation.  
To perform the immunofluorescence staining, the culture medium was aspirated, and 
cells were washed in PBS, then fixed using 4% PFA in PBS for 15 minutes at room 
temperature, after which cells were washed three times in PBS for 3 min each. Then 
a permeabilization/blocking step using 2% BSA and 0.3% Triton x100 in PBS solution 
was performed for 1 hr.  
Cells were then washed in PBS and incubated with primary antibodies overnight at 
4C. After incubation with the primary antibodies, cells were washed in PBS three 
times for 15 minutes each and incubated with secondary antibodies for 2 hrs at room 
temperature. At the end, cells were washed in PBS three times for 15 minutes each 
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and then were kept in PBS. Images were taken using Zeiss Axiovert fluorescence 
microscope.  
Working dilutions of the used antibodies are shown in table 2.1 (for the used primary 
antibodies), table 2.2 (for the used secondary antibodies). Antibody solutions were 
prepared using PBS containing 1% BSA.  
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Lee et al., 2013 
Goat anti- 
TROP2 
1:100 R&D(AF650) Ureteric trunk 
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1:200 R&D Systems 
(AF4269) 
















1:500 A generous gift from 
Tung-Tien Sun Lab 
(New York University) 




Table 2.2 Secondary antibodies 
Secondary antibodies Working 
dilution 
Company (catalogue number 
Horse AMCA anti-mouse 1:100 
 
VECTOR (C1-2000) 
Donkey anti-mouse 1:500 Alexa fluor 
Donkey anti-rabbit 
Alexa- 594 
1:500 Alexa fluor (A-21207) 
Donkey anti-goat Alexa- 
488 
1:500 Alexa flour (A-11055) 
 
 
1:100 SIGMA (116K6098) 
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tubules and β 
intercalated cells of 
the CD 
Engel et al., 
1997 Barresi et 
al.,1988 
 
2.2.2 Organoid formation and culture:  
For 3D cultures, cells from the monolayer were trypsinized after 7 days of 
differentiation and were dissociated into single cells, then re-aggregated by spinning 
down at 800 x g for 3 min. Cells were used at a density of 300,000 cells/ pellet.  
Pellets were then cultured on the surface of Transwell inserts (Costar, 0.4μm polyester 
membrane) at the gas-liquid interface. 1.5 mL of culture medium was added 
underneath the filter membrane. 
Pellets were cultured in APEL medium containing FGF9 (200ng/mL) and heparin 
(1μg/mL). Medium was changed every 2 days and careful attention was paid that the 
medium did not overflow the filter membrane. After 5 days of organoid culture (12 days 
of total differentiation), growth factors were removed, and organoids were kept in 
APEL medium without any growth factors for further 8-13 days to achieve a total 
differentiation period of 20-25 days.  
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2.2.3 Immunostaining of the organoids:  
The same method was used as for monolayers, with some differences made for better 
penetration of the antibodies and better staining results:  
- Methanol was used for fixation; the fixation step was performed overnight at - 
20C and before staining organoids were rehydrated in PBS for 1 hour. 
- The permeabilization/ blocking step was performed overnight instead of 1 hour.  
- The secondary antibodies were kept for overnight at 4C instead of 2 hours at 
room temperature.  
2.3 Physiological uptake assays 
2.3.1 Functional anion uptake test:  
20 day-differentiated Organoids (total differentiation including the initial period of 
monolayer culture) were tested for the proximal tubular function anion uptake test 
using 6-Carboxyfluorescein (6-CF; Invitrogen, C1360). Pellets were first washed with 
PBS then incubated with rhodamine conjugated peanut agglutinin (PNA) to outline the 
tubular structures (using a final concentration of 20 μg/mL; Vector Laboratories; RL-
1072) and 6-CF (1 μM) in PBS for 40 min at 37C. for the inhibitor treated samples, 
Probenecid (2.5 mM) was added simultaneously with the 6-CF. After that, pellets were 
washed in PBS and incubated with 8 mM probenecid for 10 min at 37C to prevent 6-
CF efflux. Pellets were washed once in PBS, transferred to a microscope slide, 
covered with a drop of PBS to prevent dryness, and were imaged immediately. 
2.3.2 Cation Uptake assay 
20 day-differentiated organoids were incubated overnight with biotin-conjugated LTL 
(Vector Laboratories; B-1325; using a final concentration of 20 μg/mL in APEL 
medium) in the culture medium to outline the proximal tubular structures. The 
organoids were then washed three times in culture media for 10 minutes each. 
Streptavidin Alexa Fluor 350 was added (Thermofisher; S11249; using a final 
concentration of 10 µg/mL) to the culture media and the organoids were incubated for 
1 hour at 37C. After that organoids were washed once for 5 minutes and then 
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incubated with 4-(4-(dimethylaminostyryl)-N-methylpyridinium iodide (ASP; 10 μM; 
D288, Invitrogen) for 30 minutes. For the inhibitor treated organoids, the OCT2 
inhibitor tetrapentylammonium chloride (TPA; 10 mM; 258962, Sigma) was first 
incubated with the organoids for 10 minutes and then ASP was added (still in the 
presence of TPA) for 30 more minutes. Organoids were then washed in ice cold PBS 
and transferred to a microscope slide and covered with one drop of ice-cold PBS and 
imaged immediately. 
 
2.4 Cryopreservation of the differentiated cells:  
To test the ability of the differentiated cells to survive cryopreservation, differentiated 
cells after 12 days or 18 days of differentiation were trypsinized and dissociated. After 
that the trypsin was neutralized using APEL medium and cells were centrifuged at 180 
x g for 5 min. Cells were suspended in APEL medium + ROCK inhibitor, 10% DMSO 
was added and cells were transferred to cryovials and were frozen in - 80C using 
slow freezing method (Miyazaki, Nakatsuji and Suemori, 2014).  
2.4.1 Thawing, culture, and organoid formation from cryopreserved cells:  
Once removed from -80C cells were rapidly thawed and transferred to a 15 mL tube 
containing 5 mL of APEL medium, mixed gently and spun down by centrifugation for 
5 min at 180 x g. After spinning down, the supernatant was aspirated, and cells were 
suspended in fresh APEL medium containing 10 μM ROCKI. Cells were counted and 
seeded on the surface of Matrigel-coated plates at a density of 300,000 cells/well of a 
24-well plate as monolayers. Next morning, medium was changed for APEL medium 
without any growth factors. 
For organoid formation the same described steps were followed but after spinning 
down the cells, the pellets were directly cultured on the surface of Transwell inserts at 
the gas-liquid interface using APEL medium + ROKI for overnight. Next morning, 
medium was changed as followed with monolayer culture.  
2.4.2 Cisplatin treatment for the cryopreserved cells: 
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12 day-differentiated cells were cryopreserved as described above. After thawing the 
cells were used to make organoids and were cultured for 10 days before the treatment. 
Organoids were treated with 0, 5, 10, 30 μM Cisplatin for 24 hrs. Organoids were then 
fixed in methanol and stained for ECAD, LTL and Cleaved caspase 3 (Cell Signalling 
Technology; 9661S). Images were taken using Zeiss epifluorescence microscope. 
2.5 Molecular Biology: 
2.5.1 RNA extraction: 
RNA was isolated using Rneasy mini kit (Qiagen; 74104) following the company 
instructions. On-column DNase1 treatment (RNase-Free DNase Set; Qiagen; 79254) 
was performed to remove contaminant DNA. The obtained RNA concentration was 
determined by measuring the absorbance at 260 nm using Nanodrop and A260/280 
ratio was calculated to evaluate the quality of the RNA (all samples had a ratio of 1.7-
2).  
 
2.5.2 cDNA synthesis (reverse transcription) for RT-PCR: 
 
A semi-quantitative reverse transcription was performed using 700 ng total RNA from 
each sample. For first strand cDNA synthesis, 0.5 μg (1μL) of Oligo DT 15 primers 
(Promega; C1101) was added to the RNA and the total volume was adjusted to 12.5 
μl using RNase free water, the tubes were heated to 70C  for 10 minutes to anneal 
the primers then the tubes were transferred to ice. M-MLV-Reverse transcriptase 
enzyme (Promega; M1701), M-MLV 5X reaction buffer, dNTPs, rNasin RNAse 
inhibitor (Promega, N251A) and nuclease free water were added to the annealed 
primer/template as shown in table 2.4 (one reaction= 25 μL total volume). The reaction 
was then mixed, and an extension step was performed by incubating the mixture at 
42C for 1 hr. the product was stored at -20C until used in PCR reaction 
 
 
Table 2.4 Reagents used for reverse transcription: 
Reagent  Final concentration used (volume) 
M-MLV 5X reaction buffer 1x (5 μL) 
dNTPs 1 mM (2.25 μL) 
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rNasin RNAse inhibitor 25 units (0.625 μL) 
M-MLV-Reverse transcriptase enzyme 200 units (1 μL) 
Annealed primer/template  12.5 μL 
RNAase- DNAase-free water 3.625 μL 
  
2.5.3 PCR for gene expression: 
Primers for OAT1 (SLC22A6), OCT2 (SLC22A2), and β-actin were kindly provided by 
Dr. Melanie Lawrence; their design was spanning an intron (hence the cDNA product 
had a different length from the genomic DNA). β-actin primers were included in each 
PCR reaction, with the primers for the target gene, as a control. 2.0 μL of the obtained 
cDNA were used in a PCR amplification reaction (total volume for one reaction= 25 
μL); 30 cycles were run using an annealing temperature of 58C. PCR product was 
analysed by running agarose gel electrophoresis (table 2.5; 2.6) (using 1% agarose in 
TAE buffer; the reaction was run at 80 volts for 40 minutes) and bands were visualised 
under a UV lamp and were photographed. 
The primer design was as follows:  
SLC22A6 (OAT1; product size 209 bp) 
Forward primer: AGTCCTTGTACATGGTGGGG 
Reverse primer: CATGCAGTTGAGGGAGATGC 
SLC22A2 (OCT2; product size 184 bp) 
Forward primer: CCGTAAGCTCTGCCTCCTAA 






















Table 2.5 Reagent list for RT-PCR reactions 
Component Volume (final concentration) 
cDNA 2 μL  
Go Taq green reaction buffer 5 μL  (1x) 
dNTP mix 10mM 0.5 μL (0.2 mM) 
B-actin F primer 0.4 μL  
B-actin R primer 0.4 μL 
Transporter gene F primer 1.1 μL  (0.5 μM) 
Transporter gene R primer 1.1 μL  (0.5 μM) 
Go Taq G2 DNA polymerase 0.25 μL (1.25U) 
dsH20 14.25 μL 
total 25 μL 
 
Table 2.6 Thermocycling conditions for RT-PCR 
Step                        Temperature time 
Initial denaturation   95C 2 min 
Denaturation             95C 30 s 
Annealing                 58C 30 s 
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Extension                  72C 1 min 
final extension         72C 7 min 
 
2.5.4 RNAseq analysis 
RNAseq, and trimming, filtering and normalization of raw data, was performed by 
Edinburgh Genomics. 1 ug of total RNA/sample was used for sequencing library 
preparation using Illumina TruSeq stranded mRNA kit. Sequencing was performed 
using Novaseq S1 50 Paired-end run to produce 50-64 million read pairs/sample. 
Reads were trimmed using Cutadapt (version cutadapt-1.9.dev2) and were aligned to 
the Homo Sapiens reference genome (GRCh38; from Ensembl) using STAR (version 
2.5.2b). The annotation used for counting was the standard GTF-format annotation for 
the reference genome (annotation version 84). Reads were assigned to features of 
type ‘exon’ in the input annotation grouped by gene_ID in the reference genome using 
featureCounts (version 1.5.1). The raw count data were filtered to remove very low 
expressed genes (genes consisting predominantly of near-zero counts), filtering was 
performed on counts per million to avoid artefacts due to library depth. Reads were 
normalised using the weighted trimmed mean of M-values method. Differential 
analysis (comparing the low-treated group to the control group, or the high-treated 
group to the control group) was carried out using edgeR4 (version 3.20.1). Fold 
changes were estimated as per the default behaviour of edgeR, to avoid artefacts 
which occur with empirical calculation. Statistical assessment of differential expression 
was carried out with the quasi-likelihood (QL) F-test. 
To analyse the upregulated genes in the high-treated versus the control contrast, I first 
filtered the differentially expressed genes by the lowest FDR, selected the 400 most 
significant genes, and then picked the 100 most upregulated genes (out of the 400 
most significant genes) and used them for downstream analysis. I used these 100 
most significant upregulated genes to performed PANTHER Overrepresentation Test 
using the annotation version GO Ontology database (release date 2018-10-08). For 
the functional classification, the same list of genes was used in a Panther functional 
classification analysis selecting the ontology Biological Process and the ontology 
Molecular Function. 
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2.5.5 CRISPR-Cas9 editing of HMOX1 gene in hiPSCs 
The targeting vector was designed to contain a 2A-peptide-mCherry-STOP cassette 
flanked by homologous 5’ and 3’ arms upstream (500bp) and downstream (1049bp) 
of the endogenous stop codon of the HMOX-1 gene in the hiPSCs. The vector was 
synthesized by IDT company and then subcloned into pUC18 for transfection 
(Addgene, cat. no. 50004). Guide RNAs (gRNAs) were designed using the Zhang lab 
resource (crispr.mit.edu). Undifferentiated hiPSCs were co-transfected in equimolar 
amounts with the Cas9-GFP (pCas9_GFP; Addgene, cat. no. 44719) and gRNA 
plasmids together with the targeting vector containing the repair template. After letting 
the cells recover and proliferate for 72h, cells were treated with hydrogen peroxide to 
induce oxidative stress (0, 25 or 150mM; Fisher Scientific, cat. no. BP2633-500) and 
then sorted using FACS to isolate the mCherry-targeted population. Control hiPSCs 
(wt) that had not been targeted were used as a control for gating. The enriched 
populations were recovered and expanded for a further 7 days. The low but detectable 
basal level of HMOX-1 expression in undifferentiated hiPSCs allowed the sorting of 
single, weakly mCherry-positive hiPSCs into wells of a 96-well plate without needing 
to first induce oxidative stress. Wild type (untargeted) hiPSCs (AD3) were again used 
for gating. After a further 7 days, 24 clonal populations from the single-cell sorting by 
FACS had survived and expanded. These were further expanded into individual wells 
of a 6-well plate. PCR, using primers designed to span the targeted region, was used 
to confirm that the reporter cassette had been integrated. The product size without 
cassette insertion is 1654bp, whereas product size with insertion is 2428bp, as 
expected. Clones were sequenced using primers spanning the homologous arms and 
the inserted cassette (the design and production of this cells line was done by Shuwan 
Liu; an MSC student in our lab, with the help of Dr. Melanie Lawrence). 
 
2.5.6 GATA3 gene targeting strategy: 
For details about the design of the gRNA and the repair template plasmid see chapter 
6, section 6.3 
2.5.6.1 Genomic DNA extraction from hiPSCs: 
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hiPSCs were dissociated from an 80% confluent well of a 6-well plate using the regular 
dissociation steps described earlier. The obtained cells were centrifuged at 300 x g for 
5 minutes, the supernatant was discarded, and cells were re-suspended in 200 μL 
PBS. DNA isolation was then performed using DNeasy Blood and Tissue Kit (Qiagen, 
69504) according to the manufacturer protocol. The obtained DNA concentration was 
measured using a Nanodrop and was stored at -20C for PCR. 
2.5.6.2 Targeting plasmid design and primer design: 
GATA3 cDNA sequence was obtained from Ensemble (www.ensembl.org). The repair 
template was designed with the help of Geneious Prime software. The primers for the 
upstream segment (segment 1), the downstream segment (segment 5) and the 
antibiotic selection cassette segment (segment 4) were designed using NEB builder 
assembly tool (nebuilder.neb.com). The Gibson assembly master mix settings were 
used. The primer design included overhang areas to amplify overlapping segments to 
be assembled in Gibson reaction.  Selected primers for segment 1 and 5 were checked 
for unspecific binding with BLASTn (after excluding the overhang areas) (segment 4 
was amplified from a plasmid). The list of primers used for this work is shown in table 
2.7 
Table 2.7 list of primers used for amplifying the constructing segments of the GATA3 
targeting plasmid 


















FP:   TTTCTAGGGTTAACAGGGTCTCTAGTGCTGTG 
 






Segment 2 and segment 3 were synthesised by IDT and were obtained as gBlocks. 
(the cDNA sequence for the GATA3 gene, the sequence for the PMSC-AAT-PB-PGK 
plasmid, from which segment 4 was amplified, and the sequence for the designed 
segments and the cloning vector are included in the appendix of this thesis). The PCR 
reaction was performed using Q5 high fidelity enzyme (NEB, M0492L). The PCR 
reaction reagent list and concentrations are shown in table 2.8. The obtained amplified 
products were gel purified using QIAquick Gel Extraction Kit (Qiagen, 28704) 
according to the manufacturer instructions and the purified segments were measured 
using a Nanodrop instrument. 
 
Table 2.8 Reagent list and concentrations for PCR reactions to amplify the GATA3 






Q5-high fidelity 2x master 
mix 
25 μL (1 x) 
Forward primer 2.5 μL (0.5 μM) 
Reverse primer 2.5 μL (.05 μM) 
Template DNA Variable (50 ng) 




2.1.1.1. Gibson assembly: 
The DNA segments were included in a cloning reaction using Gibson assembly master 
mix (NEB, E2611S). The reaction was performed following the kit instructions. The 
vector was used in a concentration of 100 ng. The number of pmols were calculated 
for each fragment using NEB calculator (http://nebiocalculator.neb.com). The vector 
was used in a concentration of 100 ng (0.057 pmols) and the segments were used in 
a 2-3-fold of excess with the shorter segments being used in a higher ratio (as 
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recommended by the company). The fragments were mixed with 10 μL of the Gibson 
assembly master mix and the total volume was adjusted to 20 μL using deionised 
water. The reaction was incubated at 50C for 1 hr, then was stored at -20C and was 
used for transformation. 
2.1.1.2. gRNA design and cloning 
Two gRNAs were designed using the Zhang lab resources ((https://zlab.bio/guide-
design-resources). The sequence of the selected gRNAs was as follows: 
gRNA1 sequence: GATGGCGGGTGCATCGGCGTGGG 
gRNA2 sequence:  ACCCATGGCGGTGACCATGCTGG 
The selected sequence was sent to IDT for synthesising as gBlock following the 
addgene gRNA synthesis protocol (media.addgene.org). The obtained gBlocks were 
shortly spun down for 15 seconds then TE buffer was added, to achieve a final 
concentration of 25 ng/mL. The mixture was vortexed for 15 seconds then incubated 
at 50C for 20 minutes to resuspend the pellet. The reconstituted gBlock was vortexed 
for 15 seconds then centrifuged at 800 x g for 3 minutes. The reconstituted gBlocks 
were then cloned into PCR-Blunt II-TOPO (Thermofisher, K280040). Blunt II-Topo 
cloning is a Topoisomerase I-based ligation that is designed to clone blunt-ended DNA 
fragments. The cloning reaction was performed according the company instructions 
and was as follows: 2 μL of the reconstituted gBlock were mixed with 2 μL of water, 1 
μL of salt solution (provided in the kit) and 1 μL of the Blunt II-Topo vector. The reaction 
mixture was incubated for 5 minutes at room temperature and then was used in a 
bacterial transformation reaction. 
2.5.6.3 Bacterial transformation and plasmid purification:   
Top 10 chemically competent E-coli (Thermofisher, C404003) were used for 
transforming the cloned Blunt II-Top vector (after the insertion of the gRNA gBlocks). 
5-alpha Competent E. coli (NEB, C2987H) were used for the transformation of the 
Gibson-cloned targeting plasmid. For both cases the protocol was the same. The 
bacterial cells were thawed on ice for 10 minutes. 2 μL of the plasmid DNA (~ 50 ng) 
were added to the tube of the bacterial cells. The tubes were gently flicked to mix the 
DNA and the bacterial cells. The tube was incubated on ice for 30 minutes, then heat-
shocked at 42C for 30 seconds and was placed back on ice for two minutes. 
Afterwards, 250 μL of SOC media were added to the bacterial cells (with no antibiotic 
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added) and the cells were incubated at 37C for 1 hr in a shaking incubator (to allow 
the bacteria to develop the antibiotic resistant encoded on the plasmid before plating 
on antibiotic selection agar plates). The bacterial suspension was then spread over 
the surface of 10 cm LB agar plates (containing the selection antibiotic encoded on 
the transformed plasmid; Kanamycin in the case of the Blunt II-Topo vector, and 
Ampicillin in the case of the Gibson-cloned plasmid). Two plates were inoculated with 
different densities of the bacterial cells to give better chance for getting single colonies.  
One plate   was inoculated with 100 μL of the bacterial suspension and the other plate 
was inoculated with 10 μL of the bacterial suspension diluted with 90 μL LB medium. 
The bacterial plates were incubated overnight at 37C.  
In the morning, single colonies were picked from the bacterial plates and each colony 
was resuspended in 50 μL water. Of these 50 μL bacterial suspension, 45 μL were 
inoculated into 4 mL LB medium (containing the selection antibiotic encoded on the 
transformed plasmid) and the remaining 5 μL were used in a PCR reaction to check 
for the incorporation of the gRNA gBlocks (in the case of Blunt II-Topo) or a middle 
segment of the GATA3 targeting plasmid (in the case of the Gibson-assembled 
targeting plasmid). The 4 mL of LB medium that have been inoculated with the 45 μL 
bacterial suspension were incubated in a shaking incubator at 37C overnight. In the 
morning, the bacterial suspensions were used in a miniprep reaction (Qiagen, 27104) 
to purify the plasmid (following the company instruction), the obtained plasmid was 
then analysed using restriction enzyme analysis. For the gRNA-Blunt II-Topo cloned-
plasmid, I obtained positive results both from the PCR reaction and from the miniprep 
purification and the restriction analysis, so, one colony for each gRNA-Blunt II-Topo 
cloned-plasmid was further amplified in a 200 ml of LB medium containing the 
selection antibiotic and the plasmid was purified using Maxiprep kit (Qiagen, 12963). 
The purified plasmid was analysed using restriction enzymes (EcoR I, cuts on both 
sides of the gRNA gBlock insert and Sal I, cuts in the plasmid backbone) and gel 
electrophoresis which. 
2.6 Nephrotoxicity compound screening: 
A panel of 7 compounds was used for the blind-coded validation, selected and 
supplied by an industrial company without revealing their identities, and was as 
follows: Cidofovir (cat no C5874), Cisplatin (cat no C2210000), Dexamethasone (cat 
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no D1756), Gentamicin (cat no G1264), Ifosfamide (cat no I4909), Ketoprofen (cat no 
K1751) and Puromycin (cat no P7255); all from Sigma-Aldrich. The compounds were 
divided into 3 groups based on their therapeutic Cmax values (Sjögren et al.,2018) 
and concentration ranges were designed accordingly: 0.375-24 µM for 
Dexamethasone and Puromycin, 6-384 µM for Cisplatin, Gentamycin and Ketaprofen, 
24-1536 µM for Cidofovir and Ifosfamide. These concentrations were also in 
accordance with what have been used in other toxicological studies (see discussion 
of chapter 5 and references in there).  A four-fold dilution series was prepared  for 
each compound (obtained lyophilized) and HMOX1-mCherry-hiPSC-derived renal 
cells (2D and 3D) were incubated in these dilutions for either 24h or 72h. Untreated 
control samples were included for each compound, time-point and culture type (2D or 
3D).  
 
2.7 GDNF conjugation: 
Microscale protein labelling kit was used for the conjugation (Thermofisher Scientific; 
Alexa fluor 488, A30006). Carrier-free GDNF protein (R&D; 212-GD-050/CF) was 
reconstituted to a concentration of 1mg/mL in PBS and the labelling was done 
following the instruction of the protein labelling kit. 45 µL of the GDNF was transferred 
to a reaction tube and 4.5 µL of 1 M sodium bicarbonate was added. 7 µL of freshly 
prepared Alexa fluor 488 TFP esters (11.3 nmol/µL stock solution) was added to the 
reaction tube and the reaction mixture was incubated for 25 minutes at room 
temperature. Afterwards, the reaction mixture was transferred to a spin filter with resin 
bed and was centrifuged at 16,000 x g for 1 min to purify the conjugated protein and 
remove the unreacted dye. 
To determine the concentration of the recovered protein, I first used Nanodrop 2000 
spectrophotometer to measure A280 of the protein before and after conjugation (to be 
used in this equation: Protein concentration (in mg/mL) = (A280 – 0.11(A494)) / (A280 
of protein at 1 mg/mL), however A280 of the protein at 1mg/ml was very low and so 
was difficult to determine accurately using the Nanodrop (0.38±0.2). Alternatively, the 
concentration of the recovered protein was estimated based on the expected % yield 
of the protein based on its molecular weight using this equation: concentration of the 
labelled protein (in mg/mL) = (mass (mg) starting protein × % yield) / (volume of the 
recovered protein in mL). The estimated concentration of the conjugated protein was 
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400 µg/mL. The degree of labelling was calculated using this equation: DOL = A494 / 
(71,000 × protein concentration (M)). The obtained degree of labelling was 
approximately 2.5 moles of dye/mole of protein. 
For testing the efficiency of labelling, mouse embryonic kidneys were treated with 100 
ng/mL conjugated protein in the culture media and were incubated for 1 hr, 4 hrs, or 
overnight. The embryonic kidneys were then washed three times in culture media for 
5 minutes each and were imaged. 
For tagging the UB-differentiated structures, 22-25 day-differentiated cells were 
treated overnight with 100 ng/mL conjugated GDNF in the culture media at 37C, then 
they were washed three times for 5 minutes each and imaged using Zeiss Axiovert 
fluorescence microscope. 
The live-stained UB-like structures were then dissected under fluorescent 
microdissection microscope and were used either for re-aggregation with sorted 
nephron progenitors or for testing branching competence (explained in section 2.11) 
2.8 Embryonic UB isolation and culture in gel: 
2.8.1 Dissection of mouse embryonic kidneys:  
The uterine horns of E11.5 pregnant mice (CD1) were collected (the morning of the 
vaginal plug appearance is counted as E0.5) and transferred to a 10 cm Petri dish that 
contains minimum essential media (MEM; Sigma-Aldrich, M5650).  Embryos were 
extracted from the uteri using forceps and a surgical blade. Further dissection was 
carried out under microdissection microscope (Zeiss Stemi-2000) using 25-gauge 
needles attached to 1 mL syringes. First the embryos were decapitated. The 
decapitated embryos were then cut horizontally between the upper limb buds and the 
hind limb buds. The caudal parts of the embryos were transferred to a new petri dish 
with a fresh medium and the tails were removed. Then the rear-end fragments were 
cut along the midline into right and left sides to expose the metanephric kidney 
rudiments. Kidney rudiments were identified and dissected out carefully (figure 2.3).  
2.8.2 Isolation and culture of embryonic UBs 
Isolated metanephric kidney rudiments were transferred to a 30 mm Petri dish 
containing Trypsin EDTA and were incubated at 37C for 5-7 minutes. Afterwards 
 85 
metanephric kidney rudiments were transferred to a 60 mm petri dish containing 
kidney culture medium (KCM: MEM medium containing 10% foetal bovine serum and 
1% penicillin/streptomycin) to stop the enzymatic action of the trypsin. The UBs were 
dissected free of the surrounding MM using fine needles. The isolated UBs were 
collected in a 30 mm petri dish containing fresh medium and were cut into single tips. 
The separated UB tips were then transferred to 96-well plate containing GFRM 
(Corning 354230; 60 µl/well) and were cultured suspended in Matrigel (after 
transferring the UB tip to the Matrigel, the plate was carefully turned upside down for 
~ 30 sec -1 min to prevent the tip from sinking to the bottom of the well (as this alters 
the pattern of branching); the Matrigel stayed as a hanging drop when the plate was 
inverted). Adding the Matrigel to the wells and transferring the isolated tips to the 
Matrigel containing wells was performed one well at a time to avoid solidification of the 
Matrigel before transferring the isolated tip. After transferring all the UB tips to the 
Matrigel, the plate was incubated at 37C for 10 minutes to allow for Matrigel 
solidification. After solidification of the Matrigel, branching basal medium containing 
the indicated tested growth factors was added to the Matrigel-suspended UB tips. The 
branching basal medium composition was as follows: Ad DMEM/F12 (Thermofisher, 
12634010) containing 1X antibiotic antimycotic (Gibco 15240-096), 1X B27 minus 
vitamin A (Gibco 12587-010), 1X N2 supplement (Gibco 17502-048) and 1mM 
nicotinamide (Sigma). The following growth factors were added as indicated in chapter 
7 (section 7.3.1): 125 ng/mL GDNF (Peprotech, 450-10), 250 ng/mL FGF1 (Peprotech, 
450-33A), 1 µM CHIR99201 (Tocris, 4423), 0.5 µM RA (Sigma) and 0.5 µM 9-cis-
retinol (Sigma).   
 86 
 
Figure 2.2. Illustration of metanephric kidney rudiments isolation. a) Uterine horn. b) 
Embryos are being extracted from the uterine horn. c) An extracted E11.5 embryo. d) 
The rear-end of the embryo after decapitation and removing the upper part of the 
embryo. e) The rear-end fragment of the embryo after cutting it in the midline into right 
and left halves; the arrow points to the metanephric kidney rudiment. f) An isolated 
E11.5 metanephric kidney. Scale bar is 5 mm for (a-c), 1mm for (d,e), and is 0.5 mm 





2.9 hiPSC differentiation towards UB progenitors using the 
Taguchi protocol of differentiation:  
Accutase enzyme (Thermofisher, A1110501) was used to dissociate hiPSCs. The 
dissociated cells were suspended in step 1 medium and were cultured at a density of 
10,000 cells/well of a V-bottom 96-well low cell attachment plate (Alphalaboratories, 
MS-9096V). The differentiation basal medium was composed of Ad DMEM/F12 
containing 1X B27 supplement minus vitamin A supplement, 2 mM L-Glutamine, 1% 
ITS, 1%NEAA, 90 µM 2-mercaptoethanol and 1% antibiotic antimycotic. For step 1 
differentiation, the following growth factors were added to the differentiation basal 
media: 10 µM Y27632, 10 ng/mL Activin A and 1 ng/mL BMP4. After 24 hrs, the re-
aggregated cells were transferred to a new U-bottom 96-well plate and step 2 medium 
was added (differentiation basal medium with 1 ng/mL BMP4 and 10 µM CHIR99021). 
Cells were kept in step 2 differentiation medium for 36 hrs and were then switched to 
step 3 medium (0.1 µM RA, 100 ng/mL FGF9, 100 µM SB431542, and 100 nM 
LDN193189 in differentiation basal medium). Cells were kept in step 3 differentiation 
medium for 48 hrs and then the medium was changed to step 4 differentiation medium 
containing 0.1 µM RA, 100 ng/mL FGF9, 5 µM CHIR and 30 nM LDN193189. After 42 
hrs, spheroids were dissociated and CXCR+/KIT+ cells were FACS sorted (see 
section 2.10 for details of the FACS-sorting). The sorted cells were suspended in step 
5 medium and were cultured in V-bottom 96-well low attachment plates in a density of 
5,000 cells/well. Step 5 medium contained the following growth factors: 10 μM 
Y27632, 0.1 µM RA, 1 µM CHIR, 5 ng/mL FGF9, 100 ng/mL FGF1, 10 nM LDN and 
10% GFRM. After 48 hrs, medium was changed to step 6 medium containing 10 μM 
Y27632, 0.1 µM RA, 3 µM CHIR, 5 ng/mL FGF9, 100 ng/mL FGF1, 10 nM LDN, 1 
ng/mL GDNF, and 10% GFRM. Spheroids were cultured in step 6 medium for 48 hrs 
and were then switched to step 7 medium containing 10 μM Y27632, 0.1 µM RA, 3 
µM CHIR, 100 ng/mL FGF1, 10 nM LDN, 2 ng/mL GDNF, and 10% GFRM (figure 2.4). 
At the end of the differentiation protocol the spheroids showed outgrowing buds. Single 
buds were dissected from the periphery of the spheroids using fine needles and were 
suspended in Matrigel and cultured in branching inducing medium (see section 2.11 
for more details about the culture procedure). 
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Figure 2.3. Schematic the Taguchi differentiation protocol for obtaining hiUBs 
 
 
2.10 Maintenance and passaging of mESCs: 
E14 mESCs were obtained from Professor John Mason lab. The cells were maintained 
in feeder-free culture conditions on the surface of gelatine-coated plates. Six-well 
plates were coated with 0.1% gelatine in PBS (1mL/ well) and were kept in room 
temperature for 1 hr before using to allow for polymerisation of the gelatine. Cells were 
seeded on the surface of gelatine-coated plates and were maintained in Glasgow 
minimum essential medium (GMEM; Sigma Aldrich, G5154) containing 10% FBS, 1X 
non-essential amino acids, 1X Glutamax, 1X sodium pyruvate, 0.1 mM 2-
mercaptoethanol, 1 % penicillin/streptomycin and 1 U/μl leukaemia inhibitory factor 
(LIF; Santa Cruz, SC-4989). Spent medium was changed daily and cells were split 
when they reached 80-90% confluence.  For passaging mESCs, cells were washed 
once in PBS and were then incubated with Accutase enzyme (Thermofisher; 
A1110501) for 5 minutes at 37C. Cells were then detached by pipetting up and down. 
The cell suspension was added to mESC maintenance medium (containing 10% 
serum) to stop the enzymatic reaction. The cell suspension was centrifuged at 180 x 
g for 5 min. The supernatant was discarded and cells were re-suspended in fresh 






2.10.1 mESC differentiation towards UB progenitors using the Taguchi 
protocol of differentiation: 
 
mESCs were dissociated using Accutase enzyme and were cultured at a density of 
2,000 cells/well of a 96-well U-bottom low cell-binding plates to form EBs in the 
differentiation basal medium. The differentiation basal medium was composed of 75% 
IMDM (Thermo Fisher scientific 12440-046) and 25% HAM’s/F12 (Thermo fisher, 
11765054) containing: 0.5X N2 supplement (Gibco 17502-048), 0.5X B27 supplement 
without vitamin A (Gibco 12587-010), 1X Antibiotic/Antimycotic (Gibco 15240-096), 
0.05% BSA (Gibco 15260-037), 2mM L-glutamine, 0.5mM Ascobic Acid (Sigma 
A4403), and 4.5 X 10-4 M 1-thioglycerol (Sigma M6145-25mL). 
After 48, the medium was changed to differentiation medium containing 10 ng/mL 
Activin A (R&D, 338-AC; Step 1) and spheroids were cultured for 24 hrs. Afterwards, 
the culture medium was changed to Step 2 medium (differentiation medium containing 
0.3 ng/mL BMP4 (R&D 314-BP-010) and 10 µM CHIR (Tocris, 4423) which was kept 
for 36 hrs. The medium was then switched to Step 3 medium (composed of 
differentiation medium containing 0.1 µM RA (Sigma, R2625), 100 ng/mL FGF9 (R&D, 
273-F9) and 10 µM SB431542 (Tocris, 1614)). After 24 hrs, step 4 medium was added 
(differentiation medium containing 0.1 µM RA, 100 ng/mL FGF9 and 5 µM CHIR) and 
spheroids were cultured in that medium for 18 hrs. Afterwards, CXCR+/KIT+ cells were 
FACS-sorted (see section 2.10 for details of the FACS-sorting) and the obtained cells 
were suspended in step 5 medium (containing 10 μM Y27632 (Tocris, 1254), 0.1 µM 
RA, 1 µM CHIR, 5 ng/mL FGF9, and 10% growth factor reduced Matrigel (GFRM; 
Corning, 354230)) and were cultured in U-bottom 96-well plates at a density of 3,000 
cells/well for 24 hrs. Cells were then switched to step 6 media (differentiation media 
containing 10 μM Y27632, 0.1µM RA, 3 µM CHIR, 5ng/mL FGF9, 1 ng/mL GDNF and 
10% GFRM) and were cultured for 24 hrs. Medium was then changed to step 7 
medium containing 10 μM Y27632, 0.1µM RA, 3 µM CHIR, 2 ng/mL GDNF and 10% 
GFRM. After step 7, spheroids were obtained and single buds were dissected from 
the periphery of the spheroids and were suspended in Matrigel and cultured in 





Figure 2.4. Schematic for the Taguchi differentiation protocol for obtaining miUBs 
 
2.11 FACS-sorting of mESC-derived and hiPSC-derived WD 
progenitors: 
At the end of step 4, the obtained spheroids (both from the mouse and the human 
protocols) were collected, washed once in PBS then transferred to a 30 mm petri dish 
containing 1X Trypsin EDTA and were incubated at 37 C for 5 minutes. The 
trypsinized spheroids were moved to a 15 mL falcon tube containing PBS + 5% foetal 
bovine serum (to stop the trypsin action) and were dissociated into single cells by 
pipetting up and down several times. The cell suspension was then passed through a 
cell strainer to ensure single cell suspension. The Cell suspension was spun down, 
the supernatant was discarded, and a blocking step was performed by incubating the 
cells in PBs containing 5% BSA at room temperature for 15 minutes. Cells were 
incubated with the surface markers CXCR4 (in case of mouse cells: Biolegend, 
146507; used dilution: 0.5 ug/100 µl volume. In the case of human cells: Biolegend, 
306510) and c-Kit (in the case of mouse cells: Bioscience, 12-1171-82; 0.125 ug/100 
µl volume. In the case of human cells: Biolegend, 313204) for 20 minutes on ice 
protected from light. PBS containing 1% BSA was used as the staining buffer. After 
staining, cells were washed twice with the staining buffer. The stained cells were then 
FACS analysed and the CXCR4+/c-KIT+ were sorted. The double positive cells were 






2.12 Testing branch-competence of human induced UBs (hiUBs) 
and mouse induced UBs (miUBs): 
Single isolated hiUBs (obtained either using the Takasato protocol of differentiation or 
the Taguchi protocol of differentiation) and miUBs (obtained using the Taguchi 
protocol for differentiating mESCs) were dissected (as described above) and were 
embedded in GFRM (as described above in section 2.7.2). After solidification of the 
Matrigel, branching basal media (see above) containing the following growth factors 
were added to the Matrigel-embedded UBs: 125 ng/mL GDNF, 250 ng/mL, 1 µM 
CHIR, 0.5 µM RA, and 0.5 µM 9-cis-retinol. The medium was changed every other 
day. hiUBs (both obtained using the Takasato protocol or the Taguchi protocol) were 
kept in culture for 14 days. miUBs were kept in culture for 7 days. The cultured UBs 
were imaged every other day during the duration of treatment. At the end of the culture 
period some of the obtained branched structures were extracted from the Matrigel and 
were fixed and stained (using the staining protocol described in 2.2.3). 
For propagating miUBs in Matrigel, branched miUBs (1st generation miUBs) were 
extracted from the gel, after 7 days of gel-culture, and single buds were dissected from 
their periphery and were embedded in Matrigel and cultured following the same 
procedure described above (2nd generation miUBs). The whole process was repeated 
after 7 days of gel-culture and 3rd generation miUBs were obtained and cultured 
embedded in Matrigel treated with branching inducing growth factors. 
2.13 Examining the ability of miUBs to induce nephron formation 
by aggregation with embryonic MM: 
Embryonic E11.5 metanephric kidney rudiments were dissected as described in 
section 2.7.1. The obtained metanephric rudiments were trypsinized for 2 minutes at 
37C and were then transferred to a 60 mm Petri dish containing KCM medium to stop 
the trypsin action. The MM was isolated from the embryonic UB using fine needles. 
Only kidneys that I was able to isolate and remove their UBs as intact whole T buds 
were used to avoid having embryonic UB cells within the mesenchymal cells. The 
mesenchymal cells were collected in an Eppendorf containing KCM medium and were 
dissociated by pipetting up and down several times. The cell suspension was then 
passed through a cell strainer to ensure obtaining single cells. Mesenchymal cells 
obtained from six metanephric kidney rudiments were used for constructing one 
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kidney organoid after re-aggregation with miUB. Single isolated miUBs were obtained 
by dissection either from a spheroid after the end of step 7 differentiation (as described 
in section 2.9.1) or from a branched 1st generation miUB extracted from the Matrigel 
(as described in section). In the case of extracting a branched 1st generation miUB 
from Matrigel, the dissected isolated miUB tips were cleaned from the surrounding 
Matrigel as much as possible using fine needles. The isolated single miUB tips were 
transferred to a U-bottom 96-well ultra-low attachment plate, 1 miUB tip/well, in KCM 
medium. The single cell suspension of the MM cells was centrifuged at 800 x g for 3 
min. The obtained pellet was picked and was transferred to the 96-well that contains 
the isolated miUB tip. The mesenchymal cells and the miUB tip were cultured in the 
U-bottom 96-well plate for 24 hrs to aggregate and form a spheroid. After 24 hrs, the 
aggregated spheroid was transferred to the surface of a transwell insert and was 
cultured in KCM for 4-7 days. The constructed kidney organoid was then fixed in ice-
cold methanol for 20 minutes at room temperature and was stained. 
2.14 Reprograming miUBs into urothelial fate: 
Branched 1st generation miUBs was extracted from the Matrigel after 7days of culture 
in the branching inducing medium. Single miUB tips were isolated from their periphery 
and were embedded in Matrigel and cultured as 2nd generation miUBs (as described 
in section 2.11). The miUBs were divided into two groups, the control group which was 
cultured in branching inducing medium (as described in 2.11), and the BMP4-treated 
group which was cultured in branching inducing medium to which 100 ng/mL BMP4 
was added. miUBs from both groups were cultured for 7 days during which the culture 
medium was changed every other day. At the end of the treatment duration, miUBs 
from both groups were extracted from Matrigel and were fixed in ice-cold methanol for 
20 minutes at room temperature then they were stained for Uroplakin (UP) and Gata3. 
2.15 Imaging and fluorescence quantification: 
2.15.1 Microscopes: 
Images were taken using either a Zeiss Axiovert epifluorescence microscope, a Zeiss 




2.15.2 Image processing: 
Image processing including splitting channels, channel merges, quantification, image 
adjustments, producing z-project from a stack image was performed using fiji (fiji.sc). 
2.15.3 Fluorescence quantification: 
All images used for fluorescence intensity analysis, within one experiment, were taken 
with identical exposures and settings. 
For quantifying Cleaved Caspase 3, in cryopreserved organoids in response to 
Cisplatin treatment, first images were split into separate channels. The channel for 
ECAD and LTL were then merged and were converted into grey scale, then a 
threshold was set on that channel using the default adjustment setting (that marked 
all the tubular structures in the organoids). A selection was then created on the marked 
area and that selection was transferred to the Cleaved Caspase 3 channel; the 
fluorescence in the selected area was quantified (that corresponded to all the Cleaved 
Caspase 3 signal inside the tubular structures of the organoid and excluded all the 
signal in the interstitium). This was done to limit the quantification to the inside of the 
tubular structures as a variable number of apoptotic interstitial cells could be seen in 
untreated organoids (Takasato et al., 2015) which would affect the total fluorescence 
if no selection was done. This method of quantification excludes Cisplatin-induced 
apoptosis in the interstitial cells; however, the main aim was to measure the response 
of the induced renal tubules to the toxic drug. An example of the quantification is 
shown in (figure 2.2). 
For quantifying fluorescence as a measure of HMOX1 expression, in the 
nephrotoxicity screening experiment, fluorescent images were taken after 24h or 72h 
of treatment. Each sample was imaged either 5 times with 4 replicates (2D cultures, 
24h), once with 10 replicates (2D cultures, 72h), once with 3 replicates (3D organoids, 
24h) or 3 times with 3 replicates (3D organoids, 72h).  To quantify fluorescence, a 
macro was used with a threshold value of 400-4059 to exclude the dark pixels, and 
the total fluorescence was measured. Before applying the macro, a random sample of 
images of each compound, both 2D and 3D, were manually tested for the threshold 
value to make sure that this value covered all the fluorescent signal in the image. 
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Figure 2.5. Illustration of the fluorescence quantification method: CDH1+ve and LTL+ve 
tubules were selected and then Caspase 3 total fluorescence was measured inside 
this area (excluding fluorescence outside tubular structures). 
 
2.16 Statistical analysis: 
Data analysis and producing graphs was performed using Prism 8 (GraphPad Prism 
Software Inc., La Jolla, CA, US).  Normality of the data was confirmed using 
Kolmogorov-Smirnov’s test and Shapiro-Wilk’s test. To compare between different 
treated groups, one-way ANOVA Welch was used with Dunnett’s multiple 
comparisons post-test correction to compare data between three or more groups. To 
compare between two groups, an unpaired t test with Welch’s correction was 
performed. Welch’s modification corrects for unequal variance and it is advised to be 
performed when the compared groups have different standard deviation. When data 
do have equal variance ANOVA Welch also have equal power to one-way ANOVA or 
t test (Welch, 1951; Ruxton, 2006). Data are presented as mean ± SD. 
For analysing categorical data (absence or presence of UB fate or UB branching) 95% 
confidence interval was calculated and data are presented as mean, upper and lower 
limit of the confidence interval. The 95% confidence interval is a method to quantify 
the uncertainty of observations. When an experiment that has two possible outcomes 
(success and failure, or presence and absence of a specific feature) is repeated a 
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specific number of times, the result, of success or failure, is expressed as a proportion. 
This proportion is the observed binomial proportion. The observed proportion is 
obtained from random sampling (each observation denotes a sample of the 
population); the confidence interval predicts the true proportion in the whole 
population. The 95% confidence interval estimates a range of possible proportions; 
the probability of observing a value outside this range is less than 0.05. There are 
different formulas to calculate the confidence interval of a proportion; although the aim 
is to obtain 95% confidence interval, the actual coverage probability (obtained from 
any given formula) differs depending on the specific value of n (number of trials) and 
p (the observed sample proportion). The Wilson score interval is a commonly used 
formula (Wilson, 1927); the actual confidence interval of this formula equals, on 
average, the requested one (95% interval in this case). An exception to this is when p 
is close to 0 or 1 where the coverage shows downward spikes (Wallis, 2013; Brown, 
Cai and Dasgupta, 2001). The Wilson/Brown interval is a modified Wilson interval that 
uses one-sided Poisson approximation to remove the downward spikes when x (the 
number of successful trials) is very close to 0 or n (Brown, Cai and Dasgupta, 2001). 




















Several protocols have recently been published to differentiate hiPSCs toward renal 
cells and organoids (Taguchi et al., 2014; Takasato et al., 2014; Xia et al., 2014; 
Morizane et al., 2015; Takasato and Little, 2015; Taguchi and Nishinakamura, 2017).  
Takasato et al, 2014 was one of the approaches that described obtaining both types 
of renal progenitors, UB and MM, simultaneously. The researchers described three-
step protocol for directing the differentiation of hESCs into renal cells and renal 
organoids. In the first step of the protocol, hESCs are treated with high concentration 
of CHIR for two days to induce posterior primitive streak differentiation, the progenitor 
population for the IM. CHIR stimulates WNT/β-Catenin signalling by inhibiting GSK-
3 enzyme (Wu et al., 2015; Tran and Zheng, 2017). The role of Canonical WNT 
signalling in inducing primitive streak differentiation has been highlighted in different 
studies (Gadue et al., 2006; Sumi et al., 2008; Yamamoto et al., 2018). The second 
step aims to differentiate the induced posterior primitive streak cells into IM by 
treating the cells with FGF9 for 4 days. FGF9 has been shown to be transiently 
expressed in the IM; that expression is lost upon segmentation of the IM into  
mesonephros, metanephros and genital ridge (Colvin et al., 1999). It has also been 
shown that FGF9 is expressed in the nephrogenic niche and the adjacent UB cells; 
it functions to promote survival of the MM and maintain the progenitor state in the 
nephrogenic niche (Barak et al., 2012).  In the third step of the differentiation 
protocol, treatment with FGF9 is continued for 6 days to drive the differentiation of 
MM and UB cells. Afterwards, all the growth factors are withdrawn, and the obtained 
cells are kept in culture for 6 more days to allow maturation of the progenitor cells.  
The researchers have shown that they obtained ureteric epithelium and early 
nephron markers. They also have shown that after 18 days of differentiation, cells 
could be dissociated, re-aggregated and cultured in a 3D condition; this allowed 
self-organisation, nephron patterning, and segmentation yielding 3D renal 
organoids with all major cellular components of the kidney tissue (Takasato et al., 
2014). 
This protocol was paradoxical as the two main renal progenitors, UB and MM, have 
different spatial origin from the IM; the MM originates from the posterior IM while the 
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UB originates from the anterior IM (Taguchi et al., 2014) (for more details see Chapter 
1 section 1.2.4). Through a fate mapping study, Taguchi and Nishinakamura 
suggested that the anterior IM commits earlier than the posterior IM. According to that 
study, the posterior IM is maintained in the posterior end of the embryo in a Brachyury 
(T)+ state and commits at a later stage of development after the extension of the body 
axis is completed (Taguchi et al., 2014). 
In 2015, Takasato and colleagues published a modification for their protocol. They 
hypothesized that the anterior IM mesoderm develops from early migrating cells which 
are exposed to FGF9 at an early stage. While the posterior IM cells are maintained 
under the high WNT signalling for longer duration (posteriorizing condition) and are 
exposed to FGF9 at a later stage. Based upon this, they described three slightly 
different versions of their protocol. The difference between them was in the duration 
of the initial CHIR treatment. They concluded that the shorter initial CHIR treatment (3 
days) and the early exposure to FGF9 induces more anterior IM fate and ends by more 
UBs while the longer treatment (5 days) gives more posterior IM fate (MM), midway 
between both, the 4 days treatment ends by a balance between the two fates 
(Takasato et al., 2015). 
 
3.2 Aims: 
My aim in this section was to adopt and evaluate a protocol for differentiating hiPSCs 
into renal progenitors. I choose to reproduce and evaluate the Takasato protocol. The 
reason of choosing this protocol was that, unlike other protocols which produce either 
UB or MM but not both, this protocol is reported to yield the two types of renal 
progenitors simultaneously in a physiological-like manner which allows each of the 
renal progenitors to induce further development of the other. I wanted to test the 
efficiency of that protocol in producing renal progenitors and to test the effect of 






3.3.1 hiPSCs maintenance: 
The original protocol, Takasato et al, 2015, maintained the hiPSCs on feeder cells  but 
because the feeder-based culture condition is laborious, I used feeder free, animal 
free culture conditions in which the cells were maintained on Matrigel coated dishes 
using E8 medium (Chen et al., 2011). Addition of the Rock inhibitor Y-27632 for 
overnight when cells were passaged enhanced the cell survival post dissociation 
(Watanabe et al., 2007) (figure 3.1; for more details about culture conditions that 
support hiPSC maintenance see chapter 1, section 1.4.2).  
Figure 3.1. Bright field images taken after an overnight culture of recently passaged 
cells in presence (a) or absence (b) of ROCK inhibitor. Cells were seeded in the same 
density with the only difference being the ROCK inhibitor treatment. Scale bar is 200 
μm. 
 
The passage number of the cells was kept under 25 passages from original derivation 
to avoid possible mutations that could come to dominate the population with higher 
passages. The cells were regularly tested for pluripotency markers by immunostaining 
for OCT4 and NANOG (Takahashi and Yamanaka, 2006b; Takahashi, Tanabe, et al., 
2007), and assaying for alkaline phosphatase (Loh et al., 2006; Štefková, 
Procházková and Pacherník, 2015) throughout the period of their maintenance (every 
5-7 passages) (figure 3.2). The cells were generally well maintained under these 
conditions except for an accidental problem of cell detachment, increased cell debris 
and death upon passaging which led to loss of cells (figure 3.3). New vials of 
cryopreserved cells were thawed but the same problem happened repeatedly and the 
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cells were lost.  The temperature inside the incubator was calibrated; the CO2 level 
and the humidity were also checked. Parallel to these cells, I had cultures of mESCs 
maintained in the same incubator and were looking healthy with no apparent 
abnormality. This probably indicates that the culture conditions inside the incubator 
were appropriate. To exclude possible bacterial contamination of the cells that might 
be causing their detachment and death, the spent medium was collected and spread 
over the surface of a nutrient agar plate. The plate was cultured for three days with no 
observed growth. Cells were also tested for Mycoplasma infection (Mycoalert, Lonza) 
and were negative. The problem was solved after changing the lot number of the E8 
medium (lot no 1896992) which suggests possible lot to lot variation in E8 medium 




Fig. 3.2. Immunostaining of hIPSCs to the pluripotency markers OCT4 and NANOG 
(a-c) separate channels for OCT4, NANOG and DAPI; d) merged. e-h) differentiated 
cells used as a negative control for the antibodies. i-j) Increased Alkaline phosphatase 




Fig. 3.3. a,b) Bright field images for the hiPSCs one day after passaging a) shows 
increased cellular debris and dead cells that appeared with particular lot number of 
the E8 medium b) the normal appearance of the cells after passaging and overnight 
culture. (c) an image for cells shown in (a) taken one day later showing fewer attached 
cells; the cells were lost afterwards.  Scale bar is 100 μm.  
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When thawing a new vial of cryopreserved hiPSCs two passages (average 10 days) 
were needed to allow for cell recovery before starting a new differentiation run. 
Optimising the seeding density of the cells to start differentiation was important. Cells 
were seeded in a density that gives around 40-50% confluence on the next morning 
(day 0 differentiation) (approximately 15,000 cells/cm2 were used and that number 
was adjusted depending on the growth rate of the cells). Cultures starting with higher 
cell density did not differentiate properly and did not develop structures at the end of 
differentiation suggesting overconsumption of the growth factors, while starting with 
lower density mostly ended by losing most of the cells at an early stage of 
differentiation and not having enough cells to continue differentiation (figure 3.4).   
Figure 3.4. Bright field images for 7 days differentiated monolayers a) when 
starting with low cell density; most of the cells detached with only few separated 
remaining colonies b) when starting with the right density of cells (see text); cells 
formed a confluent monolayer sheet c) sometimes the sheet of cells was seen 




3.3.2 The differentiation process: 
3.3.2.1 Primitive streak and intermediate mesoderm stages: 
The Takasato protocol directs the differentiation of the hiPSCs through different 
intermediate stages to end by renal cells. As I explained earlier Takasato and 
colleagues described three slightly different versions of their protocol, with the 
difference being in the duration of the initial CHIR99021 treatment. Here, I started by 
reproducing the three-day CHIR treatment protocol. In this protocol cells are first 
treated with CHIR for three days to induce posterior primitive streak differentiation. 
Achievement of this stage is verified by the expression of MIXL1 and T (Beddington, 
Rashbass and Wilson, 1992; Rivera-Pérez and Magnuson, 2005; Davis et al., 2008). 
Cells are then treated with FGF9 and Heparin for nine days. After four days of FGF9 
treatment (7 days of total differentiation) cells achieve the IM stage which is marked 
by the co-expression of LHX1 and PAX2 (Torres et al., 1995; Tsang et al., 2000; 
Bouchard et al., 2002). At the end of FGF9 treatment (12 days total differentiation) 
cells commit into NP and UB fate. At this stage, cells express the MM markers SIX2 
and WT1 (Armstrong et al., 1993; Kreidberg et al., 1993; Self et al., 2006; Kobayashi 
et al., 2008). At the same time the development of epithelial structures that show 
positivity to ECAD (Lee et al., 2013), PAX2, GATA3, and CALB (Davies, 1994) marks 
the simultaneous development of ureteric epithelium. Afterwards, growth factors are 
withdrawn from the culturing media and cells are kept in culture for maturation. By day 
18 of differentiation, they described obtaining elongated ECAD+ tubules surrounded 
by clumps of SIX2+, WT1+, PAX2+, and JAG1+ (Jones, Clement-Jones and Wilson, 
2000; Cheng et al., 2003) cells, a pattern that suggests obtaining ureteric epithelial 
tubules surrounded by early nephrons/renal vesicles (Takasato et al., 2014, 2015) 
(figure 3.5; for more details about the expression of different markers involved in 
metanephric kidney development see chapter1 section 1.2.5).  
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Figure 3.5. a) Schematic of the differentiation protocol illustrates the various 
intermediate stages and their expression markers. b) Illustration of organoid 
formation and culture. c) diagram showing the different segments of the nephron 
and the collecting duct and their specific expression markers. 
 
Verifying the achievement of the intermediate stages was necessary to confirm that 
the cells were going into the right direction. After 3 days of CHIR99021 treatment, most 
of the cells were positive for the primitive streak markers MIXL1 and T (n = 9 
independent samples) and the expression of the pluripotency marker OCT3/4 was lost 
(figure 3.6). This suggested successful differentiation towards primitive streak.  
It was notable that at this stage the differentiated cells started to detach from the plate 
and lost their adherence to each other (starting from the 3rd day of CHIR99021 
treatment and continuing for 2 days of FGF9 treatment; figure 3.4). When the detached 
cells were collected and re-plated on freshly prepared Matrigel-coated plates they 
adhered and were able to continue differentiation which excludes cell death as the 
cause of detachment. In order to test if this detachment was caused by proteases, 
which might be produced from the differentiated cells, that digest the Matrigel coat I 
added the protease inhibitor TIMP1 (SIGMA, SRP 3173) to the cells but the cells 
continued to detach in its presence.  
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Fig. 3. 6. Immunostaining for the first stage of differentiation; the primitive streak 
stage a,b) 3 days differentiated cells lost the expression of the pluripotency marker 
OCT4 and expressed the primitive streak stage marker T (Brachyury); c) 
Undifferentiated hiPSCs that were used as a negative control to the T antibody; 
the cells expressed OCT4 and were T-. d, e) Show MIXL1+ antibody staining after 
3 days of differentiation. f) Undifferentiated cells as negative control for MIXL1 
antibody. Scale bar is 100 μm. 
 107 
During normal development, after formation of the primitive streak, gastrulation starts 
during which cells undergo an epithelial to mesenchymal transition. In their epithelial 
state cells are regularly shaped and are tightly connected to each other, while 
mesenchymal cells are irregular in shape and detach from each other. The 
detachment and loss of adherence of the cells could be explained by simulation to the 
gastrulation process that happens in normal development. The process of primitive 
streak formation and gastrulation is regulated by several signalling pathways, the 
Canonical and non-Canonical WNT (Skromne and Stern, 2001; Yamamoto et al., 
2018) and the FGF signalling pathways are important players (Hardy et al., 2011). It 
was also observed that this state of loss of adherence was more prolonged if the cells 
were exposed to the longer duration of CHIR treatment (five days CHIR-treated cells) 
compared to the three days CHIR-treated cells. This might be explained by that, cells 
which were kept for longer duration in CHIR treatment were maintained in gastrulation-
like state for longer period (as CHIR is a Canonical-WNT agonist), while cells which 
started earlier treatment of FGF9 differentiated earlier towards IM. As mentioned 
before optimising the density of the cells to reach around 40-50% (or 60% in the case 
of 5 days CHIR treatment) confluence before starting differentiation was important not 
to lose the cells at this stage and to ensure enough cells to continue differentiation, 
also gentle dispensing of the media, on the wall of the well, during feeding was 
necessary to minimise the detachment. 
After 4 days of FGF9 treatment (7 days of total differentiation) the cells co-expressed 
LHX1 and PAX2 (n = 9 independent samples) both of which are IM and early renal 
markers (fig. 3.7 a,b). Control of hiPSCs that were seeded and kept in the same 
conditions but not exposed to the same treatment did not express these markers 







Fig. 3.7. Immunostaining for intermediate mesoderm markers after 7 days of 
differentiation a,b) show LHX1+, PAX2+ cells suggesting achieving intermediate 
mesoderm stage. c) Undifferentiated cells stained for these two markers as negative 
control. Scale bar is 100 μm.  
 109 
3.3.2.2 Renal progenitors and early nephron markers: 
At the end of the FGF9 treatment (total differentiation of 12 days) small spherical 
structures started to develop in the monolayers and could be noticed in bright field 
images; the cells showed positive expression of the early renal progenitor markers 
CALB1 (UB and collecting duct marker) and SIX2 (nephron progenitor marker) (figure 
3.8).  
At the end of the differentiation protocol (18-21 days) obvious tubules were seen in 
the monolayers. These tubules were tested for the expression of different renal 
markers: the cap mesenchyme and podocyte marker WT1, the more specific 
glomerular marker NPHS1, the proximal tubular markers JAG1 and LTL, the distal 
tubular and epithelial marker ECAD (figure 3.9 A), the UB/Collecting duct markers 
CALB and GATA3 (figure 3.9 B); these markers were all detected in the formed 
tubules. Obtaining tubular structures with characteristic expression pattern to 
developing nephrons and to the UB/Collecting duct cells suggested successful 




Figigure 3.8. Immunostaining for 12 days differentiated monolayers which showed spherical 
structures that stained positive to Calbindin (a-c); d) these spherical structures were also seen in 
bright field images. At the same stage the nephron progenitor marker SIX2 was also positive (e-
g). scale bar is 100 μm for c and d, and 200 μm for g.  
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Figure 3.9 A. 21 day-differentiated monolayers a,b) bright field images showing branching tubules that 
developed in the monolayer cultures. c-h) Immunostaining for different nephron markers c) stained for 
WT1 (MM and podocyte marker, shown in red) and ECAD (distal tubule and collecting duct marker, 
shown in green). d) Stained for NPHS1 (podocyte marker, shown in red) and ECAD (green).  In both 
(c) and (d) the ECAD stained structures separate from those stained with WT1 (c) or NPHS1 (d) e) 
shows immunostaining for LTL and JAG1 (both are proximal tubular markers) f) stained for WT1 and 
NPHS1; NPHS1 stained membranous protein while WT1 stained the nuclei of the same cells which 
matches their co-expression in the podocytes. (g, h) Are zoomed in images to show the pattern of 
expression of ECAD and NPHS1 (g) or ECAD and WT1. (h) Scale bar is 100 μm.  
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Figure 3.9 B. 21 day-differentiated monolayer stained for UB and CD markers a-d) 
shows the co expression of GATA3, PAX2 and ECAD; the co-localisation of the three 
of them indicates CD. E-g) stained for GATA3 and CALB and is showing the co-
expression of these two markers. Scale bar is 100 μm. 
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3.3.2.3 3D Organoid culture: 
Earlier studies have shown that if a single cell suspension of renal progenitor cells is 
pelleted, by centrifugation, and the obtained pellet is cultured in a 3D environment, 
cells can self-organise and form complex renal organoids that contain branched 
collecting ducts and segmented nephrons (Unbekandt and Davies, 2010). Takasato 
and colleagues examined the self-organising ability of their obtained renal cells after 
18 days of differentiation (Takasato et al., 2014) and at an earlier stage (after 7 days 
of differentiation) (Takasato et al., 2015). They reported that the self-organising 
property allowed the cells to take particular patterns in relation to each other and 
enhanced the formation of more complex structures (Takasato et al., 2014). In their 
protocol that was published in 2015, they focused more on making organoids at the 
early stage (after 7 days of differentiation) and showed that the 3D condition allowed 
for better maturation of the renal structures with evidence of proximal-distal patterning 
of the nephrons. 
I aimed to examine the ability of the obtained cells to self-organise and form more 
complex 3D renal organoids. For this purpose, cells were dissociated after 7 days of 
differentiation, pelleted then cultured at on the surface of a filter membrane at gas-
liquid interface until the end of the differentiation protocol. The 3D environment 
enhanced tubulogenesis and allowed for the development of more densely packed 
structures compared to the 2D cultures (figure 3.10). The resulting 3D organoids were 
investigated for the expression of different renal markers; ECAD positive tubules 
(marker for distal tubules and CD) were detected and appeared connected to LTL+ 
tubules (proximal tubular marker) and surrounded by clusters of cells that stained 
positive for WT1 and NPHS1 (podocyte markers). Organoids also had tubules which 
stained positive for the UB markers CALB and GATA3 (figure 3.11). Collectively the 
data suggested successful obtaining of renal organoids. 
Immunostaining allowed not only for detecting if these markers were expressed or not, 
but it also showed the pattern of expression, the co-localisation of some markers or 
the expression of other markers in separate populations which were collectively taken 
to evaluate the differentiation. ECAD, LTL and WT1 were expressed in separate 
populations (figure 3.11 c) which matches their specificity to different parts of the 
nephron; WT1 and NPHS1 (both stain for podocytes) were co-localised (figure 9A f). 
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The co-localisation of GATA3, ECAD and PAX2 or GATA3 and CALB were taken as 
an indicator of UB development (figure 11 e,f). 
 
Figure 3.10. a,b) Bright field images showing differentiated monolayer (a) or organoid 
(b); some tubular structures developed in isolated areas of the monolayer culture, 
however the organoid developed into densely packed tubular structure. c,d) 
Immunofluorescence staining  for ECAD and WT1 in monolayer (c) or organoid (d) 
showing robust tubulogenesis in the organoid. Scale bar is 200 μm. 
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Figure 3.11.   21 day-differentiated organoids. a) Shows brightfield image of the organoid. b) 
Immunostaining for the distal tubular and the CD marker ECAD and the glomerular marker NPHS1 
which shows expression of these two markers in separate populations. c) Shows expression of 
WT1 (staining podocytes), LTL (staining proximal tubules) and ECAD (staining distal tubules and 
CDs) in separate populations. d) The proximal tubular markers LTL and JAG1 are co-expressed 
in the organoids e) Shows the co-expression of ECAD, GATA3 and PAX2 in one of the tubules. f) 
Shows co-expression of CALB, and GATA3; the arrow points to a branching structure suggesting 
branching UB g) Zoomed in image for the expression of WT1, LTL and ECAD. (a) Scale bar is 1 
mm, (b-f) scale bar is 100 um and (g) scale bar is 25 μm. 
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3.3.3 Variable results: 
As mentioned before, the co-expression of GATA3 with CALB or the co-expression of 
GATA3, ECAD and PAX2 (or GATA3 + ECAD) were taken as positive indication of UB  
and collecting duct differentiation; ECAD is expressed both in the distal tubules and 
the UBs, and PAX2 is expressed in the IM and the early renal structures including MM, 
UB and renal vesicle (Bouchard et al., 2002 Torres et al., 1995) and only their co-
expression with GATA3 (Grote et al., 2006, 2008) was taken as a marker of UB. Both 
ECAD and PAX2 were always present in all the organoids or monolayers tested for 
them, however in some of the runs GATA3 was either negative or expressed 
surrounding the ECAD+/PAX2+ tubules (i.e. in between the tubules). In cases where 
the GATA3 expression was seen in the interstitial cells, in between the tubules, CALB 
staining was also negative, which precludes obtaining UB and CD fate in these runs 
(figure 3.12). Achieving UB differentiation was confirmed either by the co-expression 
of GATA3 and CALB or the co-expression of GATA3, ECAD and PAX2. From a total 
of 41 tested organoids 22 showed negative UB differentiation and 19 organoids were 
positive for UBs; all tested samples were positive for the different markers of the 








Fig. 3.12. Shows the variability in GATA3 expression in a) GATA3 is only seen in 
interstitial cells surrounding the ECAD+, PAX2+ tubules and does not appear inside 
tubules while in b) GATA3 co-localises with ECAD and PAX2 in one of the tubules. c) 
shows GATA3+ interstitial cells that do not localise inside tubular structures and CALB 
was not expressed in that organoid while d) shows GATA3+ tubules that are co-
expressing CALB in some parts. Scale bar is 100 μm. e) Shows the 95% confidence 
interval (Wilson/Brown) for obtaining positive or negative UB fate in organoids 
obtained by using the Takasato protocol; a total of 41 samples were tested for the 
presence or absence of the UB fate (taking the co-expression of GATA3, ECAD and 
PAX2 or the co-expression of CALB and GATA3 as markers for positive UB fate) 19/41 
samples were positive for the UB fate while 22 /41samples were negative. 
 
3.3.4 Comparing the three different timings of initial CHIR99021 treatment 
The Takasato protocol compared between three different timings of initial CHIR99021 
treatment; 3days, 4 days and 5 days and concluded that the shorter period of 
CHIR99021 treatment yields more UBs at the end of differentiation and that the longer 
CHIR99021 treatment gives more MM fate, while midway between them; the 4 days 
initial treatment makes a balance between the UB fate and the MM fate.  
I had quite variable results in the UB direction, despite using the treatment that should 
give more UB fate according to the study. I wanted to check the difference between 
the different timings and whether any of them could give more consistent differentiation 
towards UB.  Four different runs were differentiated and evaluated for UB markers, 
the three different timings of CHIR treatment were set parallel to each other at the 
same time to minimise causes of technical variability. Organoids from the three 
different timings all formed tubular structures and were all expressing nephron 
markers (WT1, LTL, and ECAD) with some variability in-between the different 
organoids in the percentage of the area that stained positive for each marker 
compared to the total area of the organoid (Figure 3.13). Neither of the different timings 
of CHIR treatment included in this comparison showed co-expression of GATA3 and 
CALB (figure 3.13) which suggests variability between runs in obtaining UB fate in my 






Figure 3.13.  comparing between the three different initial CHIR treatment duration. 
a) Shows the % area stained positive for WT1, LTL, ECAD, or GATA3 and CALB to 
the whole area of the organoid compared between the three different durations of initial 
CHIR treatment (for GATA3/CALB 8 different organoids obtained from 4 different 
differentiation runs, 2 organoids/run, were included for each of the different CHIR 
treatment durations and were all negative. For the rest of the markers four different 
organoids obtained from 4 different differentiation runs were included for each marker 
in each of the different CHIR treatment). b,c) Mouse embryonic kidney stained for 
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ECAD, WT1, and LTL (b) or GATA3 and CALB1 (c) to show the expression of these 
markers in mouse kidney. 
3.3.5 Possible cell death during the process of organoid formation: 
Data presented in section 3.3.3; 3.3.4 were obtained from 3D organoids. I then 
observed that some of the examined differentiation runs showed GATA3+/ECAD+ 
tubules in the 2D cultures but not in the 3D organoids that were set in parallel. This 
suggested that anoikis of the early UB progenitor cells during the process of 
dissociation/re-aggregation of the cells to form organoids might be the reason for not 
obtaining UB-differentiated structures. The study that was done by Unbekandt and 
Davies, in 2010, has shown that when the embryonic mouse kidneys are dissociated 
into single cells then pelleted and cultured as 3D re-aggregate, many cells die unless 
ROCK inhibitor is added to the culture for 24 hrs. A recent study has also shown that 
dissociated embryonic UBs need ROCK inhibitor treatment to survive and form 
colonies (Yuri et al., 2017). ROCK inhibitor is known to inhibit anoikis and has been 
shown to increase the efficiency of hPSC single cell survival (Watanabe et al., 2007).  
I set out experiment to compare between organoids cultured in presence or absence 
of ROCK inhibitor (for the initial 24 hrs of organoid culture); the organoids were 
cultured in the same conditions afterwards until the end of the differentiation protocol 
and were then stained for the UB markers. 3/10 of the organoids cultured without 
adding the ROCK inhibitor showed positive UB structures while 5/10 of the organoids 
that were treated with ROCK inhibitor showed positive UB structures. The number of 
obtained UB-like tubules was also higher in the ROCK inhibitor treated organoids 
(figure 3.14 a, b). 2D cultures were also set in parallel to these organoids; 6/10 of the 
2D cultures showed positive UB markers. This result supports the idea that the UB 
progenitor cells might undergo dissociation induced apoptosis during the process of 
organoid formation but still does not exclude a source of variability in obtaining UB fate 
using the Takasato protocol. Therefore, I wanted to isolate these UB-like structures to 
further evaluate them (this will be discussed in chapter 6 and 7). 
Adding the ROCK inhibitor to the culture media for the first 24 hrs of organoid culture 
and longer culture duration of the differentiated cells (20-23 days instead of 18 days 
in the original protocol) were the only modifications I did to the Takasato protocol and 




Figure 3.14. Comparing between ROCK inhibitor treated (a,b) and untreated (c,d) 
organoids in obtaining UB-like structures; the treated organoids developed more UB-
like structures. d) Developed few UB-like structures; (c) Is negative for UB fate. e) 
shows the 95% confidence interval for obtaining UB fate in each group (see section 
2.16); n = 10 for each group. 
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3.4 Discussion  
Here, I reproduced the Takasato protocol of differentiation; I achieved stepwise 
differentiation of the hiPSC into nephron progenitors and showed the development of 
entities reminiscent to developing nephrons. I also evaluated the formation of 3D 
organoids by dissociating the cells and culturing them as 3D aggregates. The results 
indicate that the 3D environment enhanced the development of the renal-like tubules.  
Markers for different segments of the nephron were consistently obtained but results 
for the UB and CD fate were quite variable. The Co-expression of GATA3 and CALB1 
or GATA3 and ECAD (or GATA3+ECAD+PAX2+) was taken as a marker for obtaining 
UB fate. Some of the organoids showed the expression of GATA3 only in interstitial 
cells, but not in tubular epithelial structures. GATA3 is an important transcription factor 
that is expressed in the WD and the UB where it plays an important role in kidney 
development and its deficiency in mice leads to renal agenesis (Grote et al., 2008; 
Michos, 2010). A recent study has shown that GATA3 is also expressed in glomerular 
mesangial cells where it plays an important role in maintaining renal glomerular 
function (Moriguchi et al., 2016). The pattern of GATA3 staining interstitial cells might 
be due to the differentiation of some cells into mesangial-like cells. ECAD and PAX2 
showed positive expression in all the tested samples, however, ECAD is expressed in 
the distal tubules, connecting tubules, CD and UB (Lee et al., 2013).  PAX2 is also 
expressed in the IM, MM, renal vesicle and UB (Torres et al., 1995; Bouchard et al., 
2002) and so ECAD and PAX2 are not specific to UB cells; only their co-expression 
with GATA3 was taken as a marker for UB and CD. CALB1 is a more specific marker 
for the UB and CD; a recent study has shown that in human fetal kidney between 8-
11 weeks CALB1 was only detected in the CDs and was not seen in any nephron 
segments (Lindström et al., 2018). Like GATA3, CALB1 expression in the obtained 
organoids was variable. 21/41 tested organoids were negative for UB fate and only 
19/41 showed positive criteria for obtaining UB fate. 
I also compared between the effect of the three different timings of initial CHIR 
treatment. The effect of the initial CHIR treatment duration in determining cell fate 
commitment was not as clear in my results as Takasato and colleagues described. 
None of the tested samples (8 organoids for each of the compared CHIR treatment 
duration, obtained from 4 different differentiation runs) showed co-expression of 
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GATA3 and CALB1. All the samples obtained from the different CHIR treatments did 
show positive nephron markers, albeit with, individual variation in the amount of each 
positive marker in relation to the total area of the organoid (Fig. 3.13). Collectively, the 
data suggests variability between runs in the ability to obtain UB-differentiated cells 
In a recent study, Taguchi and Nishinkamura developed a protocol for differentiating 
mESCs and hiPSCs mainly to UB cells; they found that obtaining UB fate needed “a 
rigid time window for AIM induction” which was achieved by 1.5 days of CHIR 
treatment and according to their results the UB fate was not induced when longer 
durations of CHIR treatment was used (Taguchi and Nishinakamura, 2018). 
A very recent study published by the same group that published the Takasato protocol; 
the Melissa Little group, performed single-cell transcriptomic analysis to investigate 
congruence and difference between their obtained organoids and human fetal kidney 
(Combes et al., 2019). Interestingly, they reported that they did not find distinct cluster 
of cells that represents ureteric identity in either the organoids or the fetal kidneys. The 
absence of ureteric epithelial cell cluster in the fetal kidney led the researchers to 
suggest that the cells of the ureteric epithelium are resistant to single cell dissociation. 
However, they also mentioned that immunofluorescence staining for those particular 
set of organoids, which were included in the profiling experiment, did not show ureteric 
structures, or that they were present in low frequency. The study concluded that the 
GATA3+ve epithelial structure require further studies to investigate the identity of these 
structures.  
In my results, the UB fate was seen in some of the samples; some of the tubules that 
co-expressed GATA3 and CALB showed branching (Fig. 3.11 f) which suggests that 
these tubules might be UB-like structures despite the variability in obtaining these 
structures. It is likely that early UB progenitor cells undergo dissociation induced 
apoptosis during the process of organoid formation as the possibility of obtaining UB 
fate was increased when the organoids were treated with ROCK inhibitor for the first 
24 hrs of organoid culture. death of the UB cells upon dissociation into single cells has 
been reported in previous studies. These studies have also shown that ROCK inhibitor 
treatment increases the survival of the dissociated UB cells (Unbekandt and Davies, 
2010; Yuri et al., 2017). However, a source of variability in obtaining UB fate using the 
Takasato protocol could not be excluded; 2D cultures, which are kept without 
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dissociation throughout the differentiation protocol, still show variable results in 
obtaining UB-like structures. Optimising conditions to minimise this variability and 
more characterisation for these structures is still required.  
In conclusion, the MM fate and its derivatives (different segments of the nephron) were 
efficiently obtained in all the tested samples, so in the next chapters (chapter 4, 5), I 
try to investigate some functional capacities of these cells and to evaluate their 
possible suitability for use in nephrotoxicity screening. The UB fate was variable, so in 
following chapters (chapter 6, 7), I try to isolate the UB-like structures for further 




























4 Investigating aspects of renal tubular physiology in hiPSC-




Despite lacking the intricate cortico-medullary zonation and the correct anatomical 
arrangement of nephrons around a single central collecting duct tree, compared to the 
normal organ, hiPSCs-derived renal organoids are quite similar to embryonic kidneys 
at the micro-scale anatomy level, as shown by their expressing specific markers for 
different segments of the nephron and for the collecting ducts. While correct macro-
scale anatomy is important for the use of these organoids in regenerative medicine 
and transplantation purposes, it is important, before going on to engineer a more 
anatomically realistic tissue and trying to organise these structures, to test whether 
the developing nephrons are functional; having functioning nephrons growing in 
culture could have many implications including their use for screening drugs for 
potential nephrotoxicity, which could be an early application of organoids as it does 
not require correct macro-scale anatomy.  
Research aim: 
In this chapter, I wanted to evaluate some physiological aspects of the renal-
differentiated organoids.  
4.2 Proximal tubular transporters and their role in kidney 
function and drug toxicity: 
Kidneys receive 20-25% of the cardiac output; 20% of the renal plasma flow is filtered 
at the glomeruli while the remaining blood circulates through the efferent arteriole to 
the peritubular capillaries. This makes a glomerular filtration rate of (GFR) of 
approximately 160-170 L/day; the composition of the primary filtrate being almost the 
same as plasma excluding plasma proteins. The high GFR necessitates intensive 
reabsorption mechanisms to prevent water and electrolyte disturbance, pH 
disturbance, and nutrient loss. Proximal tubules reabsorb almost all of the filtered 
glucose and amino acids, 60-70% of the filtered water and NaCl, and most of the 
filtered NaHCO3 (Zhuo and Li, 2013).  
In addition to reabsorbing valuable components of the ultrafiltrate, proximal tubules 
also play a key role in secreting metabolic waste products and xenobiotics into urine. 
This is specifically important for eliminating protein-bound substances that do not 
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cross the glomerular filtration barrier (Wang and Kestenbaum, 2018). Tubular 
secretion was first proposed by Heidenhain who assumed that tubular epithelial cells 
mainly perform a secretory function (Heidenhain, 1874). Marshall and Vickers were 
the first to provide a proof of tubular secretion; they demonstrated the uptake of phenol 
red by proximal tubules and observed that the elimination of that protein-bound dye 
was far more than what could be achieved through glomerular filtration (Marshall and 
Vickers, 1923). Later on, Smith and colleagues showed that Phenol red clearance 
could be used to measure the effective renal blood flow and the tubular excretory mass 
(Smith, Goldring and Chasis, 1938). 
Together with glomerular filtration, tubular secretion and reabsorption are key to the 
clearance of toxins, metabolic waste products and drugs (Dickson et al., 2014; Suchy-
Dicey et al., 2016; Wang and Kestenbaum, 2018). 
4.2.1 Molecular mechanisms of trans-epithelial tubular transport: 
While glomerular filtration depends on passive diffusion regulated by hydrostatic 
pressure, trans-epithelial tubular transport mostly requires the function of transporters 
located on the basolateral or the apical membranes of the tubular epithelial cells. 
Transporters are membrane proteins that mediate the uptake or efflux of specific 
substrates into or out of the cells; they tend to have charge-selectivity either to anions 
or cations, nevertheless, some studies suggest a degree of overlap (Pritchard and 
Miller, 1996; Sanjay K Nigam, 2015; Nigam et al., 2015; Yin and Wang, 2016). 
4.2.1.1 Basolateral membrane transporters: 
On the basolateral membrane of the proximal tubules the main transporters 
responsible for the uptake of organic anions and cations are organic anion transporters 
(OATs) and organic cation transporters (OCTs) respectively (Burckhardt, 2012; Wang 
and Kestenbaum, 2018). Both types of transporters are members of the SLC22 family 
(figure 4.1).  
In humans, three OCT isoforms have been identified; OCT1-3. OCT2 is the main 
cation transporter expressed in the kidney (Koepsell et al., 1998), where it is localised 
to the basolateral membrane of the three segments of proximal tubules S1, S2, S3 
(Motohashi et al., 2002; Motohashi and Inui, 2013). OCT1 is mainly found in liver 
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(Zhang et al., 1997), and OCT3 is widely expressed in different organs including 
placenta, skeletal muscle, heart and salivary glands (Kekuda et al., 1998; Koepsell, 
Lips and Volk, 2007b; R. W. S. Li et al., 2013). 
 
 
Figure 4.1. Schematic illustration of tubular transport for organic anions and cations 
mediated through proximal tubular transporters. Organic cations and anion are taken 
into the proximal tubular cells through the basolateral membrane transporters and then 
the apical transporters mediate their secretion into the tubular lumen.  
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OCT2 takes up cations from the circulation into the tubular cells, thus mediating the 
first step of cation secretion (Motohashi et al., 2002, 2013; Fujita et al., 2006). OCT2 
transports cations down an electrochemical gradient, created by the inside-negative 
membrane potential of the tubular cells, via facilitated diffusion (Motohashi and Inui, 
2013; Wang and Kestenbaum, 2018). Rat and mouse kidneys show strong expression 
of Oct1 while the human kidney expresses it only in small amounts (Koepsell, Lips and 
Volk, 2007a) 
Common substrates for OCT2 include:  
- Drugs of different categories: the chemotherapeutic drugs Cisplatin (Yonezawa et 
al., 2006; Filipski et al., 2009; Ciarimboli et al., 2010; More et al., 2010) and 
Ifosfamide (Ciarimboli et al., 2011); the oral hypoglycemic drug metformin (Nies et 
al., 2011; Ren et al., 2015); the anti-hypertensive drug atenolol (Ren et al., 2015; 
Yin et al., 2015); the H2 receptor blockers Famotidine, Cimetidine and Ranitidine 
(Nies et al., 2011); and the anti-Parkinsonian drug amantadine (Li et al., 2017). 
- Toxins: the mycotoxin AflatoxinB1, the herbicide Paraquat and the commonly used          
fluorescent nucleic acid stain Ethidium bromide (Nies et al., 2011). 
- Endogenous substrates: creatinine is an important substrate for OCT2. Creatinine 
clearance is usually used to estimate GFR, however, because of the tubular 
secretion of creatinine this usually gives false higher estimates of GFR so 
creatinine tubular secretion should be considered carefully in patients with 
glomerular disorders (Urakami et al., 2004). 
- Model cations: including ASP, TEA, TPA, N1-methylnicotinamide and MPP 
(Pietruck et al., 2006).  
OAT1 and OAT3 are the main organic anion transporters on the basolateral 
membrane (Sekine et al., 1997; Burckhardt, Wolff and Bahn, 2002; Motohashi et al., 
2002). They mediate the first step of organic anion secretion in the renal proximal 
tubules by taking anions from blood into tubular cells in exchange with the dicarboxylic 
acid -ketoglutarate (Sweet et al., 2003, 2006; Burckhardt, 2012). They contribute to 
the secretion of a wide range of drugs and toxins in the renal proximal tubules thus 
protecting from putative toxic compounds. There is considerable overlap between 
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OAT1 and OAT3 regarding their substrate specificity, with some substrates having 
higher affinity to one over the other (Burckhardt, 2012; Huo and Liu, 2018). 
Substrates for OAT1 and OAT3 include: 
- Endogenous substrates such as Urates thus OAT1 and 3 contribute to purine 
metabolite excretion (Koepsell, 2013). 
- Drugs of different categories including antibiotics as tetracyclines and 
cephalosporins, antineoplastic drugs as methotrexate (OAT3 binds to 
methotrexate with much higher affinity than OAT1), antiviral drugs as acyclovir and 
cidofovir (Zhou and You, 2007; Huo and Liu, 2018). 
Another important basolateral membrane transporter involved in anion uptake is 
OATP4C1 transporter which transports larger and more hydrophobic anions; it also 
transports some neutral and even positively charged substrates (Suzuki et al., 2011). 
4.2.1.2 Apical membrane transporters: 
Members of the ABC family; the multidrug-associated resistance proteins (MRP) 2 and 
4 (also known as ABCC2 and ABCC4) are the main apical surface transporters 
involved in efflux of the anions that are taken into the tubular cells by OAT1 and 3; 
OAT4 and URAT1 are other transporters that also have role in apical efflux (Hediger 
et al., 2005; Miyazaki et al., 2005; Nigam et al., 2015) (figure 4.1).  
Transporters involved in cation apical efflux include the multi drug and toxin extrusion 
(MATE) transporter 1, the human kidney-specific multidrug and toxin extrusion 
transporter (MATE2K), and the organic cation/carnitine transporter (OCTN) 1 and 2 
(Masuda et al., 2006; Tanihara et al., 2007; Nigam et al., 2015; Wang and 
Kestenbaum, 2018). In addition to their role in efflux, MATEs have been shown to be 
also involved in cation uptake depending on the cation concentration gradient 






Transport of organic anions and cations cannot take place without transporters, so my 
first step in assessing functional capacity of the organoids was to test the expression 
of selected proximal tubular transporters; adequate expression of these transporters 
is fundamental for the use of those cells for nephrotoxicity screening purposes.  
4.2.2.1 Testing the expression of OAT1 and OCT2 using RT-PCR: 
OAT1 expression is detected in the proximal tubules of the 14-16 week human foetal 
kidney (Lindström et al., 2018) but little is known about when exactly these 
transporters first start to be expressed in the human foetal kidney. 3D Organoids were 
tested at two different maturation points; 11 day and 20 day differentiated organoids.  
Also, the expression was tested in 20 day differentiated 2D monolayers. A clear band 
was seen for both OAT1 and OCT2 in 20 day-differentiated 3D organoids indicating 
their expression at this point of maturation, however, OAT1 and OCT2 were not 
detected in the 20 day-differentiated 2D cells (n=2) (Figure 4.2 I).  
4.2.2.2 Transporter functional assays: 
I next wanted to see if the expressed transporters were truly functional. Recently, 
some studies used renal-differentiated organoids, made using the Takasato protocol, 
for in-vivo functional assessment after their transplantation in experimental animals 
(Bantounas, Ranjzad, Tengku, Silajdžić, Forster, M.-C. Asselin, et al., 2018; van den 
Berg et al., 2018). Neither of these studies examined the expression and function of 
the proximal tubular transporters. While testing glomerular filtration needs existing 
vascular system in the organoids with active blood circulation, testing tubular 
transporter function does not require blood flow (Lawrence, Elhendawi and Davies, 
2019) and transporter functional assays can be performed on in-vitro organoid culture 
models and can be used as a way to assess some functional aspects of the hiPSC-
derived renal organoids without the need for transplanting them into experimental 





Figure 4.2. I) RT-PCR result showing expression of OCT2 (SLC22A2) and OAT1 (SLC22A6) in 
20 day differentiated 3D organoids. II) a,b) functional uptake assay for the organic anion 6-CF in 
20 day differentiated 3D organoid a) in absence of and b) in presence of the transporter inhibitor, 
Probenecid; c, d) 6-CF uptake in E15.5 mouse kidney as a control of the experiment showing 
uptake of 6-CF into the proximal tubules in c) where there is no inhibitor added but not in d) that 
was treated with the inhibitor (Probenecid). Scale bar is 100 μm. 
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4.2.2.2.1 Anion uptake assay: 
A group of fluorescent and radiolabelled model substrates have been used in in-vitro 
metanephric cultures for testing OAT function. 6-CF was chosen as a fluorescent 
anion to avoid the risk of using a radiolabelled substrate and at the same time it could 
be imaged easily to assess the uptake. 6-CF is taken into the proximal tubular cells 
through the basolateral anion transporters in a Na-dependant manner (mediated by 
OAT1 and OAT3) and its efflux into the lumen is mediated uphill through the apical 
membrane transporters (mostly through MRP2 and 4) (Miller, Letcher and Barnes, 
1996; Masereeuw et al., 1999; Breen et al., 2001; Sweet et al., 2006; Lawrence, 
Chang and Davies, 2015b).   
Uptake was tested by incubating living iPSC-derived renal organoids with the 6CF 
anion for 40 minutes; in some samples probenecid, a potent anion transporter inhibitor, 
was applied simultaneously with 6-CF to test the specificity of the uptake. After 40 
minutes of incubation with 6-CF, in the absence or presence of probenecid, both 
conditions were washed and kept in PBS containing 8 mM probenecid to prevent efflux 
of the 6-CF thus, trapping the fluorophore and allowing for imaging. PNA was used as 
a pan-tubular marker to mark the tubules (figure 4.2 II). E15.5 mouse kidneys were 
used as a positive control for the whole experiment as their ability to take up 6-CF and 
the inhibition of the uptake with Probenecid is already known (Sweet et al., 2006; 
Lawrence, Chang and Davies, 2015b). 
As expected, 13 day differentiated organoids did not show 6-CF accumulation, 
indicating that at this stage nephrons had not acquired functioning transporters. 
Consistent with the RT-PCR results which showed that OAT1 was expressed in the 
20d differentiated organoids, 6-CF accumulated in tubular structures within these 
organoids. Probenecid treatment inhibited the uptake of 6-CF in the organoids, 
indicating that the uptake was inhibitor sensitive (n = 5 independent samples). The 
inhibitor-sensitive uptake of 6-CF suggests functional anion transporters in the renal-




4.2.2.2.2 Cation uptake assay: 
For testing the function of the cation transporters, I used 4-(4-dimethylamino-styryl)-
N-methylpyridinium (ASP); ASP is a fluorescent substrate for renal organic cation 
transporters (Pietruck et al., 2006). TPA, which is another cation substrate 
(Schophuizen et al., 2013), was used as a competitive inhibitor for the uptake of ASP 
in the inhibitor-treated samples. LTL was used to live-stain the proximal tubule cells 
before starting the uptake experiment. The inhibitor-treated samples were incubated 
with TPA for 20 min prior to ASP treatment, after that both conditions (test samples 
and inhibitor treated samples) were treated with ASP (still in presence of the inhibitor 
in case of the inhibitor treated-samples) and incubated for 20 minutes to allow for the 
uptake; the fluorescent dye was taken up by LTL-marked tubules, suggesting uptake 
inside the proximal tubular cells. ASP uptake was much lower in the organoids treated 
with TPA compared to the test samples; in addition, ASP uptake decreased with 
increasing concentration of the TPA (Figure 4.3). The ability of organoids to transport 
ASP in an inhibitor-sensitive way (n = 5 independent samples) confirms the presence 





Figure 4.3. Cation uptake assay using the fluorescent cation ASP. a) Shows uptake 
of ASP into LTL labelled proximal tubules; no inhibitor was added. b) Shows 
decreased ASP uptake in an organoid that was treated with low dose of TPA 
(competitive ASP inhibitor). c) Shows almost no uptake in organoid treated with higher 










4.3 Can renal-differentiated cells be cryopreserved? 
Having demonstrated that the cells obtained by applying the Takasato protocol of 
differentiation develop into renal-like structures (chapter 3) and can perform some 
renal tubular functions (section 4.2.2 of this chapter), I wanted to investigate whether 
the differentiated cells could survive cryopreservation and retain their ability to self-
organize, to form renal-like tubules, and to perform tubular function. The differentiation 
protocol takes 20-23 days to obtain renal-differentiated organoids from hiPSCs, plus 
the need to maintain, passage the iPSCs and regularly test them for pluripotency; all 
these requirements make the process of making renal organoids laborious. In addition, 
maintaining hiPSCs in culture could be a cause of variability (Takasato et al., 2016) 
and mutations can be problematic, especially with high passages. I therefore wanted 
to assess the possibility of cryopreserving and reviving renal-differentiated cells. 
Recent studies have shown the possibility of cryopreserving cardiomyocyte-
differentiated, and brain endothelial cell-differentiated hPSCs (Xu et al., 2011; Wilson 
et al., 2016). If this proved feasible with renal-differentiated hiPSCs, it could save a lot 
of time and effort and it could be of specific importance for the use of those cells in 
nephrotoxicity screening where high throughput model is needed.  
4.3.1 Cryopreserving and reviving 12 days differentiated cells: 
I tried to dissociate and cryopreserve renal-differentiated cells at day twelve of the 
differentiation protocol. In the differentiation scheme, cells achieve renal progenitor 
stage around day 12 of differentiation. After that point, cells are kept in culture medium 
without the need of adding any growth factors, therefore cells at that stage requires 
less manipulation and saves considerable time. So, I trypsinised 12 day differentiated 
cells and dissociated them into single cells to evaluate the possibility of cryopreserving 
and reviving them. The dissociated cells were suspended in culture media that 
contains 10 μM ROCK inhibitor + 10% DMSO and were cryopreserved at – 80  C. 
ROCK inhibitor was added to prevent anoikis (Watanabe et al., 2007). When thawing 
the cells after cryopreservation, the viability was assessed using trypan blue stain and 
cells were counted on a haemocytometer. 95%± 2% of the cells were viable. 
Afterwards, cells were either seeded on Matrigel coated culture dishes and grown as 
monolayers or aggregated as pellets and cultured in 3D culture system as organoids.  
The attachment of the cells to the culture dishes was assessed in the presence and 
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absence of ROCK inhibitor (10 μM) for the first 24 hrs post-thawing. When cells were 
thawed without adding ROCK inhibitor for the first 24 hrs post-thawing, most of the 
cells did not attach and died afterwards (figure 4.4). Similarly, only 3D cultures that 
were treated with ROCK inhibitor for the first 24 hrs developed and showed tubular 
structures at the end of the culture period. Without it, they either remained unattached 
and died (in monolayers) or did not develop or form any structures (in the 3D culture 
system). After the first 24 hrs post-thaw, the ROCK inhibitor was removed, and the 
differentiation protocol was continued as usual without any further addition of growth 
factors figure 4.5 a). 
 
Figure 4.4. Shows the importance of adding ROCK inhibitor for the first 24 hr of culture 
post thawing; a) cultured in presence of ROCK inhibitor b) in absence of ROCK 
inhibitor; very few cells attached to the culture dish. The arrows point to unattached 
cells which formed aggregates in untreated cells. Scale bar is 200 μm. 
 
4.3.1.1 Verification for the ability of the cells to revive and form renal 
structures: 
Cells that were cultured after a period of cryo-storage continued to differentiate in 
mostly the same way as regular differentiated monolayers and organoids did. 
Cryopreserved cells that were cultured as monolayers after thawing developed tubular 
structures at the end of the differentiation (9 days post thawing). When these 2D 
cultures were fixed and stained they showed positive expression for different renal 
markers, ECAD1, WT1 and NPHS1, indicating the development of nephron structures 
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(figure 4.5) (for more details about these expression markers see chapter 3 section 
3.3.2.2 and 3.3.2.3). Similarly, all the pellets formed from cryopreserved cells 
succeeded in forming complex 3D organoids that showed ECAD+ tubules (in the distal 
tubules and collecting ducts) connected to LTL+ tubules (proximal tubules) and 
surrounded by clusters of WT1+ and NPHS1+ cells (both expressed in podocytes); 
collectively that expression pattern suggested the development of patterned nephrons. 
Organoids also showed positive expression of GATA3 and Calbindin, which suggests 
obtaining UB/CD tubules (fig. 4.6; for more details about the differentiation markers 




Figure 4.5. a) Schematic illustration of the cryopreservation, thawing and culture of 
the cells. b,c) Monolayer immunostaining of the cryopreserved cells after 9 days post-
thawing b) stained for NPHS1 and ECAD, c) stained for WT1 and ECAD. Scale bar is 
100 μm.  
 140 
Figure 4.6. Immunostaining for organoids made from cryopreserved cells showing 
their ability to make 3D renal organoids that express different renal markers a) stained 
for the glomerular marker WT1, the proximal tubular marker LTL and the distal tubular 
and the collecting duct marker ECAD; b) stained for the specific glomerular membrane 
marker NPHS1 and ECAD; c) showing the co-localisation of the collecting duct 
markers CALB1 and GATA3 in branching tubular structures. Scale bar is 100 μm. 
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4.3.1.2 Functional assessment of the organoids obtained from 
cryopreserved differentiated cells 
Next I used the functional assays described in section 4.2.2 to assess if organoids 
obtained from cryopreserved differentiated cells possess functional anion and cation 
transporters. The 3D organoids were examined for the uptake of 6-CF and ASP, after 
10 days of post thawing culture, in presence or absence of inhibitor (as described 
earlier in section 4.2.2). The organoids showed positive uptake of 6-CF and ASP; that 
uptake was inhibitor sensitive in both cases which suggests the presence of functional 
proximal tubular transporters (figure 4.7).  
 
Figure 4.7. Functional uptake assays for the 3D organoids made from cryopreserved 
cells a,b) show 6-CF uptake in absence of (a) or presence of (b) probenecid as an 
inhibitor of the organic anion transporters. c, d) Show the uptake of the fluorescent 
cation ASP in absence of (c) or presence of (d) TPA, a competitive inhibitor of ASP. 
Scale bar is 100 μm. 
4.3.1.3 Test the ability of renal organoids made from cryopreserved cells 
to detect nephrotoxicity: 
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To further assess the function of the proximal tubular cation transporters in the 
cryopreserved cells and to assess whether they can detect nephrotoxic compound in 
a predicted way, I used Cisplatin. Cisplatin is a chemotherapeutic drug; its 
nephrotoxicity is a major drawback for its clinical use. Cisplatin nephrotoxicity primarily 
affects proximal tubular cells. It accumulates in the proximal tubular cells mainly via 
OCT2 uptake where it interferes with DNA synthesis and causes DNA damage and 
results in dose dependent apoptosis and necrosis to the tubular cells (Yonezawa and 
Inui, 2011b; Volarevic et al., 2019). Organoids obtained from cryopreserved cells were 
treated with increasing doses of Cisplatin after 10 days of post-thawing culture (0, 5, 
10 and 30 μM) for 24 hrs. The treated organoids were then fixed and immuno-stained 
for ECAD1, LTL and Caspase3, an apoptosis marker. The toxic response was 
assessed by quantifying Caspase3 inside the organoid tubular structures. Increase in 
Caspase3 inside the proximal tubules was seen indicating dose-related apoptosis of 













Figure 4.8. Response of the 3D organoids derived from cryopreserved cells to 
treatment with increasing concentrations of Cisplatin a) shows increase in the 
apoptotic marker Caspase 3 in response to the treatment; scale bar is 100 μm. b) 
Graph shows the relative increase in caspase 3 in the treated groups compared to the 
control, untreated cells, using total fluorescence quantification of Caspase 3 in stained 










4.3.2 Test the possibility of cryopreserving fully differentiated cells: 
Finally, I wanted to see if cells were dissociated and cryopreserved after being 
differentiated as monolayers until the end of the differentiation protocol (18 days) will 
still be able to form organoids after thawing. The fully differentiated cryopreserved cells 
were aggregated after thawing and cultured as pellets in presence of ROCK inhibitor 
for the first 24 hrs and without any additional growth factors or inducers for three more 
days, after which they were fixed and stained (figure 4.9). The organoids showed 
development of tubular structures with positive expression of ECAD1, WT1 and LTL 
indicating developing nephrons (for more details about see section 3.3.2.2 and section 
3.3.2.3).  Moreover, these organoids showed 6-CF uptake when live-incubated with it 
(using the same functional assays described in section 4.2.2.2.1) suggesting 
functional anion transporters and suggesting successful revival of differentiated cells 
(figure 4.9 C, D). I have to clarify that I cryopreserved only one run of differentiation 
after the end of the differentiation protocol, and successfully revived samples of it on 
three different occasions, while I investigated cryopreserving the cells after 12 days of 
differentiation more thoroughly and was able to revive them successfully for up to one 


















Figure 4.9. Organoids made from cryopreserved cells (cells were differentiated until 
the end of the differentiation protocol (18 days) then dissociated and cryopreserved). 
A) Organoid cultured in 3 D culture for 1 day after thawing and removal of the ROK 
inhibitor. B) Organoids cultured for 3 days after thawing and removal of ROK inhibitor. 
LTL shown in blue, ECAD shown in green, WT1 shown in red. LTL was negative when 
organoids were stained after one day of culture. C, D) 6-CF uptake test to 3D 
organoids made from cryopreserved fully differentiated cells after 4 days of culture 
post-thawing C) in absence of probenecid, D) in presence of probenecid. Scale bar is 







Proximal tubular secretion and reabsorption are key to the reabsorption of valuable 
nutrients and solutes, and the clearance of toxins and metabolic waste products, 
especially for those protein-bound solutes that do not cross the glomerular filtration 
barrier, and they are of a particular importance in renal drug clearance. Organoids 
obtained by this protocol have recently been engrafted into animal hosts, either 
subcutaneous (Bantounas et al., 2018) or under the renal capsule (van den Berg et 
al., 2018), and were shown to acquire a blood supply from the animal host with some 
evidence of glomerular perfusion. While glomerular filtration is a crucial aspect of renal 
function, trans-epithelial tubular transport is another important partner in renal function 
(Wang and Kestenbaum, 2018). Renal organoids produced using the Takasato 
protocol of differentiation have not been assessed for their trans-epithelial transport 
capacity before. Here, I reported the expression OAT1 and OCT2, the major anion 
and cation transporters on the basolateral membrane of proximal tubular cells. I 
assessed the function of these transporters and showed that 3D renal organoids can 
take up 6-CF in an inhibitor-sensitive way suggesting functional anion transporters.  
Similarly, ASP uptake was seen in proximal tubular structures in the 3D organoids and 
was inhibited with TPA in a dose dependant manner which reflects physiological 
function of organic cation transporters in this model.  
The presence of functional proximal tubular transporters in renal organoids makes 
them a promising tool  in regenerative medicine; which could probably be used to 
develop cell-based bioartificial kidney capable of removing anionic and cationic uremic 
toxins thus improving the currently available dialysis procedures (Jansen et al., 2015; 
Masereeuw and Stamatialis, 2017a; Oxburgh et al., 2017), or they could be used to 
engineer human embryonic kidney with one collecting duct tree and organised cortex 
and medulla which, if achieved, could be transplanted into a host to allow its 
maturation into a replacement organ (Davies and Chang, 2014), however, in the 
current situation, the use of hiPSCs-derived renal cells for detecting nephrotoxicity 
could be more realistic and of a great impact. So, in the next chapter, I aim to evaluate 
renal-differentiated cells as a potential model to detect nephrotoxicity.   
Next, I investigated the possibility of cryopreserving differentiated cells without losing 
the ability to express key renal proteins and showed that the thawed cells after few 
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days in culture were able to make renal organoids with positive expression pattern to 
different segments of the nephron and to the UB/CDs. To my knowledge, the ability to 
cryopreserve renal differentiated cells has never been investigated before. I reported 
that treatment with ROCK inhibitor for 24 hrs post thawing was critical for the revival 
of the cells as cells did not revive in its absence and underwent apoptosis. The 
importance of ROCK inhibitor to prevent dissociation induced apoptosis has been 
shown in different applications that involves stem cell dissociation including passaging 
and cryopreservation (Watanabe et al., 2007; Kurosawa, 2012; Claassen, Desler and 
Rizzino, 2009). It has also been shown to be important for the survival of dissociated 
renal progenitors cells (Unbekandt and Davies, 2010). Reports have also shown its 
importance for successful cryopreservation of hiPSC-derived cardiomyocytes (Kim et 
al., 2011; Xu et al., 2011), hiPSC-derived neural progenitors (Nemati et al., 2011) and 
hiPSC derived brain endothelial cell progenitors (Wilson et al., 2016). Here, I reported 
that ROCK inhibitor is similarly important for successful cryopreservation and reviving 
of hiPSC-derived renal progenitors.  
I showed that cells frozen after 12 days of differentiation were able to revive, 
maintained their capacity to self-organise making tubular structures which showed 
positive markers for different segments of the nephron and for the collecting ducts, 
and possessed organic anion and cation transport-ability. Cells were cryopreserved, 
and successfully revived, for up to one year.  
Importantly, organoids made from cryopreserved renal progenitors were able to detect 
cisplatin toxicity by increasing the apoptotic marker Caspase3; the toxic effect of 
cisplatin was manifest at 5 μM dose treatment. This was comparable to what other 
studies have shown (Takasato et al., 2015; Bajaj, A. David Rodrigues, et al., 2018), 
and was much more sensitive than what has been shown in a recent study performed 
on hPSC-derived renal organoid and detected cisplatin induced apoptosis at 16 μM 
dose treatment (Czerniecki et al., 2018). Additionally, I have demonstrated that 18 
days differentiated cells could be dissociated and cryopreserved. However, I have to 
clarify that I investigated cryopreserving the cells after 12 days of differentiation more 
thoroughly than cryopreserving them after 18 days of differentiation. For the latter, I 
cryopreserved only one run of differentiated cells and successfully revived them on 
three different occasions.  
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Employing cryopreserved cells for nephrotoxicity screening can save time, and effort, 
allow for high throughput analysis and streamline the use of these cells for drug 
discovery purposes. Yet, wide scale assessment of the ability of the cryopreserved 















The primary role of renal cells is eliminating various drugs, metabolites and toxins; in 
addition,  the high renal blood flow results in a high rate of toxicant delivery to the 
kidney,  making renal cells highly vulnerable to different forms of injury and toxicity 
(Perazella, 2009; Pazhayattil and Shirali, 2014). Drug-induced nephrotoxicity is a 
serious adverse effect of various categories of drugs. Based on the mechanism of 
toxicity of individual drugs, the damage can affect glomeruli, tubules, vascular cells or 
interstitial cells and can manifest as acute or chronic functional affection (Awdishu and 
Mehta, 2017). 
Drug research and development goes classically through different steps where the 
potential compound is first tested in in-vitro 2D cell cultures, then further assessed in 
experimental animals and finally, it has to proceed through phase I to phase III clinical 
trials in human before being available for widespread clinical use in markets (Davies, 
2018). Until recently, the potential of drug-induced nephrotoxicity has conventionally 
been tested both in animal models (Gautier et al., 2010, 2016; Harpur et al., 2011) and 
monolayer cell cultures either of primary cell cultures or cell lines (Huang et al., 2015). 
Experimental animals for testing toxicity, despite providing an in-vivo multi-organ 
complex system for assessing drugs, have one major drawback for their use, which is 
interspecies differences in vulnerability to toxins. Only a small percentage of drugs 
that reach to phase I clinical trials eventually succeed to proceed to marketing and 
become available for widespread use (Seruga et al., 2015; Miranda et al., 2018). While 
cell cultures are an alternative to the use of animals in drug screening, 2D cultures 
lack the in-vivo complexity where interaction between different types of cells contribute 
to the effect of the drug (Davies, 2018; Elhendawi and Liu, 2018; Miranda et al., 2018). 
Also, some of the immortalised proximal tubular cell lines that  are used to screen for 
nephrotoxicity lack certain anion and cation drug transporters (Jenkinson et al., 2012) 
which makes them less predictive for toxicity. 
There is therefore an increasing interest in the use of renal organoids, being a 
miniature renal tissue, as a model for high throughput compound screening for 
nephrotoxicity. Some recent reports have demonstrated a predicted response of 
iPSCs-derived proximal tubules (Kandasamy et al., 2015) or iPSCs-derived 
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multicellular renal organoids (Bajaj, A David Rodrigues, et al., 2018) to known 
nephrotoxic compounds. 
In this section, I wanted to evaluate the ability of renal-differentiated cells to detect 
nephrotoxic compounds. Because the anatomical complexity of organoids can be 
problematic as it makes obtaining a simple quantitative response to toxic stimuli 
challenging, I address this problem by exploiting a nephrotoxicant-stimulated 
fluorescent reporter system to screen for toxic compounds in renal organoids. 
5.2 Gentamicin treatment and RNA-seq experiment: 
The Aminoglycoside family of antibiotics is mainly active against gram-negative 
bacteria; Gentamicin and Tobramycin are two commonly prescribed members of this 
family. Nephrotoxicity and ototoxicity are the most serious side effects associated with 
aminoglycoside exposure; renal injury manifest in the form of non-oliguric acute renal 
failure with different degrees of tubular dysfunction. Decrease in glomerular filtration 
rate can occur later after 5-7 days of treatment (Begg and Barclay, 1995).  
Aminoglycoside-induced toxicity mainly targets proximal tubular cells 
(Moestrup et al., 1995). The drug filters freely through the glomeruli then accumulates 
inside the proximal tubular cells through an apical uptake pathway that is different from 
the transport via anion and cation transporters. Aminoglycoside drugs are polybasic 
compounds, they bind to an apical anion phospholipid, Megalin, which is a multi-ligand 
endocytic receptor that mediates their endocytosis (Moestrup et al., 1995). 
Physiological Megalin ligands include low molecular weight proteins that filter through 
the glomeruli such as transthyretin, insulin, vitamin D binding protein, retinol binding 
protein, α1-microglobulin and β2-microglobulin; it is highly expressed in the proximal 
tubules and mice deficient in Megalin receptor experience low-molecular-weight 
proteinuria (Nielsen et al., 1995; Christensen and Willnow, 1999; Leheste et al., 1999; 
Christensen and Birn, 2001; Schmitz et al., 2002). Schmitz et al demonstrated that 
Megalin mediated endocytosis is the principal pathway for renal aminoglycoside 
accumulation and that Megalin knockout mice are protected against renal 
aminoglycoside accumulation and nephrotoxicity (Schmitz et al., 2002).  Inside the 
cell, the aminoglycoside is translocated into lysosomes where it inhibits the function of 
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lysosomal enzymes and causes accumulation of damaged organelles and membrane 
fragments in the form of myeloid bodies (Quiros et al., 2011).  
5.2.1 The aim of this experiment was: 
- To evaluate the expression of different proximal tubular transporters and receptors. 
The expression of these transporters and receptors is critical for renal drug uptake 
and toxic response. 
- To test the response of the cells to aminoglycoside and whether that response 
matches the pre-known nephrotoxic effect of aminoglycoside 
-  The main aim of this experiment was to find a potential marker that could be used 
to report toxic insults in renal-differentiated cells through analysing the differentially 
expressed transcripts, between control untreated renal cells and gentamicin-treated 
cells, and identifying a highly expressed injury marker. Engineering an iPSC line to 
report the expression of this marker would enable the production of injury reporting 
renal cells. 
5.3 Results: 
In this experiment RNA-seq was performed for three groups of 2D renal-differentiated 
cells: control group (untreated) and two treated groups of different concentrations; 1 
mg/mL (low concentration treated group) and 4 mg/mL (high concentration treated 
group). 
5.3.1 Analysing gene expression data obtained from the control group: 
I first used the gene expression data obtained from the control samples to examine 
the expression of important proximal tubular receptors; the endocytic receptor Megalin 
and the closely associated receptor Cubilin were both expressed in the untreated 
samples. Megalin and Cubilin are the main endocytic receptors involved in Gentamicin 
uptake into proximal tubular cells and the response of the cells to gentamicin is 
dependent on their expression and function (figure 5.1). I also used the RNA-seq data 
to examine the expression of the different proximal tubular transporters. OAT1, and 3, 
were both not detected in the three tested control samples, however, OATP4C was 
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expressed which still could work as an entry site for anionic drugs and toxins. OCT2 
was either not expressed or detected in low levels.  
MRP 2 and 4, which are the major apical transporters that mediate efflux of anions 
into the urine, were both expressed. MATE1, OCTN1 and 2, and P-gp, the main cation 
efflux transporters on the apical membrane, were also expressed (figure 5.1). 
 
Figure 5.1. The expression of important proximal tubular receptors and transporters 
in untreated renal-differentiated cells by RNA-seq transcript analyses. A) Expression 
of the endocytic receptors Megalin and Cubilin. B) Expression of the anion 
transporters. C) Expression of the cation transporters. FPKM: Fragments Per Kilobase 
of transcript per Million mapped reads. 
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My previous RT-PCR results suggested that OAT1 and OCT2 were expressed in 3D 
organoids but not in the 2D differentiated cells; the result of gene expression obtained 
from the RNA-seq was consistent with the previous RT-PCR results which confirmed 
the absence of these transporters in the 2D cultures (or, in the case of OCT2, presence 
in low levels in some of the samples).  As discussed before OAT1, OAT3 and OCT1 
are the main anion and cation transporters expressed on the basolateral membrane 
of proximal tubular cells; they mediate the first step of tubular secretion for many drugs, 
toxins and metabolic waste products by transporting them from the blood to the tubular 
cells and their absence in the 2D cultures could affect their ability to detect the toxicity 
of some substrates (for more details see chapter 4). However, the results of the RNA-
seq showed that other important renal transporters were detected in the 2D renal-
differentiated cells (OATP4C1, MRP2, MRP4, MATE1, OCTN1, OCTN2, P-gp and 
BCRP1). 
5.3.2 Analysing differentially expressed genes between the control group 
and the low-dose gentamicin-treated groups: 
I next looked at the differentially expressed genes in response to gentamicin treatment 
in two different contrast groups (the low treated group versus the control group and 
the high treated group versus the control group). After applying a stringent FDR cut-
off of 0.05 there were no genes detected to be expressed significantly different 
between the low-treated group and the control group. However, when setting a less 
stringent FDR cut-off, 0.1, there were 14 significantly upregulated genes in that 
contrast. Setting an FDR cut-off of 0.1 increases the possibility of detecting false 
positive genes (1.4/14 genes would be expected to be false positive), however, my 
aim was not to analyse the individual upregulated genes but rather to evaluate the 
overall response of the treated cells based on a cluster analysis of the upregulated 
genes; having upregulated cluster of gene involved in particular biological process or 
molecular function will be more significant than looking at the individual genes.  
After endocytosis, aminoglycosides accumulate inside the lysosomes, Golgi 
apparatus and the endoplasmic reticulum (Silverblatt and Kuehn, 1979; Giurgea-
Marion et al., 1986; Sandoval and Molitoris, 2004). The aminoglycoside drug causes 
lysosomal phospholipidosis as it binds to phospholipids and inhibits the function of the 
phospholipase enzyme; it also causes deposition and accumulation of polar lipids in a 
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multi-lamellar way known as myeloid bodies, the enlarged lysosomes then rupture with 
subsequent release of the myeloid bodies into the cytoplasm (Silverblatt, 1982). The 
accumulation of the aminoglycoside in the endoplasmic reticulum can cause 
endoplasmic reticulum stress which initiates unfolded protein response and arrest in 
the cell cycle (Zhang et al., 2006). It has also been shown that gentamicin binds to 
calreticulin affecting its chaperon activity for correct protein folding (Horibe et al., 
2004). At certain concentration, aminoglycoside leaks outside the lysosomes where it 
acts on the mitochondria and triggers cytochrome C mediated intrinsic pathway of 
apoptosis, which disrupts electron transport and ATP production and results in the 
production of reactive oxygen species (Servais et al., 2006; Morales et al., 2010). 
Lysosomal cathepsins escape into the cytoplasm and also activate the intrinsic 
pathway of apoptosis and necrosis in higher concentrations (Schnellmann and 
Williams, 1998) (Quiros et al., 2011; McWilliam et al., 2017).  
 When the upregulated genes were used in gene ontology (GO) term analysis, using 
Panther overrepresentation test (http://www.pantherdb.org), they were linked to 
relevant GO terms (detoxification of inorganic compounds, response to endoplasmic 
reticulum stress, response to unfolded protein, protein refolding, cellular response to 
stress etc) (table 5.1). As shown from the GO term enrichment analysis, there was 
enrichment in the GO terms linked to endoplasmic reticulum stress and unfolded 
protein response which suggested an early response to gentamicin detected at this 
concentration,1 mg/mL. The upregulated genes in the low-treated group versus the 
control group were further upregulated with higher significance in the high vs control 
contrast which further suggests the significance and relevance of the upregulated 










Table 5.1. Panther Gene Ontology term enrichment analysis for the 14 upregulated 
genes when comparing the low dose-treated group to the control cells. 
GO biological process 









(GO:0061684) 4 2 0 > 100 4.41E-03 
negative regulation of inclusion 
body assembly (GO:0090084) 11 2 0.01 > 100 1.74E-02 
protein refolding (GO:0042026) 22 4 0.01 > 100 3.18E-06 
stress response to metal ion 
(GO:0097501) 18 3 0.01 > 100 3.48E-04 
PERK-mediated unfolded 
protein response (GO:0036499) 12 2 0.01 > 100 1.96E-02 
chaperone cofactor-dependent 
protein refolding (GO:0051085) 31 5 0.02 > 100 8.54E-08 
'de novo' posttranslational 
protein folding (GO:0051084) 37 5 0.02 > 100 1.54E-07 
detoxification of copper ion 
(GO:0010273) 16 2 0.01 > 100 2.99E-02 
stress response to copper ion 
(GO:1990169) 16 2 0.01 > 100 2.90E-02 
'de novo' protein folding 
(GO:0006458) 41 5 0.03 > 100 1.77E-07 
regulation of inclusion body 
assembly (GO:0090083) 17 2 0.01 > 100 3.15E-02 
detoxification of inorganic 
compound (GO:0061687) 17 2 0.01 > 100 3.06E-02 
regulation of cellular response to 
heat (GO:1900034) 45 5 0.03 > 100 2.39E-07 
chaperone-mediated protein 
folding (GO:0061077) 59 6 0.04 > 100 1.06E-08 
cellular response to heat 
(GO:0034605) 69 4 0.05 87.13 1.57E-04 
response to unfolded protein 
(GO:0006986) 155 8 0.1 77.57 2.47E-10 
response to topologically 
incorrect protein (GO:0035966) 175 9 0.12 77.3 7.43E-12 
regulation of response to 
endoplasmic reticulum stress 
(GO:1905897) 79 3 0.05 57.08 1.22E-02 
Endoplasmic reticulum 
associated protein degradation 
pathway (GO:0036503) 82 3 0.05 54.99 1.31E-02 
cellular response to unfolded 
protein (GO:0034620) 119 4 0.08 50.52 9.85E-04 
protein folding (GO:0006457) 220 7 0.15 47.82 1.31E-07 
positive regulation of cellular 
protein catabolic process 
(GO:1903364) 138 3 0.09 32.67 4.32E-02 
regulation of protein 
ubiquitination (GO:0031396) 194 4 0.13 30.99 4.84E-03 
regulation of protein modification 
by small protein conjugation or 
removal (GO:1903320) 221 4 0.15 27.2 7.68E-03 
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response to endoplasmic 
reticulum stress (GO:0034976) 235 4 0.16 25.58 9.35E-03 
regulation of cellular response to 
stress (GO:0080135) 661 8 0.44 18.19 3.99E-06 
protein catabolic process 
(GO:0030163) 649 5 0.43 11.58 2.30E-02 
cellular response to stress 
(GO:0033554) 1609 8 1.07 7.47 1.95E-03 
response to organic substance 
(GO:0010033) 2840 10 1.89 5.29 1.06E-03 
cellular response to chemical 
stimulus (GO:0070887) 2737 8 1.82 4.39 4.95E-02 
Response to stress 
(GO:0006950) 3484 12 2.32 5.17 4.16E-05 
 
Table 5.2. 14 genes significantly upregulated between the low gentamicin treated 
group and the control group when setting an FDR cut-off of 0.1 and their pattern of 





FDR ( Low vs 
Control) 
Log2 FC (High 
vs Control) 
FDR (High vs 
Control) 
INHBE 3.79984787 0.0638602 4.23778322 2.04E-05 
MT1F 3.00769486 0.0795063 10.4795115 3.53E-07 
MT1G 2.95685361 0.0638602 11.1376446 2.84E-06 
HSPA1B 1.56376516 0.0644929 2.88661362 3.26E-05 
HSPH1 1.5051937 0.056884 3.25824117 6.97E-05 
HERPUD1 1.4915876 0.0739903 2.24188376 0.00013004 
HSP90AA1 1.36179404 0.0638602 2.24736257 0.00043464 
SLC1A4 1.35630098 0.0976128 2.73449285 2.04E-05 
HSPA5 1.33756392 0.0638602 1.17364026 0.00071785 
SDF2L1 1.27341455 0.0535053 1.04490022 0.00072075 
DNAJB1 1.26359077 0.0646176 2.34979089 2.33E-05 
MANF 1.24856294 0.0535053 1.31794135 0.00048054 
HSPA8 1.09427653 0.0795063 1.36458984 0.00011121 
PDIA4 1.08036286 0.0638602 0.64442267 0.00084008 
 
5.3.3 Analysing differentially expressed genes between the control group 
and the high-dose gentamicin-treated groups: 
Applying an FDR cut-off of 0.05 (for statistical significance) and a fold change cut-off 
of 2 (for biological importance) there were 2221 upregulated genes and 1770 
downregulated genes in the high treated versus the control contrast. To analyse the 
upregulated genes comparing the high treated group to the control group, I first filtered 
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the genes by the lowest FDR and then selected the 100 most upregulated genes. I 
next used these genes to perform GO term enrichment analysis using the PANTHER 
Over-representation test. The GO terms of the enriched genes included classes highly 
relevant to toxic insults, including response to toxic substance, detoxification, 
regulation of cell death, cellular response to stress, response to unfolded and 
misfolded proteins, chaperone mediated protein folding and chaperone cofactor-
dependent protein refolding (table 5.3). 
The GO terms linked to the most upregulated genes clearly showed that the cells were 
exposed to toxic substance that caused injury. INHBE gene was one of the most 
upregulated genes (log fold change = 4.23, FDR = 2.04 -05) it encodes for a member 
of the TGF-beta superfamily. After proteolytic processing it generates inhibin beta 
subunit; inhibins have a role in regulating numerous processes, including proliferation 
and apoptosis, and could be upregulated in cases of ER stress (NCBI, 2018). Other 
genes involved in apoptosis signalling and apoptosis modulation were also highly 
upregulated including: LTA, JUN, FOS, HRK, GADD45B. The oxidative stress marker 
HMOX1 was one of the 100 most significant upregulated genes (log fold change: 6.55; 
FDR: 0.00015) in that contrast (table 5.4).  
The expression of KIM-1, a biomarker commonly associated with renal tubular 
necrosis was significantly increased when comparing the high treated group to the 
control (log fold change: 1.67; FDR: 0.03) and the expression of Megalin was 
significantly decreased (Log fold change = -3.62, FDR = 0.010) which could be 
explained as a protective mechanism to decrease the influx of the offending drug (table 
5.4). 
To find a potential marker that could be used as a reporter for injury and toxicity, I did 
functional classification, for the same 100 most significant upregulated genes 
comparing the high treated group to the control group, using PANTHER classification 
system. The six major gene ontology categories (biological regulation, cellular 
process, metabolic process, response to stimulus, binding and catalytic activity) were 
further analysed for the intersection between them to find a marker that can represent 
most of the toxicity response mechanisms. Two genes were common between the six 
groups: TRIB3 (4.4 fold increase; FDR 2.15 x 10 -5) and HMOX1 (93.84 fold increase; 
FDR 0.00014) (figure 5.2). Although KIM1 and NGAL are highlighted as classical in-
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vivo renal injury markers, reports on their suitability for in-vitro nephrotoxicity screening 
in cell culture model have been mixed. Adler and colleagues reported that KIM1 was 
not upregulated in response to injury using HPTEC cells in both 2D cultures and 3D 
microfluidic-based cultures, while according to that study HMOX1 was a more 
sensitive marker for predicting nephrotoxicity (Adler et al., 2016). Similar results were 
obtained by Li et al who also used HPTEC cells and demonstrated either lack of 
response or low level of upregulation of KIM1 and NGAL respectively (Y. Li et al., 
2013a). On the opposite side, Huang et al showed an increase in KIM1 and other 
injury markers when exposed HPTEC cells, but not proximal tubular cell lines, to toxic 
compounds (Huang et al., 2015) . 
Table 5.3. Enriched GO terms when comparing the untreated group to the high 
gentamicin treated group (4 mg/ml) and analysing the 100 most significant 
upregulated genes. 










detoxification of copper ion  14 8 0.07 > 100 4.25E-10 
  detoxification of inorganic 
compound  15 9 0.08 > 100 3.27E-11 
     detoxification  110 10 0.57 17.64 5.67E-07 
      response to toxic substance  482 17 2.48 6.84 5.71E-07 
  stress response to copper ion  14 8 0.07 > 100 3.40E-10 
    stress response to metal ion  16 9 0.08 > 100 2.54E-11 
      response to stress  3290 40 16.95 2.36 3.21E-05 
cellular response to zinc ion  22 8 0.11 70.57 3.01E-09 
PERK-mediated unfolded protein 
response 12 3 0.06 48.52 2.34E-03 
  cellular response to unfolded 
protein 118 7 0.61 11.51 1.20E-03 
    response to unfolded protein  154 10 0.79 12.6 9.07E-06 
      response to topologically 
incorrect protein 174 10 0.9 11.15 2.28E-05 
cellular response to cadmium ion  36 9 0.19 48.52 2.25E-09 
chaperone cofactor-dependent 
protein refolding  28 5 0.14 34.66 2.81E-04 
  chaperone-mediated protein folding  56 8 0.29 27.72 1.10E-06 
  'de novo' posttranslational protein 
folding  33 5 0.17 29.4 5.26E-04 
protein refolding  21 4 0.11 36.97  
regulation of cellular response to 
heat  45 6 0.23 25.88 1.11E-04 
  regulation of cellular response to 
stress  654 12 3.37 3.56 3.31E-02 
positive regulation of proteasomal 
ubiquitin-dependent  81 5 0.42 11.98 1.91E-02 
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protein catabolic process  
  positive regulation of proteasomal 
protein catabolic process  102 5 0.53 9.51 4.72E-02 
negative regulation of cell death  999 16 5.15 3.11 1.38E-02 
 
Table 5.4. Important differentially expressed genes between the control and the High 
gentamicin treated group (4 mg/ml). 
 
Gene name Log2 Fold change FDR 
Genes involved in 
apotosis   
LTA 3.873178046 0.000126499 
HSPA1B 2.886613617 3.26E-05 
JDP2 1.881787141 7.10E-05 
HSPA1A 2.663259915 1.75E-05 
HSPA6 5.205504565 3.52E-05 
ATF3 3.080254651 0.000376849 
FOS 3.87052057 0.00059826 
JUN 1.372582654 0.022640799 
HRK 3.327710653 0.001257237 
 The endocytic receptor 
Megalin   
Megalin -3.618874339 0.010592678 
Important renal injury 
markers   
KIM1 1.669097501 0.031340852 
HMOX1 6.552266071 0.000147085 






Figure 5.2. RNA-seq analyses of renal-differentiated hiPSCs treated with gentamicin 
(1mg/ml or 4mg/ml) or left untreated. a,b) Functional classification for the 100 most 
significant upregulated genes between the high gentamicin treated group and the 
control group using the biological process ontology (a) and the molecular function 
ontology (b). c) Venn diagram for the intersection between the six main categories of 
genes, obtained using the two different ontologies, showing HMOX1 and TRIB3 were 
common between the six groups (full details of the Venn diagram are shown in table 
5.5). d) Heat map showing the 50 most variable genes when comparing the three 
groups together (untreated, low dose-treated and high dose-treated cells); HMOX1 




Table 5.5. Shows the detailed intersection between the six main categories of genes 
using GO classification 
Names total elements 
Binding MF, Biological Regulation BP, Catalytic Activity MF, 
Cellular Process BP, Metabolic Process BP, Response to 
Stimulus BP 
2 TRIB3, HMOX1 
Binding MF, Catalytic Act MF, Cellular Proc BP, Metabolic 
Process BP, Response to Stimulus BP 
3 HSPA6, HSPA1B, HSPA1A 
Binding MF, Catalytic Activity MF, Cellular Proc BP, 
Metabolic Process BP 
3 ASNS, FKBP4, TSPYL2 
Binding MF, Cellular Process BP, Metabolic Process BP, 
Response to Stimulus BP 
2 INHBE, MSTN 
Binding MF, Biological Regulation BP, Cellular Process BP, 
Metabolic Proc BP 
1 HIST1H2AG 
Binding MF, Biological Regulation BP, Cellular Process BP, 
Response to Stimulus BP 
2 LRG1, EGF 
Catalytic Activity MF, Cellular Process BP, Metabolic 
Process BP, Response to Stim BP 
1 PPP1R15A 
Biological Regulation BP, Catalytic Activity MF, Cellular 
Process BP, Metabolic Process BP 
3 DIO3, GCLM, CES1 
Binding MF, Cellular Process BP, Metabolic Process BP 6 SFPQ, PSPC1, GCM1, DNAJB1, ATF5, JDP2 
Binding MF, Cellular Process BP, Response to Stimulus BP 1 LTA 
Binding MF, Biological Regulation BP, Cellular Process BP 2 FTH1, FTL 
Binding MF, Biological Regulation BP, Metabolic Process BP 1 ID2 
Catalytic Activity MF, Cellular Process BP, Metabolic 
Process BP 
6 UAP1L1, WARS, BAAT, HTRA3, B3GALNT2, 
ABCC3 




CASS4, SLC30A2, GABRR2 
Binding MF, Cellular Process BP 3 CHORDC1, TUBB3, AVIL 
Binding MF, Metabolic Process BP 1 BRPF3 
Catalytic Activity MF, Cellular Process BP 2 ME1, NEURL3 
Catalytic Act MF, Metabolic Process BP 2 CHKA, ASPRV1 
Cellular Process BP, Metabolic Process BP 2 SLC1A4, ZNF425 
Binding MF 4 ZFAND2A, CNN1, SQSTM1, MRPL18 
Cellular Proc BP 8 SLC38A10, SLC7A11, GATA2, MC1R, RRAD, 
SCFD2, MYH15, RASL11A 
Metab Proc BP 1 ANXA1 
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5.4 Human iPSC HMOX-1 reporter cell line-derived renal cells to 
test for nephrotoxic compounds:  
The RNA-seq experiment suggested HMOX1 as a good marker for detecting toxicity, 
few other studies have also shown HMOX1 as a sensitive marker for renal toxicity 
either in HEPTEC cells (Adler et al., 2016) or hiPSCs-derived renal organoids (Bajaj 
et al., 2018). In collaboration with other members in my lab and an industrial company, 
I used HMOX1 reporter hiPCS cell line (the production of this line was done by an MSc 
student in our lab) that produces mCherry under the control of HMOX1 promotor to 
blindly test the response of the renal-differentiated 2D and 3D cell models to different 
compounds. Before starting the compound screening experiment, the HMOX1-
mCherry-hiPSC reporter cells were first evaluated for their ability to respond to 
hydrogen peroxide, an oxidative stress inducer that stimulates the production of 
HMOX1, both by quantifying the fluorescence, as an indication of mCherry production, 
and by measuring HMOX1 expression using qPCR and comparing the results (this 
evaluation was performed by Dr. Melanie Lawrence; figure 5.3 a-c).  
Next, I tested the ability of these cells to differentiate into renal cells, both in 2D and 
3D formats, and evaluated the obtained cells for the expression of different specific 
renal markers using immunofluorescence staining to exclude that HMOX1 targeting 
could have affected the ability of these cells to make renal organoids. the differentiated 
cells showed positive expression of the glomerular markers, WT1 and NPHS1; the 
proximal tubular markers, Jagged1 and LTL and the distal tubular marker, ECAD. 
Some of the tubules also showed co-expression of ECAD and GATA3 indicating 
ureteric epithelial structures (figure 5.3 d-g); collectively the data indicated that the 
targeting strategy did not affect the ability of the cells to differentiate into renal cells.  
Afterwards the differentiated cells were treated with the known nephrotoxicant; 
cisplatin or gentamicin, in an increasing concentrations and the mCherry fluorescence 
was quantified and compared to the HMOX1-mRNA response to confirm that the 
reporter response matches the transcript expression response (this evaluation step 
was performed by Dr. Melanie Lawrence; figure 5.3 h-m).  
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Figure 5.3. Verification of the reporting activity and the renal-differentiation ability of 
the HMOX1-mCherry-hiPSCs. a-c) The response of the undifferentiated HMOX1-
mCherry-iPSCs to increasing concentrations of the known oxidative stress inducer 
hydrogen peroxide. a) Shows quantification of the total fluorescence in the treated 
cells compared to the control; b) representative images for the fluorescing cells; c) 
shows the fold change of HMOX1 expression in the treated cells compared to the 
control using qPCR. d-g) The HMOX1-mCherry-iPSC reporter cells are able to 
differentiate into renal cells, as shown by the expression of renal markers, both in 2D 
(d, e) and 3D (f, g) differentiation forms. h-j) The response of 2D renal-differentiated 
cells to increasing concentrations of the known nephrotoxic drug gentamicin. h) The 
increase in fluorescence in response to the treatment; i) representative images for the 
treated cells; j) qPCR result showing the fold increase in HMOX1 transcript level in 
response to gentamicin. k-m) The increase in HMOX1 level in response to Cisplatin 
treatment using total fluorescence quantification of mCherry as an indicator of HMOX1 
expression (k) and using qPCR to quantify the transcript level (m); l) representative 
images for the treated cells. Scale bars are 100 µm for d-g and 200 µm for the rest of 
the images.  
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5.4.1 Nephrotoxicity compound screening: 
Renal cells derived from the HMOX1 reporter cell line were used to test a panel of 
blind-coded compounds, supplied by Collaborators in Sweden, for potential 
nephrotoxicity. HMOX1-mCherry-hiPSCs were differentiated for 21 days in two 
different formats, 2D cultures and 3D organoids. A four-fold dilution series of each 
compound was prepared, and HMOX1-mCherry-hiPS renal cells were incubated in 
these dilutions for either 24 hrs or 72 hrs (as some of the drugs could induce early 
toxic response while others could induce toxicity after prolonged exposure), then 
fluorescent images were taken. The images were quantified for total fluorescence as 
a measure of HMOX-1 expression in response to the different compounds. Compound 
screening and analysis of the fluorescent images were completed before revealing the 
nature of the compounds (figure 5.4 a and 5.4 b). 
The 2D and the 3D models were both able to identify Dexamethasone as a benign 
compound that did not induce significant increase in fluorescence upon exposure to 
the drug for 24 hrs or 72 hrs.  
Ketoprofen is a very widely used non-steroidal anti-inflammatory (NSAID) drug that 
can have detrimental effect on the renal function mainly through affecting renal blood 
flow (Catella-Lawson et al., 1999; Whelton et al., 2000; Harirforoosh and Jamali, 2009; 
Hörl, 2010); increase in fluorescence was detected only in response to the highest 
concentration tested of Ketoprofen.  
Puromycin affects the post-translational modification of glomerular proteoglycans and 
downregulates its expression hence leads to thinning of the glomerular glycocalyx 
which affects the glomerular selectivity and leads to proteinuria (Björnson et al., 2005; 
Jeansson et al., 2009). Puromycin induced increase in fluorescence, both in 2D and 
3D cultures, mainly in response to the highest concentration tested. 
Cidofovir, an antiviral drug that has wide spectrum activity against DNA viruses, is 
transported to the proximal tubular cells through OAT1 transporter on the basolateral 
membrane and causes proximal tubular cell injury, apoptosis and acute renal failure 
(Ortiz et al., 2005). Cidofovir induced significant increase in fluorescence in response 
to all tested concentrations after 72 hrs in the 2D model and a significant response 
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only to the highest concentration tested in the 3D cultures after 24 hrs; no significant 
response was noticed in the 2D cultures after 24 hrs or in the 3D cultures after 72 hrs.  
Cisplatin and Ifosfamide are both taken into the proximal tubular cells through OCT2 
transporter. Cisplatin is a chemotherapeutic drug, its enrichment in the proximal 
tubular cells, caused by the OCT2 transporter activity, leads to tubular cell apoptosis 
and necrosis (Ban, Hettich and Huguet, 1994); the nephrotoxic effect of Cisplatin is 
mediated by persistent inhibition of DNA synthesis and depletion of glutathion which 
results in lipid peroxidation, mitochondrial damage and oxidative stress (Kuhlmann, 
Burkhardt and Köhler, 1997; Huang et al., 2001). Ifosfamide is an antineoplastic; inside 
the renal proximal cells Ifosfamide is oxidized into a toxic metabolite; 
chloroacetaldehyde (CAA) which causes  Fanconi syndrome and proximal tubular 
dysfunction(Aleksa et al., 2005; Nissim et al., 2006). Both Cisplatin and Ifosfamide 
induced dose dependent increase in fluorescence in the 3D system both after 24 hrs 
and 72 hrs of exposure. The 2D system showed significant increase in fluorescence 
only in response to the highest concentration tested after 24 hr treatment of both drugs 
(384 µM for Cisplatin, 384 and 1536 µM for Ifosfamide); after 72 hrs of treatment the 
increase of fluorescence was significant for all tested concentrations of Ifosfamide and 
for the two highest concentrations of Cisplatin (96 and 384 µM). The 3D cultures 
showed significant increase in fluorescence in response to most of the tested 
concentrations. 
Gentamicin showed increase in fluorescence in response to most of the tested 
concentrations in 3D cultures at the two evaluated time points; 24 hrs and 72 hrs post 
exposure. The 2D cultures showed dose related increase in fluorescence after 24 hrs 
exposure but after 72 hrs exposure the response was only significant in response to 







Figure 5.4 a. Compound screening for potential nephrotoxicity using 2D renal-
differentiated cells derived from HMOX1-mCherry-hiPSC reporter cell line. 2D renal 
cells were treated with increasing concentrations of the indicated drugs, in a blind-
coded way, for either 24 or 72 hrs followed by imaging and quantifying the total 
fluorescence in the mCherry channel (as an indicator of HMOX1 expression). Each 
time-point was carried out as a separated experiment and included an untreated 
control. Drug concentrations are shown in µM. Significance of fluorescence intensity 
increase compared to the control was assessed using a T-test with Welch’s correction. 
n=4 for each group in the 24-hr treatment and n= 10 for each group in the 72-hr 






Figure 5.4 b. Compound screening for potential nephrotoxicity using 3D renal-
differentiated cells derived from HMOX1-mCherry-hiPSC reporter cell line. Renal 
organoids were treated with increasing concentrations of the indicated drugs, in a 
blind-coded way, for either 24 or 72 hrs followed by imaging and quantifying the total 
fluorescence in the mCherry channel (as an indicator of HMOX1 expression). Each 
time-point was carried out as a separated experiment; each experiment included an 
untreated control. Drug concentrations are shown in µM. Significance of fluorescence 
intensity increase compared to the control was assessed using a T-test with Welch’s 





Kidneys are at major risk of drug toxicity and so establishing high throughput models 
that can accurately predict nephrotoxicity is fundamental for drug development. An 
ideal platform for screening potential drugs and compounds is one that shows 
structural and functional similarity to human renal tissue (Adler et al., 2016). I have 
shown in the previous chapters that the iPSCs-derived renal organoids show gene 
expression pattern similar to the developing human nephrons, I also showed that the 
3D organoids expressed OAT1 and OCT2 and were able to transport fluorescent 
organic anion and cation substrates which suggested that they also share, at least in 
part, functional similarity to human renal tissue. To test the response of the renal-
differentiated cells to detect nephrotoxicity 2D renal-differentiated cells were 
investigated for their response to gentamicin using RNA-seq. The reason for using 2D 
cultures in this experiment was that they could be easily adapted to high-throughput 
applications; in particular, early phases of compound screening necessitate a model 
that allow testing tens of thousands of compounds (Davies, 2018); in this regards the 
use of the 2D cultures has the advantage of being less time consuming, less expensive 
and could be applicable on larger scale compared to the 3D organoids as they could 
be obtained in 24 wells, 96 wells or even 384 well formats. The 2D cultures start by 
seeding the iPSCs as monolayers on Matrigel-coated plates, but later, upon 
differentiation, they develop structures and form tubules and so are not actual 
monolayers or 2D, but rather, they could be considered as pseudo 2D cultures.  
Gene expression data, RT-PCR and RNA-seq, showed absence, or negligible levels, 
of OAT1 and OCT2 in the 2D renal-differentiated which probably suggests that the 3D 
cultures offer a better environment for the development of these transporters, 
however, RNA-seq data showed that other important proximal tubular transporters 
were detected in the 2D cultures including OCTN2, OAT4, OATP4c1, MATE1, MRP2, 
4, and BCRP. In addition to the aforementioned transporters, the 2D cultures also 
showed expression of the endocytic receptors Megalin and Cubilin, both of which are 
highly expressed in the renal proximal tubules and have an important role in 
reabsorbing low molecular weight proteins that can filter through the glomerular 
barrier; in addition to rescuing the filtered protein these endocytic receptors also play 
a role in xenobiotic uptake into the proximal tubular cells and the toxic effect of 
gentamicin is mainly dependent on their expression and function (Christensen and 
 170 
Birn, 2001; Quiros et al., 2011). The ability of the renal-differentiated cells to detect 
nephrotoxicity is highly dependent on the expression of these transporters and 
receptors as they represent the entry site for a lot of drugs and toxic compounds. 
Although my data showed the detection of many proximal tubular receptors and 
transporters hiPSC-derived renal cells, performing qPCR to quantify their level of 
expression and to compare it to the physiological level is still needed.  
Analysis of transcriptomic data obtained from gentamicin treated cells showed that 
cells exposed to 1 mg/ml drug concentration upregulated the expression of genes 
involved the response to endoplasmic reticulum stress, cellular response to unfolded 
and topologically incorrect proteins, and in the regulation of cellular response to stress. 
This reflected a typical image of early gentamicin toxicity. Other publications reported 
the toxic manifestations of gentamicin to be detected in cultured cells only upon 
treatment with doses above 1 - 2 mg/ml with apoptosis being the main response 
(Servais et al., 2006; Pessoa et al., 2009; Quiros et al., 2011; Bajaj, A David 
Rodrigues, et al., 2018); my results here suggest an early response to gentamicin in 
my cells, at 1 mg/ml, that mainly involved endoplasmic reticulum stress and unfolded 
protein response.  
GO term enrichment analysis for the most significant most upregulated genes when 
comparing the high dose treated group (4 mg/ml) to the untreated group showed 
enrichment of highly relevant GOT: detoxification (18.30 fold enrichment), response to 
toxic substance (7.29 fold enrichment), PERK-mediated unfolded protein response 
(52.60 fold enrichment), cellular response to unfolded protein (12.07 fold enrichment), 
cellular response to topologically incorrect proteins (10.37 fold enrichment). In 
addition, the high dose treated cells highly upregulated genes involved in apoptosis 
signalling and regulation. Collectively, the data showed that the cells were able to 
detect gentamicin as nephrotoxic substance.  
The purpose of the RNA-seq experiment was primarily to find a reporter of 
nephrotoxicity that could be engineered into hiPSCs, and then to assess the 
performance of that reporter using blind-coded test compounds. In my RNA-seq 
analyses, HMOX1 was one of the 50 most variable genes between the three compared 
groups and functional classification for the most significant upregulated genes, 
between the 4 mg/mL group and the control group, showed that HMOX1 could be a 
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potential useful marker to detect nephrotoxicity. HMOX1 is ubiquitously expressed in 
cells but cellular injury caused by oxidative stress, proinflammatory response, 
exposure to heavy metals, hypoxia, and ischemia highly induces its expression 
(Agarwal and Bolisetty, 2013; Nath, 2014). Under oxidative stress conditions, 
hemeproteins release their heme group; free heme catalyses free radical production. 
HMOX1 exerts a cytoprotective anti-apoptotic action via catabolizing the free pro-
oxidant heme into iron, carbon monoxide and biliverdin thus preventing the free heme 
from inducing and sensitising cells to undergo apoptosis (Gozzelino, Jeney and 
Soares, 2010). HMOX1 inhibition sensitises the cells to damaging agents by 
decreasing the antioxidative capacity of the cells; this property was used to increase 
the sensitivity of tumour cells to anti-cancer treatment (P. O. Berberat et al., 2005; 
Pascal O Berberat et al., 2005). Recent studies have highlighted HMOX1 as a 
potential marker for detecting nephrotoxicity; in-vivo studies have shown the 
upregulation of HMOX1 in the urine of patients with acute kidney injury and patients 
with tubulo-interstitial diseases (Yokoyama et al., 2011; Zager, Johnson and Becker, 
2012). Adler et al., performed a multiplexed gene expression profiling on HPTECs 
after exposing them to increasing concentrations of nine different nephrotoxicants plus 
a control of benign compound and showed that HMOX1 significantly increased in 
response to increasing dose of six out of nine tested compounds and it was the marker 
that was able to detect the most of the nephrotixcants, compared to the other tested 
markers. The same study also has shown that increase in HMOX1 in response to 
tubular toxicity is translatable to animal in-vivo toxicity models through computational 
digging in tow large rat toxicogenomic databases. Another very recent study has also 
demonstrated that HMOX1 is a more sensitive marker for detecting renal tubular 
toxicity when compared to one of the conventionally used biomarkers; KIM1, in 
hESCs-derived renal cells (Bajaj et al, 2018). Based on the intersection of HMOX1 in 
several different toxicity pathways as well as its high level of upregulation, I identified 
HMOX1 as a promising toxicity reporter. 
An hiPSC-HMOX1-reporter cell line was developed and evaluated in our lab with the 
aim of its use in nephrotoxicity screening; Seven different compounds were used in 
blind compound screening for nephrotoxicity using 2D and 3D renal organoids that 
were derived from that cell line. The response to the compounds was evaluated by 
measuring total fluorescence in response to increasing concentrations of each 
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compound. Dexamethasone is a benign compound that does not cause nephrotoxicity 
(Y. Li et al., 2013b; Kandasamy et al., 2015); our model correctly identified it as non-
toxic compound that did not induce significant increase in fluorescence.  The response 
to Cisplatin and Ifosfamide was more manifest in the 3D cultures compared to the 2D 
cultures, which showed delayed response after 72 hrs of exposure or only response 
to the highest concentrations tested after 24 hr exposure. The uptake of these two 
drugs is mainly mediated by the OCT2 receptor which was detected in the 3D 
organoids but not in the 2D cultures; this might explain the earlier and more manifest 
response in the 3D cultures to these two compounds. The 3D model detected cisplatin 
toxicity at the first concentration tested (6 μM); that concentration was slightly higher 
than that shown in other hiPSCs-derived renal cells (Kandasamy et al., 2015) which 
showed increase in IL6 and IL8 in response to 3.3 μM concentration, but was still either 
similar to what was used in a recent study that was using hPSCs-derived renal 
organoids (Bajaj, A David Rodrigues, et al., 2018) or lower than those showed in other 
studies that used primary human proximal tubular cells (Jang et al., 2013; Adler et al., 
2016); likewise the 3D model detected Ifosfamide toxicity at a concentration lower than 
that reported by a study that used primary human proximal tubular cells (Y. Li et al., 
2013a). 
The response to the glomerular toxin Puromycin was in accordance to what was 
reported in Kandasamy et al, 2015 who showed increase in IL6 expression that first 
appeared in response to 1 ug/mL (3.3 μM) of puromycin and further increased in 
response to higher concentrations.  
The gentamicin toxicity was detected at a lower concentration in this model compared 
to the gene expression data that were obtained from the RNA-seq experiment in which 
the response to gentamicin toxicity started to manifest in response to 1 mg/mL 
treatment. This might be because of the longer half-life of the mCherry protein 
compared to the HMOX1 transcript; the mCherry protein reflects the cumulative 
activity of the promotor and the stability of the fluorescent protein and might not 
correlate well with the message stability (Snapp, 2009), thus it could accumulate and 
be detected in response to a lower concentration compared to the transcript.  
Ketoprofen causes oxidative gastrointestinal injury and increase the risk of 
gastrointestinal ulceration (Cheng et al., 2013); reports have also shown that NSAIDs 
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can rarely cause hepatotoxicity (Agúndez et al., 2011; Sriuttha, Sirichanchuen and 
Permsuwan, 2018).  NSAIDs could have toxic effects on the kidney especially when 
combined with other toxic compounds or conditions, e.g. their use in elderly, heart 
failure and diabetic patients, patients complaining of liver cirrhosis, or in combination 
with renin-angiotensin blockers or diuretics can increase the renal side effects of the 
drug (Harirforoosh and Jamali, 2009; Hörl, 2010).  NSAIDs exert their effect by 
inhibiting COX1 and 2 enzymes both of which are expressed in the kidney. COX1 has 
role in controlling renal hemodynamics and GFR, while COX2 is implicated in salt 
water excretion (Catella-Lawson et al., 1999; Whelton et al., 2000; Weir, 2002). 
Therefore, inhibition of these enzymes could have adverse effects on the kidney. In 
our model, Ketoprofen induced increase in fluorescence only in response to the 
highest concentration tested.  
Setting the statistical significance of predicting toxicity to a cut off of p<0.01 
(considering higher p values to be non-toxic response), the overall performance of the 
HMOX1-mCherry-hiPSC-derived renal cells in predicting nephrotoxicity is 
summarised in table 5.6. As indicated in the table, no single combination of timing or 
culture form was completely reliable at predicting toxicity. 3D organoids were in 
general more sensitive, using them at both 24h and 72h and regarding a positive 
indication as one that is positive in at least one of these, was sufficient to identify the 
toxicity of all the blind-coded samples correctly.  
 
Table 5.6. toxicity prediction based on the increase in fluorescence intensity. 
 
Compound 2D 24h 2D 72h 3D 24h 3D 72h 
Dexamethasone N N N N 
Ketoprofen Y Y N N 
Puromycin N Y N Y 
Cisplatin Y Y Y Y 
Gentamicin Y N Y Y 
Cidofovir N Y Y N 
Isofamide Y Y Y Y 
 
Table 5.6: Y = predicted toxicity, N = did not predict toxicity. Green indicates results 
that are consistent with known clinical data. Prediction score is based on data in Figure 
5.4 a and b. A p value of 0.01 or less for one or more of the treatment concentrations 
is designated as having predicted toxicity. 
In conclusion, the reporter-hiPSC-derived renal organoids can predict renal toxicity, 
however, they are variable in their individual responses to compound treatment and 
certain culture form (2D or 3D) may be better suited to different classes of drugs. The 
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inherent variability of the iPSC-derived organoids may also have a role in these results 
and tackling this will be crucial for the future use of organoids in large scale drug 
screening. In addition, it is important to note that both the 2D and 3D renal organoids 
are closer to human embryonic kidneys than adult kidneys (Takasato et al., 2015); this 
immaturity may account for some of the differences between the observed response 
and the predicted one. Some compounds required longer incubation to induce a 
significant response via the oxidative stress pathway, this may be due to different 
mechanisms of toxicity of these compounds. Further investigations to identify the 
increase in fluorescence in particular renal compartments (podocytes, proximal 
tubules, distal tubules) may help to explain some differences in compound responses 
and may also be an additional useful tool to study mechanisms of toxicity. Collectively 
the data suggest that the HMOX1-reporting renal cells could be a promising tool for 
nephrotoxicity screening, yet further validation and optimisation of this model is 
required including testing a much larger set of compounds (both nephrotoxic and non-
nephrotoxic) for better assessment of the system and its predictive power. 
As briefly discussed earlier, renal drug transporters play a pivotal role in handling 
drugs and uremic toxins. We performed RNA-seq analysis and looked at the 
expression of the different drug transporters in our 2D differentiated cells. 
Transcriptomic data showed that 2D renal-differentiated cells expressed important 
drug transporters including MRP2 and 4, OCTN1 and 2, MATE1, P-gp and OATP4C, 
in addition to the expression of the important receptors LRP2 and CUBN. However 
other main transporters were not detected (OAT1 and 3, and OCT2). This matches 
with a recent study that evaluated transporter expression in renal organoids obtained 
from hESCs and repoted that OAT1 and 3, OCT2 were very lowly expressed while 
other tubular transporters were well represented (Bajaj, A. David Rodrigues, et al., 
2018). Importantly, OAT1 and OCT2 were both expressed in our 3D renal organoids 
which suggests that the 3D environment is needed for promoting the expression of 











In 2010, Unbekandt and Davies showed that mouse embryonic kidneys, after being 
dissociated into single cell suspension and cultured in presence of ROK inhibitor (to 
inhibit dissociation induced apoptosis), were able to self-organize and form renal 
structures. Within these re-aggregated cells, UB progenitors developed into multiple 
collecting duct (CD) trees, around which nephron progenitors condensed and 
differentiated into different parts of the nephron (Unbekandt and Davies, 2010). While 
the renal organoids obtained by that way, ‘Unbekandt-style renal organoids’, are 
histologically similar to embryonic renal tissue, they lack the anatomical organisation 
of the kidney which is crucial for proper function; the normal anatomical organisation 
of the kidney allows a central ramified collecting system to convey urine to a single 
clear exit. Later on, that technique was modified to produce renal tissue arranged 
around  
central branched collecting duct using a serial re-aggregation technique. This is a two-
step process. The first step produces a Unbekandt-style renal organoid, containing 
multiple collecting ducts, while in the second step, only one of these collecting ducts 
is dissected and cultured with fresh MM to make engineered kidney tissue arranged 
around single CD, ‘Ganeva-style renal organoid’ (Ganeva, Unbekandt and Davies, 
2011).  More recently, a modification of that technique succeeded in reprograming one 
of the CD branches into an exit, a ureter-like structure that expresses the ureteric 
epithelial marker Uroplakin. This step increased the anatomical realism of renal 
organoids made from dissociated embryonic kidneys and yielded organoids that look 
much like foetal kidney (Mills et al., 2017) (figure 6.1).  
So far, renal organoids that we (or anyone else) can make from hiPSCs are more like 
Unbekandt-style renal organoids that are composed of multiple dispersed CDs 
connected to developing nephrons. I wanted to try to make more organised organoids 
that could be equivalent to Ganeva-style organoids. As explained earlier, a first step 
towards making this type of renal organoid would necessitate isolating a single UB 
structure to use it in a second-step aggregation with nephron progenitors, depleted 
from any other source of UB cells, so that we can obtain renal tissue in which nephrons 




Figure 6.1. Illustrates the sequential steps of engineering organised renal tissue from 
mouse embryonic kidney cells. a) The first developed method to obtain renal 
organoids involved dissociation of mouse embryonic kidneys into single cells, re-
aggregation of the dissociated cells and culturing them for few days. The result of that 
culture was renal tissue that has multiple non-connected collecting systems.  b) Step 
2 in engineering organised kidney tissue; one UB epithelial structure is isolated from 
the re-aggregates obtained from (a) after few days of culture and re-aggregated with 
fresh pure MM that has been depleted of its UB cells. That yields renal tissue with 
single connected collecting tree. C) Step 3 adding a single exit to organoids developed 
from (b) by reprograming one of the UB branches into ureter-like structure. UB: ureteric 
bud; MM: metanephric mesenchyme.  
Developing more organised renal organoids could be useful for different applications: 
first, it would offer a model for studying the pathogenesis of different human disorders. 
Having the advantage that those renal organoids are obtained from the patient’s own 
cells, they could even allow for developing new patient-tailored therapeutic modalities 
for various disorders. Second, it would provide better organoids for the use in 
nephrotoxicity screening and drug development. I have shown in the previous section 
that these organoids can perform some of the physiological function of the kidney and 
could be a promising tool for screening drugs for nephrotoxicity, yet they are equivalent 
to embryonic renal tissue, which could make them less predictive of toxic compounds, 
so finding a suitable environment that could potentiate their maturation is necessary. 
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A recent study has transplanted foetal human kidneys into adult rats and indicated that 
the transplanted kidneys showed a dramatic increase in size and maturation of 
function and were able to support the survival of the nephrectomised rats for an 
average of 122 days compared to 3 days for rats that did not receive transplant (Chang 
et al., 2015); if we were able to organise renal organoids derived from hiPSCs and 
increase their anatomical realism in a way that resembles what we can currently obtain 
from dissociated mouse embryonic kidneys, Mills-style renal organoids, probably 
transplanting those organoids in an animal host could also allow for better maturation 
of the function and increase in the size and could provide an in-vivo human kidney 
model for drug testing and discovery. Third, a long term aimed application could be 
obtaining larger organised renal tissue that might hopefully, after allowing its 
maturation in a host, be of a clinical use as a transplantable organ. While this could 
be a very ambitious application and is quite unclear how feasible it would be, the 
individual steps towards developing more organised organoids could alternatively be 
combined with other different in-vitro kidney engineering strategies as these steps 
would involve isolation of pure population of renal cells which means that these cells 
could be used for populating decellularized scaffolds or bio-printing purposes for which 
obtaining pure specialised cells is a prerequisite (Kim et al., 2015; Montserrat, Garreta 
and Izpisua Belmonte, 2016; Hueso et al., 2019). 
6.2 Aims: 
The main aim of this chapter was to try to engineer an organised human renal tissue 
arranged around a single collecting tree, similar to Ganeva-style organoids that could 
be made from dissociated mouse embryonic kidneys but not, so far, possible to make 
from hiPSCs. To do this I wanted to: 
- Develop and optimise a technique to isolate hiPSC-derived UB-like cells from 
the surrounding cells in renal organoids. 
- Try to combine iPSC-derived UB, as a single intact epithelial structure, with 
nephron progenitors, derived also from hiPSCs, in a trial to obtain renal 
organoid organised around single ramified CD. 
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6.3 Engineering iPSCs to report GATA3 expression using 
CRISPR-Cas9 
One way to isolate the hiPSC-derived UBs would be to tag them using a UB marker 
in order to discriminate them from the surrounding cell types, thus enabling the use of 
FACS or manual dissection under a fluorescence microscope to select them. For this 
purpose, I wanted to engineer an hiPS cell line with a fluorescent reporter inserted into 
the GATA3 locus, as a marker of UB structures. This would enable GATA3 detection 
once it starts to be expressed and hence allow for the selection of the UB-like 
structures. A possible way to engineer the reporter cell line was to use the CRISPR-
Cas9 technology. 
CRISPR-Cas9 is a powerful gene-editing tool that employs the Cas9 nuclease activity 
under the control of gRNA (Brouns et al., 2008; Marraffini and Sontheimer, 2008) to 
produce a targeted double-stranded DNA break (DSB) (Cong et al., 2013; Mali et al., 
2013). Guide RNA (gRNA) is a short RNA segment composed of two parts: a scaffold 
sequence which binds to the Cas9 and a targeting guide sequence, also known as 
spacer sequence, which is specific to the target gene (Mali et al., 2013) (figure 6.2 a).  
The Cas9 genomic target is identified based on the targeting sequence of its gRNA; 
after the expression of Cas9 enzyme, it complexes with the gRNA, through an 
interaction between the Cas9 and the scaffold domain of the gRNA, to make a 
riboprotein complex. That binding turns the Cas9 nuclease enzyme into its active-DNA 
binding form. Afterwards, the guide sequence of the gRNA localises the complex to its 
specific DNA target, via complementary base-pairing with the target sequence (figure 
6.2 b). Binding of a protospacer adjacent motif (PAM), immediately adjacent to the 
genomic DNA target, directs the Cas9 nuclease to cleave the target DNA (Bolotin et 
al., 2005; Deveau et al., 2008) (figure 6.2 c). The produced targeted DSB stimulates 
repair mechanisms by one of two general pathways: error-prone Nonhomologous End 
joining (NHEJ) or Homology Directed Repair (HDR). The latter is used for introducing 
precise nucleotide changes, such as inserting reporter into the genomic target, by 
integrating exogenous repair template that contains sequence homology to the target 
site, via homologous recombination (Jinek et al., 2012, 2013; Cho et al., 2013; Mali et 
al., 2013).  For gene editing purposes using the HDR pathway, DNA repair template 
which contains the desired change is introduced to the cells together with the Cas9 
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and the gRNA. The repair template must have homology arms to the DNA target 
flanking the sought edit sequence. One important thing while designing the repair 
template is to mutate the PAM sequence, otherwise, the repair template becomes a 
target for the gRNA-Cas9 cleavage. 
I designed the repair template plasmid for my experiment, to introduce a reporter under 
the control of the GATA3 promotor, as separate segments that were meant to be 
assembled via Gibson cloning. Gibson assembly is a method to assemble overlapping 
DNA fragments through the action of three enzymes (5’ exonuclease, DNA 
polymerase and ligase enzyme) into a one large DNA molecule; this reaction can 
combine multiple segments in one reaction provided that the segments have 
homologous overlapping sequences(Gibson et al., 2009) (figure 6.2 d). 
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Figure 6.2. a-c) Illustration of the CRISPR/Cas9 targeting technique; the Cas9 
enzyme binds to the scaffold sequence of the gRNA which changes the Cas9 into its 
active-DNA binding state, the target sequence (spacer sequence) of the gRNA then 
binds to its genomic target which must be immediately adjacent to a PAM sequence; 
the Cas9 enzyme cuts the DNA 3-4 bp upstream to the PAM; adapted from 
addgene.org. d) Illustrates Gibson assembly strategy to join segments with 





6.3.1.1 gRNA design: 
Two different gRNAs were designed (to be used separately so that I could choose the 
one which gives better results) and synthesized as gene blocks by IDT. For designing 
the gRNA, the GATA3 genomic coding sequence (CDS) was obtained from Ensemble 
and 20 base-pair target sequence was selected close to the stop codon of the gene, 
using Zhang lab gRNA design resources (https://zlab.bio/guide-design-resources). 
The gRNA sequence was chosen to allow the Cas9 to cleave the GATA3 genomic 
area close to the stop codon: 78 bp from the stop codon in case of gRNA1 and 26 bp 
in case of gRNA2. The chosen sequence was then incorporated into a DNA sequence 
that contains all components necessary for its expression and function (promotor, 
scaffold sequence and termination signal) (following the addgene gRNA synthesis 
protocol, https://media.addgene.org/cms/files/hCRISPR_gRNA_Synthesis.pdf) (Mali 
et al., 2013); the whole sequence was sent to IDT for synthesis.  
6.3.1.2 gRNA cloning and transformation: 
The obtained gRNA gene blocks were cloned into a PCR-Blunt II-TOPO plasmid 
(https://media.addgene.org/cms/files/hCRISP_gRNA_Synthesis) and transformed 
into TOP10 bacterial strain; single bacterial colonies were selected from overnight-
cultured bacterial plates (five single colonies for each of the two gRNAs) and checked 
for the incorporation of the gRNA gene block inserts by PCR (using M13 primers; their 
binding sites on the plasmid are indicated in figure 6.3 c) and gel electrophoresis. All 
selected colonies for gRNA1 and 4 out of 5 colonies for gRNA2 had the correct length 
segment (698 bp) suggesting successful cloning and transformation (figure 6.3). 
One of the tested colonies for each of the two gRNAs was further amplified in an 
overnight culture and the plasmid DNA was purified, using Maxiprep, and analysed 
using restriction enzymes (EcoRI, cuts on both sides of the gRNA gene block insert 
giving 473 bp segment, which represents the gRNA insert, and 3501 bp segment, 
which represents the backbone; and SalI, which cuts in the plasmid backbone to give 
3519 bp linear segment; figure 6.3 c). Gel electrophoresis was then performed, to 
analyse the restriction enzyme action, which showed the presence of the correct size 
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segments suggesting incorporation of the gene block insert into the plasmid backbone 








 Figure 6.3. gRNA design, cloning and amplification. a) Two gRNAs were selected 
close to the GATA3 stop codon (gRNA1 78 bp and gRNA2 23 bp upstream to the stop 
codon); the PAM sequence for each of the gRNAs is indicated. b) The selected target 
sequence of each of the gRNAs was incorporated into a DNA fragment to make a 455 
bp fragment that codes for a promotor, gRNA target sequence, gRNA scaffold 
sequence and termination signal (following the gRNA synthesis protocol, Mali et al 
2013); the designed fragment was sent for synthesis as a gene block. c) The obtained 
gene blocks (one for each of the gRNAs) were cloned into a PCR-Blunt-TOPO II 
plasmid; this plasmid has M13 primers and EcoRI restriction sites on both sides of the 
insert. d) The plasmid was transformed into Top 10 bacterial cells; five colonies for 
each gRNA were picked and were first analysed by PCR (using M13 primers). All five 
colonies for gRNA1 and 4/5 for gRNA2 contained the right size insert (698 bp 
segment). e) One colony for each gRNA was amplified in an overnight culture and the 
plasmid DNA was purified, using Maxiprep, and analysed using restriction enzymes: 
EcoR I cut twice and yielded 473 bp segment, the incorporated insert, and 3501 bp 
segment, the vector plasmid; Sal I cut once to give a linear plasmid (3947 bp).  
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6.3.1.3 Repair template plasmid design: 
The repair template plasmid was designed to insert a 2A-peptide-mCherry cassette, 
to report the expression of the GATA3 gene, and a puʌtk positive/negative selection 
cassette, placed in a piggybac transposon, flanked by two homologous (5’ and 3’) 
arms upstream and downstream to the Cas9 cleavage site in the GATA3 gene (figure 
6.4).  
The puʌtk cassette encodes for a bifunctional fusion protein between puromycin N-
acetyltransferase (Puro) and a truncated version of the herpes simplex virus type 1 
thymidine kinase (ʌTk); cells that incorporate that cassette become resistant to 
puromycin, and hence cells that incorporate the repair insert could be positively 
selected using puromycin, but sensitive to 1-(-2-deoxy-2-fluoro-1-b-D-arabino-
furanosyl)-5-iodouracil (FIAU) (Chen and Bradley, 2000). The puʌtk cassette was 
flanked by the piggybac inverted repeats to allow for footprint-free removal, using 
piggybac transposase, of the cassette after its use in positive selection of the cells that 
successfully incorporated the insert. After removing the piggybac transposon, cells 
that did not successfully clear the transposon could be negatively selected using FIAU 
thus avoiding any possible interference of the antibiotic selection cassette with the 
expression and function of the GATA3 gene.   
The DNA repair template design was subdivided into five segments (figure 6.4), each 
of which had 25-40 bp homology to the adjacent segment, to be cloned into a vector 
plasmid using Gibson assembly. Segment 1 (420 bp) and Segment 5 (480 bp) 
represented the upstream (5’) and downstream (3’) homology arms to the cleavage 
site of the Cas9 respectively. Segment 2 (912 bp) contained the mCherry cassette 
introduced immediately before the GATA3’s stop codon and separated from the end 
of the GATA3 gene by a 2A peptide. The small genomic sequence that lies between 
the site of Cas9 cut and the stop codon was also included in that segment (upstream 
to the 2A-mCherry cassette). In segment 2, a silent mutation was introduced to one of 
the guanine nucleotides constituting the PAM sequence of each of the gRNA1 and 2, 
to avoid cleavage of the repair template by the Cas9. Segment 3 (272 bp) contained 
the GATA3 genomic sequence starting from the stop codon to the first TTAA sequence 
(to ensure footprint-free removal of the piggybac transposon, it should be integrated 
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into a TTAA chromosomal site). Segment 4 (3276 bp) represented the piggybac 






Figure 6.4. Illustrating the GATA3 targeting plasmid. a) The binding sites of the gRNAs 
are shown in red and are indicated by asterisks and the arrows indicate the PAM 
sequences. After Cas9 cleavage, the circled region should be replaced by the repair 
insert that has two homology arms to the cleavage site. The whole insert was 
composed of five segments designed to be assembled using Gibson cloning; Segment 
1 represents the 5’ homology arm and was obtained by PCR amplification from the 
genomic DNA (the primer binding sites are indicated on the genomic sequence 
(bottom line)), Segment 2 included the genomic sequence that lies between the 
cleavage area and the stop codon (75 bp) in addition to a 2A peptide-mCherry-stop 
sequence, Segment 3 included the genomic sequence starting from the GATA3 gene 
stop codon to the first TTAA sequence which is necessary to ensure seamless 
excision of the piggybac  (Segment 4) after its use in selecting the successfully edited 
cells. Segment 2 and 3 were obtained as gene blocks. Segment 4 included 
positive/negative selection cassette on a transposon and Segment 5 represented the 
3’ homology arm (obtained by PCR amplification, the primer binding sites are indicated 
on the genomic sequence). b) Shows the map for pMSC-AAT-PB-PGK plasmid from 
which Segment 4 was amplified (the primer binding sites are indicated). In a and b) 
the indented areas on the sides of the primers, indicated by arrow-heads, refer to 
overhang areas added to the primer sequence to obtain overlapping segments. c) Gel 
analysis for the amplified segment 1, 4 and 5; segment 2 and 3 were obtained as gene 
blocks. d) The design for the virtual-cloned repair plasmid with the ligation sites 
indicated by arrows and blue marks (to be assembled using Gibson assembly). e) 
Shows the detailed sequence of the repair plasmid; in segment 4: left repeat and right 
repeat are the recognition sites of the transposase enzyme, PGK is an eukaryotic 
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promotor, puʌtk is the positive/negative selection cassette and bGH-pA is a poly A 
signal. 
 
6.3.1.4 Synthesis and cloning of the different segments of the repair 
plasmid: 
Genomic DNA was extracted from hiPSCs and was used to amplify segment 1 and 5 
using PCR primers; segment 1 (5’ homology arm) forward primer had an overhang 
area to amplify the segment with homology arm to the vector. Likewise, segment 5 
(downstream homology arm) forward and reverse primers were designed with 
overhang areas to add homology arms to segment 4 and the vector respectively (figure 
6.4 a, c). Segment 4 (piggybac transposon with the antibiotic selection cassette) was 
amplified from the PMSC-AAT-PB-PGK plasmid using primers with overhangs to add 
homology arms to the adjacent segments (figure 6.4 b, c). The amplified products were 
gel purified and were sent for sequencing. 
Segment 2 and 3 were both obtained as gene blocks from IDT. A PUC18 plasmid, 
used as a vector, was digested using XbaI enzyme and was gel purified then the 
enzyme was inactivated by incubating at 62 ͦ C for 20 minutes. 
The vector and the five segments were used in a Gibson assembly reaction. After 
running the Gibson cloning, four different sets of primers were used (in four different 
PCR reactions) to test the assembly of the segments. Primer pairs that bridge over 
the boundaries of the segments were used: the first primer pair was used to amplify 
an area between the vector and segment 2, spanning segment 1 (561 bp); the second 
pair to amplify an area between segment 2 and segment 3 (450 bp); the third pair to 
amplify an area between segment 3 and segment 4 (487 bp); and the fourth primer 
pair was used to amplify an area between segment 4 and the vector, spanning 
segment 5 (958 bp) (figure 6.5 a). The amplified products were run on a gel and all 
four segments were detected, in the right size, which suggested successful assembly 
of the different adjacent segments (figure 6.5 b). 
The cloning reaction mixture was then transformed into 5-alpha bacterial cells; at the 
same time control cells were transformed with the PUC18 intact plasmid as a positive 
control for the transformation step. After an overnight culture, a high number of 
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colonies were seen in the cells transformed with the intact control plasmid, but very 
few colonies in the cells transformed with the assembled plasmid (figure 6.5 c, d). I 
picked single colonies from the transformation plate and first checked the 
incorporation of my insert by running a PCR reaction which amplifies an area that lies 
in the middle of my insert (the area between segment 3 and segment 4); 2 out of 12 
selected colonies amplified the segment (figure 6.5 e). These two colonies (together 
with some of the colonies that were negative for the presence of the middle segment 
in the preliminary PCR) were expanded in an overnight culture, their plasmid DNA was 
purified, using a miniprep kit, and was analysed using restriction enzymes (NcoI and 
HpaI), but none of the analysed colonies showed the correct restriction pattern (figure 
6.5 f, g).  
I repeated the Gibson cloning three times and did two transformations from each 
cloning reaction and got similar results. One possible solution could be using 
electrocompetent bacterial cells and electroporation to increase the efficiency of the 
transformation process. However, I was working to find and optimise a different 
approach to isolate the differentiated UB structures, in parallel to this technique, and 
it did show encouraging results (discussed in the following section). I wanted to focus 
on isolating the UB-like structures and evaluating them so, I did not repeat the 
transformation. Also, I did not expect to have enough time, even if I managed to clone 
and purify the repair template plasmid, to transfect the iPSCs, select the correctly 






Figure 6.5. a) Illustrates the design for the Gibson cloning and shows the binding sites 
for the primers that were designed to test the assembly of the different segments after 
running the Gibson reaction; the primers were designed to span ligation areas and thus 
ligated segments only should be amplified. b) After running the assembly reaction, the 
reaction mixture was tested using the four sets of primers shown in (a); all four segments 
of the correct size were detected suggesting assembly of the adjacent segments. c and 
d) 5-alpha bacterial cells were transformed with an intact plasmid (c) or cloned plasmid 
(d); the intact plasmid plate had many colonies, which suggests suitable transformation 
conditions, while very few colonies grew in the plate of cells transformed with the 
assembled plasmid. e) 12 colonies were picked from the cells that were transformed 
with the cloned plasmid and were analysed by PCR (using S3-S4 primers shown in a) 
as a preliminary check for the incorporation of the assembled insert; only two colonies 
amplified the correct size segment. f) Those two colonies, together with other colonies 
picked from the same plate, were amplified in an overnight culture and their plasmid 
DNA was amplified, using miniprep, and examined by restriction analysis. None of the 
analysed colonies showed the expected restriction analysis pattern for the correctly 




6.4 GDNF conjugation to tag and isolate UB-like structures: 
Another possible way to isolate the differentiated UBs, was to employ the interaction 
between the GDNF protein and its receptor, RET, to live-tag the developing UBs in 
live-cell cultures and isolate them. GDNF/RET is a critical pathway for the outgrowth 
and subsequent development and branching of the UB. In the developing kidney, the 
MM secrets GDNF protein, that stimulates RET receptors in the ND and the UB, first 
to induce proliferation and outgrowth of the UB from the ND and then after the budding 
to induce the UB tips to further proliferate and branch (see section 1.2.5 for more 
details). Labelling RET receptors, through their binding to a fluorescent-tagged GDNF 
protein, could be one way to isolate iPSC-derived UB-like structures (figure 6.6 a).  
6.4.1 Results: 
For this experiment, a microscale protein labelling kit was used to conjugate the GDNF 
protein to a fluorophore; 488 reactive dye. The reactive dye in the labelling kit has a 
tetrafluorophenyl ester moiety that reacts with primary amines of the protein forming 
dye-protein conjugate. The protein, 1 mg/ml concentration, was incubated with 488 
tetrafluorophenyl esters to allow for the reaction then the formed dye-protein conjugate 
was purified using a spin filter filled with gel resin to remove the excess dye.      
The recovered protein concentration was 400 µg/ml, estimated based on the % yield 
expected for the protein molecular weight, with a degree of labelling of approximately 
2.5 moles of dye/mole of protein. 
To test the efficiency of the labelling process, I used mouse embryonic kidneys. E11.5 
kidneys that have been cultured for 1.5-3.5 days were treated with the conjugated 
GDNF (GDNF/488) (100 ng/ml) and were checked for signal after 1 hr, 4 hrs and 
overnight incubation at 37 C. No signal was detected after 1 or 4 hr of incubation but 
after overnight incubation, mouse UBs were seen tagged in green (figure 6.6 d, e); the 
need for the longer incubation period might be because the conjugated protein 
competes with the normally secreted GDNF from the MM on the receptor binding sites.  
In the early stage of metanephric kidney development, E10.5-E11.5, RET expression 
is detected all-over the WD and the outgrowing UB with higher expression level in the 
UB tips; by E12.5, Ret expression becomes restricted to the UB tips. Consistent with 
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that, when E11.5 kidneys that have been cultured in-vitro for 1.5 days were treated 
with the conjugated protein, a bright stain was seen in the branching tips and a less 
bright signal was seen in stalks (figure 6.6 d) (n=3). However, E11.5 kidneys that were 
cultured for 3.5 days had only their tips tagged (figure 6. 6 e) (n=3).  
Tagging the UB tips confirmed that the protein had successfully been conjugated to 
the fluorophore without damaging its ability to bind the Ret receptor and suggested 
that the degree of labelling was enough to be detected under a fluorescence dissecting 
microscope.  
 
Figure 6.6. a) Schematic for tagging UBs by conjugating the GDNF protein to a 
fluorophore. RET receptors, expressed on the UB tips, bind to the GDNF protein, 
secreted from the adjacent MM cells; the MM is not shown. This interaction induces 
the tip cells to proliferate and undergo branching. b, c) GDNF protein was conjugated 
to a 488-fluorophore and thus binding of the GDNF/488 to the RET receptors will be 
marking the UBs with the fluorophore. d, e) Embryonic mouse kidney explants treated 
with the GDNF/488 to test the efficiency of the conjugation and the efficacy of the 
tagging process; E11.5 kidneys cultured in-vitro for 1.5 days before GDNF/488 
treatment had their tips and stalks stained with brighter signal in the tips (d), while 
E11.5 kidneys that were cultured for 3.5 days before the treatment only showed signal 





6.4.1.1 Conjugated GDNF tags UB-like structures in a renal-differentiated 
mixed population: 
I next treated the renal-differentiated cells with the conjugated GDNF protein using the 
same conditions that were used with mouse embryonic kidneys (overnight incubation; 
100 ng/ml concentration); a signal was detected in the terminal ends of some of the 
tubular structures (figure 6.7a) in a way that suggested UB tip structures. 
To further evaluate the live-cell staining process, the cultures were fixed with PFA and 
stained for GATA3 and CDH1; while the GDNF/488 signal was lost after the fixation, 
staining and washing process, GATA3+/CDH1+ structures were seen in equivalent 
areas (figure 6.7b) to those that were tagged with the GDNF/488 suggesting that the 
GATA3+/CDH1+ tubular structures, which are expected to be UB-differentiated cells, 
were expressing functional RET receptors and could be labelled with GDNF/488.  
 
Figure 6.7. a) 20 day-differentiated monolayers that had been treated with the 
GDNF/488 protein showing bud-like structures labelled with the protein (the three 
images are for three different samples). b) Same samples shown in a) after fixation 
and staining for GATA3 and CDH1, UB markers, showing GATA3+/CDH1+ structures 
almost equivalent to those that were stained by the GDNF/488. Scale bar is 100 μm. 
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6.5 Trial to reconstruct organised renal organoids using the 
isolated hiPSC-derived UB structures: 
We next wanted to combine the isolated iPSC-derived UB structures with a pure 
nephron progenitor population, sorted from iPSC-derived renal organoids. The aim 
was to reconstruct an organised renal organoid, equivalent to the Ganeva-style renal 
tissue that we can achieve from dissociated mouse embryonic kidneys, by adding the 
UB cells as a single intact epithelial structure and excluding all other UB cells from the 
culture. Having a single source of UB cells was assumed to develop a single ramified 
collecting system that induces nephron formation around its growing tips. 
This experiment was done in collaboration with another member of the lab, Weijia Liu, 
who sorted the nephron progenitors using magnetic cell sorting; I will briefly explain 
the principle that was used for sorting before presenting the results. Dekel and 
colleagues have performed several studies through which they identified specific 
surface markers for the different compartments and structures of the human foetal 
kidney. They identified NCAM1 as a surface marker for the CM, where it is most 
prominent. NCAM1 is also weakly expressed in early nephron stages (renal vesicle, 
comma shaped body and S-shaped body) but is completely lost upon further nephron 
maturation and epithelisation. In contrast, they detected CD133 expression in the 
mature epithelial structures and to a lesser extent in the comma shaped body and the 
S-shaped body. CD133 is completely absent from the CM undifferentiated cells. Thus, 
sorting NCAM+/CD133- cells would be a way for enriching progenitor cells and 
excluding differentiated cells. In addition, they identified EPCAM as a surface epithelial 
maker that is expressed brightly in the UB and more mature nephron tubules and less 
brightly in the early MM-derived epithelial structures, the comma shaped body and the 
S-shaped body, but is completely absent from the CM. Thus sorting for 
NCAM+/CD133-/EPCAM- would exclude UB cells and nephron epithelial structures and 
select only the CM progenitors (Metsuyanim et al., 2009; Harari-Steinberg et al., 2013; 
Pode-Shakked et al., 2016, 2017). 
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Figure 6.8. a) 12 day-differentiated cells stained for the nephron progenitor marker 
SIX2 and the surface marker NCAM. b) 17 day-differentiated cells stained for the UB 
marker GATA3 and the surface marker EPCAM; a, b) were done as an optimisation 
for the magnetic sorting of the nephron progenitors and were performed by Weijia Liu. 
c, d) Trial to make organised renal structures by isolating GDNF-tagged UB structures 
and reaggregating them with sorted nephron progenitors; the reaggregates were kept 
in culture for 7 days then stained for Laminin (marks the basement membrane for both 
nephron structures and UBs) and GATA3 (UB and CD marker); no structures were 
formed. This experiment was done in collaboration with Weijia Liu. Scale bar is 100 
μm. 
Nephron progenitors were sorted from iPSC-derived renal organoids first by excluding 
EPCAM+/CD133+ cells then selecting NCAM+ cells; the sorted cells were 
reaggregated with GDNF/488-tagged UBs, which were dissected from a different 
culture of iPSC-derived renal cells, the re-aggregated cells were kept in culture for 
seven days but did not develop any structures and neither UB branching nor nephron 
formation was observed (n=4) (figure 6.8). This might be caused by either the UB, 
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being unable to branch and induce nephrons, or the NPs, not giving the correct signal 
for the UB. So, I thought that investigating the ability of the isolated UB-like structures 
to branch, in a defined system independent of the NPs, would be a logical next step. 
This will be described in the next chapter. 
6.6 Discussion: 
Earlier techniques developed in dissociated mouse embryonic kidneys can make 
organised renal tissue with nephrons arranged around single collecting system 
(Unbekandt and Davies, 2010; Ganeva, Unbekandt and Davies, 2011; Mills et al., 
2017) and containing functional subunits (Lawrence, Chang and Davies, 2015a). More 
recently, Taguchi and Nishinakamura published a paper in which they managed to 
make similar organised renal tissue from mESCs, still needed to add stromal 
progenitors from embryonic kidneys as there is no available protocol for obtaining 
them from pluripotent cells so far (Taguchi and Nishinakamura, 2017). In this chapter, 
I wanted to try making a similar organised tissue from hiPSCs as this has never been 
done so far; for that purpose, a way to isolate the correctly reprogrammed UBs is 
required. I developed an approach to isolate UB-like structures from iPSC-derived 
renal organoids as a step towards improving the currently available model of renal 
organoids.  
The central role of the GDNF/RET signalling pathway in inducing UB outgrowth and 
branching has long been recognised (Moore et al., 1996; Michael and Davies, 2004); 
specifically, RET is highly expressed in the tips of UBs. Here, I conjugated GDNF 
protein and used it to label UBs; I showed that mouse embryonic kidney explants that 
were treated with the conjugated protein had their UBs specifically stained; RET 
expression, according to the staining results, was detected in both tips and stalks, but 
was excluded from the main stalk (the extra-renal ureter), in kidney explants that were 
kept in culture for short period (E11.5 + 1.5 day in culture) but only in the tips of those 
rudiments that were cultured for longer duration (E11.5+3.5 day in culture); this finding 
matches earlier studies that show that RET is first detected all over the WD and the 
whole UB at E11.5 and then becomes restricted to the proliferating tips (Marose et al., 
2008). 
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The pattern of the obtained labelling in iPSC-derived renal cells also suggested 
successful staining of UB tip structures. Despite losing the fluorescence signal of the 
live-stain after fixing and washing the samples, immunofluorescence results showed 
co-expression of GATA3 and CDH1 in roughly equivalent areas, of the developed 
tubules, to those that were marked by the GDNF/488. The co-localisation of GATA3 
and CDH1  as an indicator of successful differentiation towards UBs, however, as I 
have shown in chapter 3 (section 3.3), results obtained in that context were variable 
with some differentiation runs that did not yield UB structures. An earlier study has 
shown the importance of GATA3 in activating and maintaining the expression of RET 
receptors and that GATA3 inactivation causes loss of RET expression (Grote et al., 
2008). It was important to show that GDNF/488 is roughly tagging GATA3 positive 
structures and not, for example, marking a new population of cells that would be 
considered non-UB fate according to the previously optimised conditions. Having a 
marker that can detect UB structures in live culture might be a useful tool for optimising 
conditions to decrease variability. 
I have tried to use the CRISPR/CAS9 gene-editing tool to engineer a reporter cell line 
for reporting GATA3 expression as a different strategy to isolate UB structures, but 
that work was not completed; it would be useful to be able to detect the development 
of these structures in real-time as this could facilitate tracing the source of variability. 
It is worth noting that GATA3 is expressed in different tissues during embryogenesis 
including the parathyroid gland, the inner ear, the developing kidney (where it is 
expressed in the ureteric bud, the collecting ducts and the mesangial cells), the central 
and peripheral nervous system, and the hematopoietic organs (Debacker, Catala and 
Labastie, 1999; Van Esch and Devriendt, 2001). Hence, the mere expression of 
GATA3 in the differentiated hiPSCs doesn’t guarantee that these cells are ureteric 
duct cells. In case of having this reporter cell line working, further assessment of the 
reporting cells either by testing the co-expression of other UB and CD markers (see 
chapter 3) or by functional assessment of the reporting structures, through examining 
their ability to branch and induce nephrons, would be necessary. 
Initial result for trying to reconstruct organised renal tissue by reaggregating 
GDNF/488-tagged UB with sorted nephron progenitors was not successful as no 
formed structures were seen after 7 days of incubation. This could be due to more 
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than one reason; one possibility is that the UB and or the nephron progenitors are not 
mature enough or not fully reprogrammed, so, in the next chapter I set experiments to 
evaluate the maturity and branching capacity of the isolated UBs. If those UBs proved 
to be branch-competent and were able to make complex 3D collecting system, then 
they could be used for making organised kidney tissue by adopting a different strategy; 
one way might be to induce and allow them to branch before mixing them with nephron 
progenitors; they might also be used as a cell source for populating scaffolds or 3D 




























Branching morphogenesis is the developmental process by which epithelial structures 
undergo repeated branching into their surrounding mesenchyme thus forming a 
complex epithelial tree-like structure and shaping the organ geometry (Ochoa-
Espinosa and Affolter, 2012; Varner and Nelson, 2014). The ability of the UB tip cells 
to proliferate and eventually form a ramified collecting system in response to signals 
emanating from the condensing MM plays a pivotal role in the metanephric kidney 
development. Indeed, the number of branches produced by the UB is an important 
determinant of nephron endowment and hence defects in branching morphogenesis 
are a predisposing factor to renal disease (Shah et al., 2004; Schedl, 2007).  
In the previous chapter, I showed that the attempt to reconstruct organised renal 
organoids by mixing isolated UB structure with sorted nephron progenitors was not 
successful. One possible explanation could be that the UB and/or the nephron 
progenitors are not mature enough to induce and respond back to one another. This 
finding, together with the variability that was sometimes seen in obtaining the UB fate 
using the Takasato protocol, directed me to further evaluate the obtained UB-like 
structures and examine their branching capacity, in an MM free condition. In regular 
2D and 3D organoid culture conditions no more than one branching event was 
observed and it was important to investigate if those structures can show higher 
branching capacity when isolated and induced to branch. 
In particular, the variability that this protocol showed in producing UB cells made me 
also decide to try a different differentiation protocol that directs hiPSCs mainly to UB 
fate and compare between the UBs obtained from both of them with respect to their 
efficiency in producing branch-competent UBs.  Recently, Taguchi and Nishinakamura 
published a protocol that aims to differentiate mESCs and hiPSCs towards UBs. To 
develop their protocol, they first performed a backward in-vivo study, using mouse 
embryos. They started by studying the gene expression pattern in the late maturation 
stage of WD and UB development, from E9.5 to E11.5, and identified the growth 
factors that are involved in inducing maturation of E9.5 WD cells into E11.5 UB cells. 
They then moved a step backward to study an earlier stage of WD development, from 
E8.75 to E9.5, and in the same way they identified the growth factors that were able 
to induce maturation of sorted E8.75 WD cells into E9.5 stage. They used the 
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information obtained from those two steps to delineate a three-day induction protocol 
that induces the maturation of E8.75 sorted WD cells into UB like structures with 
similar gene expression pattern to the E11.5 UB. Afterwards, they employed mESCs 
to define a four-step differentiation protocol that directs the differentiation of mESCs 
into E8.75 WD precursors. Finally, they combined the information obtained from in-
vivo analysis of WD and UB progenitor cells with the information obtained from mESC 
directed differentiation  to define an optimised differentiation protocol that derives the 
differentiation of entities similar to E11.5 UBs from mESCs in 9.25 days (including 
initial 2 days for embryoid body formation) (Taguchi and Nishinakamura, 2017).  
Taguchi and Nishinakamura showed that their induced mESC-derived UBs (miUBs) 
were able to branch and form ramified trees when cultured isolated in gel upon 
treatment with specified growth factors. Furthermore, they showed that isolated miUBs 
were able to branch and induce nephrogenesis forming an organised renal tissue 
when mixed with mouse embryonic isolated MM. Finally, they transferred their 
optimised protocol to hiPSCs, with slight modification, and indicated that they obtained 
UBs with some branching capacities from hiPSCs (hiUBs). The branching that they 
presented from hiUBs was however obtained from a whole organoid cultured in gel 
not from isolated UB structures and they commented that the hiUB branching in the 
gel was significantly slower than that obtained from mouse cells. They also tried to 
construct an organised renal tissue by mixing hiUB with hiPSC-derived nephron 
progenitors, but they did not get much success. 
 
7.2 Aims: 
I wanted to evaluate and compare the branching capacity of hiUBs obtained from two 
different differentiation protocols: the Taguchi and Nishinakamura protocol, 2017, and 
the Takasato et al. protocol, 2015. As discussed earlier, the ability to respond to 
branching inducing signals to form a ramified three-dimensional network of collecting 
ducts is an inherent criterion of the normal UBs that is essential for the use of these 
cells either in therapeutic purposes or in physiological, toxicological or disease 
modelling studies. 
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For that purpose, I first used isolated mouse embryonic UBs, as their ability to branch 
and form collecting duct trees is undoubted (Grobstein, 1955), to optimise culture 
conditions that can support growth and induce branching in isolated UBs. 
7.3 Optimising conditions for evaluating branch-competence 
using isolated mouse embryonic UBs: 
UBs cultured in isolation from the MM cannot branch and eventually die unless they 
receive external growth factors that can replace the natural presence of the MM 
(Saxén and Lehtonen, 1987; Qiao, Sakurai and Nigam, 1999; Sakurai, Bush and 
Nigam, 2001). 
Identifying the exact nature of the inducing signals that control UB branching 
morphogenesis has been deeply investigated over the past few decades using murine 
embryonic kidney explants. These investigations revealed the importance of 
extracellular matrices, such as Matrigel, collagen I and IV (Sakurai et al., 1997; Qiao, 
Sakurai and Nigam, 1999; Sakurai, Bush and Nigam, 2001), and different growth 
factors with GDNF, signalling through the tyrosine kinase receptor RET and its co-
receptor GFRA1, been highlighted as a predominant stimulus of branching (Sainio, 
Suvanto, et al., 1997); however, GDNF as a single growth factor is not enough to 
induce branching in UBs isolated from MM and cultured in an extracellular matrix 
(Sakurai et al. 2001; Yuri et al. 2017, and data in figure 7.1). Other growth factors that 
were shown to have a role in branching induction include HGF (Cantley et al., 1994), 
EGF, VEGF-A, Heregulin (Sakurai, Bush and Nigam, 2005) and Pleiotrophin (Sakurai, 
Bush and Nigam, 2001). In addition, the stromal-derived RA has also been shown to 
be important for maintaining the expression of RET in the tip cells and thus modulating 
branching (Mendelsohn et al., 1999; Batourina et al., 2001; Rosselot et al., 2010).  
The first trials that aimed to culture UBs in isolation of the MM either used MM-
conditioned medium or growth factors purified from the conditioned medium and 
reported that they were not able to reproduce the same results using commercially 
available factors (Sakurai, Bush and Nigam, 2001, 2005; Bush et al., 2004; Meyer et 
al., 2004). A recent study has published a protocol for recapitulating branching 
morphogenesis from isolated UBs in a completely defined, MM free culture condition 
(Yuri et al., 2017). That study identified two conditions to maintain the UB tip cell 
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identity and induce their proliferation and branching, these two conditions were either 
the combination of GDNF, FGF1, and CHIR99021 (WNT-B catenin signalling) or the 
combination of GDNF and RA. While any of these two conditions was enough, 
according to the study, for promoting survival and inducing extensive proliferation in 
isolated embryonic UBs, they showed that the combination of the four factors, FGF1, 
GDNF, CHIR99021, RA together with ROCK inhibitor was the optimum condition to 
prevent apoptosis, promote colony formation and proliferation, and induce branching 
from dissociated single UB cells (Yuri et al., 2017). 
Aim: 
I wanted to reproduce and optimise the Yuri protocol in isolated mouse embryonic UBs 
with the aim of trying to transfer it to hiUBs. 
Results: 
E11.5 mouse UBs were completely dissected and cleaned from the surrounding MM, 
then their tips were isolated and cultured suspended in growth factor-reduced Matrigel 
and the effect of the above-mentioned growth factors (GDNF, FGF1, CHIR, RA) was 
tested.  As expected, GDNF treatment alone was not enough to promote survival and 
inhibit apoptosis in isolated embryonic UB tips; tips cultured only in presence of GDNF 
appeared to be dying from the first day of culture and were completely dead by the 
third day as shown by the uptake of the nuclear dye DAPI or Sytox green (figure 7.1 
a, c; n= 6). The addition of FGF1 to GDNF in the culture media that was added to the 
isolated UB tips inhibited apoptosis and the cultured tips increased in size, probably 
indicating proliferation of the UB tip cells, but the cultured tips did not show any 
branching in response to these two factors (figure 7.1 b, d; n= 6).  
The combination of GDNF, FGF1 and CHIR induced branching in some, but not all, of 
the isolated tips (n=11, 5/11 did not branch and 6/11 branched). Some of the isolated 
UB tips, treated with that combination, increased in size without showing branching. 
There are usually individual variations in the maturity of embryonic kidneys obtained 
from the same age, the reason that some of the isolated UB tips did not branch in 
response to the treatment with GDNF, FGF1 and CHIR could be that these tips were 
less mature and needed an extra signal to enable them to respond to the growth 
factors (figure 7.2 a, b).  
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Adding RA to the previous combination induced robust branching in a very consistent 
and reproducible way, in addition, the tips of the branching structures showed the 
characteristic dichotomous tip morphology (figure 7.2 c, d; n=11 for the initial 
optimisation and was used afterwards as a control for the culture condition with all the 
following experiments). In contrast, the branching that occurred in response to GDNF, 
FGF1, and CHIR without RA, in addition to being inconsistent, was slower, limited and 
showed somehow aberrant tip morphology compared to the branching-response to 
the same combination plus RA.  
 
Figure 7.1. Isolated mouse embryonic UBs cultured in Matrigel treated with GDNF (a) or GDNF+ 
FGF1 (b); none of them branched. c) Isolated UBs that were cultured in the presence of GDNF 
alone stained positive for sytox green (upper image) or DAPI (lower image) indicating dead cells. 
d) addition of FGF1 to GDNF inhibited apoptosis. Scale bar is 100 μm. 
Therefore, the combination of GDNF, FGF1, CHIR and RA was chosen as a suitable 
condition for culturing isolated UB tips and inducing branching morphogenesis. I next 
tried to culture the isolated UB tips on the surface of filter membranes, using trans-
wells, instead of being suspended in Matrigel, and treated them with the combination 
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of GDNF, FGF1, CHIR and RA. UB tips cultured on trans wells did not branch even 
when 10% Matrigel was added to the culture media, only tips that were suspended in 
a Matrigel layer were able to branch which probably suggests the importance of the 
extracellular matrix for UB growth and branching in isolation from the MM. 
 
 
Figure 7.2. a, b) Treatment of the isolated mouse embryonic UBs with a combination 
of GDNF, FGF1, and CHIR. This combination induced branching in (a) but not in (b) 
suggesting inconsistency in the response to these factors. b) Showed abnormal 
projections from the cultured bud on prolonged incubation but not actual branching. c, 
d) Treatment with GDNF, FGF1, CHIR and RA induced robust branching in a 
consistent way; arrows in (d, day 9) point to the bifurcating tips. Scale bar is 100 μm. 
After optimising a defined condition to examine the branching capacity of isolated UBs, 
I performed the following experiments to compare between hiUBs obtained from two 
different differentiation protocols, the Takasato et al protocol and the Taguchi and 
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Nishinakamura protocol. The obtained UBs were compared for their ability to respond 
to these defined factors and recapitulate branching morphogenesis. Although these 
experiments were run in parallel, they are presented here one after the other to avoid 
confusion. 
7.4 Evaluating branch-competence of isolated hiUBs obtained 
from the Takasato protocol: 
Aim:  
In this section, I wanted to test the ability of hiPSC-derived UB-like structure to branch 
forming a ramified tree using the defined culture condition that efficiently induced 
branching in isolated mouse embryonic UBs . To my knowledge, no other study, so far, 
has managed to isolate the UB structures obtained using the Takasato protocol of 
differentiation nor assessed the branching capacity of these structures. 
Results: 
Renal-differentiated hiPSCs were treated with GDNF/488 to label the hiUB structures, 
bright-tagged structures were dissected under a fluorescence dissecting microscope, 
cultured suspended in Matrigel and treated with the combination of GDNF, FGF1, CHIR 
and RA. The isolated UB-like structures were kept in this culture condition for a total of 
14 days. After 4-5 days in culture the isolated structures started to form outgrowing buds 
that then grew and started to branch; by the end of the treatment duration, the isolated 
hiUBs, that all started as single spheroid structures, made branched connected 
epithelial tubules (figure 7.3, n=5, each repeat included a culture of 8-9 individual 
isolated hiUBs; a total of 44 isolated hiUBs were examined. 32/44 formed ramified 
trees).  
Compared to the mouse embryonic UBs, the branching response of the hiPSCs-derived 
UBs was slower and the total number of branches was less; this could be due to the 
inter-species difference as embryogenesis and organogenesis duration is generally 
much longer in human. The expression of RET in these branching structures was 
examined by live-treating them with GDNF/488 which showed positive staining 
especially at the tips. The branched epithelial structures were then extracted from the 
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Matrigel and stained for different UB markers; they showed expression of GATA3, 
CDH1, CALB1 and CK8 (figure 7.4). 
The ability to branch in response to branching inducing factors, an environment which 
mimics that created by the MM, and the expression of RET together with other ureteric 
markers could be considered as a way of functional assessment of the obtained hiUBs. 
 
 
Figure 7.3. a) Differentiated cells using Takasato protocol treated with GDNF/488 to 
tag the UB structures; the tagged structures were isolated and cultured in Matrigel 
treated with branching inducing mixture. b) Shows the isolated hiUBs on day 0, 5, and 
14 of culture in branching inducing matrix. Scale bar is 100 μm except for the insert in 
(a), when it is 50 μm. 
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Figure 7.4. a, b) Shows c-RET expression in hiUB obtained using the Takasato 
protocol (a) hiUB on day 0 of gel-culture and (b) on day 14 of gel-culture showing the 
ramified structures. c, d) Immunostaining of the branched structures for different UB 
markers. Scale bar is 100 μm. 
 
7.5 Evaluating branch-competence of isolated hiUBs obtained 
from the Taguchi and Nishinakamura protocol: 
Aim: 
In this section, I wanted to reproduce the Taguchi and Nishinakamura protocol for 
obtaining hiUBs with the aim of comparing between the branch-competence of the 
hiUBs obtained by this protocol and those obtained by the Takasato protocol.  
Results: 
hiPSCs were dissociated and reaggregated in the bottom of ultra-low attachment 
plates to form embryoid bodies in presence the of Activin A and BMP4 for 1 day (step 
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1) followed by high concentration CHIR treatment in combination with BMP4 for 1.5 
days (step 2) to induce nascent mesoderm fate. RA, FGF9, LDN 193189 (to inhibit 
BMP signalling) and SB 431542 (to inhibit SMAD2/3 signalling) were added for 2 days 
to induce AIM fate (step 3) then SB431542 was replaced with CHIR and the treatment 
was continued for 1.75 more days (step 4) to obtain WD progenitors (figure 7.5 a). 
After the completion of step 4, the developed spheroids were dissociated and FACS 
analysed for the co-expression of CXCR4/KIT surface markers, as an indicator of 
obtaining WD progenitors. An average population of 20% showed positivity to these 
two markers (n= 3; figure 7.5 b and d). That population was sorted and recovered, 
then the differentiation protocol was continued to induce maturation of the obtained 
WD progenitor cells into UB cells as follows: first, WD progenitor cells were treated 
with a combination of RA, CHIR, FGF9, FGF1 and LDN for 2 days (step 5) then low 
concentration of GDNF was added to the same combination of growth factors and the 
treatment was continued for further 2 days (step 6); lastly FGF9 was removed from 




Figure 7.5. Differentiating hiPSCs into UBs using the Taguchi protocol. a) Illustration 
of the differentiation protocol; the numbers indicate the concentration of the growth 
factors CHIR, SB, RA and Y27632 are shown in μM concentration, LDN is shown in 
nM concentration and the rest of the growth factors are indicated in ng/ml. b) FACS 
results after step 4; CXCR4+/KIT+ cells were sorted and recovered. c) Shows a 
spheroid at the end of the differentiation protocol with buds seen outgrowing from the 
periphery. Scale bar is 100 μm. d) The gating strategy for Wolffian duct progenitors 
that were obtained from hiPSCs after applying the Taguchi protocol of differentiation 
for 6.5 days. Intact singlets represented 46.6% of the total events; 19.6% of these 
intact singlets (15,156/ 77,163) were KIT+/CXCR++. These cells were sorted, 
recovered and cultured for the end of the differentiation protocol as explained in 
section 7.5.  
At the end of the differentiation protocol (after step 7), the cultured spheroids showed 
multiple outgrowing buds (figure 7.5 c). Those buds started to appear after step 5 of 
differentiation and increased afterwards. Obtaining UB fate was evaluated at the end 
of step 7 by co-staining for CDH1, GATA3 and PAX2; the co-expression of the three 
of them was detected (n=3; figure 7.6 a, b). 
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Figure 7.6. a, b) Immunostaining of the spheroids obtained by applying the Taguchi protocol on 
hiPSCs. At the end of the differentiation protocol, the spheroids showed  expression of GATA3, 
CDH1 and PAX2. c) Single buds were isolated from the spheroids after the end of the 
differentiation. d) The isolated bud on day 0 of gel culture; e) the same bud after 14 days of gel 
culture, no branching was seen. Scale bar is 100 μm. NB: PAX2 staining in (a) and (b) is 
suboptimal; the nuclear PAX2 staining is weak with quite high background. This staining problem 
is most likely due to the big thickness of the spheroids which might have been problematic for the 
antibody penetration. 
The fully differentiated spheroids were obtained and single buds were dissected from 
its periphery and cultured in the same conditions that were used to induce branching 
in embryonic mouse UBs and hiUBs obtained from the Takasato protocol; no 
branching was observed in these isolated structures until the end of the treatment 
duration (14 days) (n=3, each repeat contained 10 isolated hiUBs obtained from one 
run of differentiation; a total of 30 isolated hiUBs were examined; figure 7.6 c-e); hiUBs 
obtained from Takasato protocol were cultured in parallel and were able to branch 
which excludes insufficiency of the culture conditions (figure 7.7). 
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Figure 7.7. a, b) Graph illustrates the 95% confidence interval for obtaining branched (or 
unbranched) isolated hiUBs in gel a) using the Takasato protocol and b) using the Taguchi 
protocol; data are presented as mean, upper and lower limits of confidence. c) The table shows 
the 95% confidence interval (Wilson/Brown; see section 2.16) for obtaining branched tree from 
isolated hiUB using the two different protocols. n= 44 for hiUBs obtained using the Takasato 
protocol and 30 for hiUBs obtained using the Taguchi protocol. 
7.6 Reproducing Taguchi and Nishinakamura protocol for 
obtaining miUBs: 
The Taguchi protocol was originally developed using mESCs; thorough in-vivo and in-
vitro analyses were employed to develop it with meticulous optimisation to every single 
step included and then transferred to hiPSCs.  
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When I tried to recapitulate their human protocol, surprisingly the resulting iUBs did 
not branch when cultured isolated in Matrigel and treated with branching inducing 
growth factors. Their experiment to evaluate the branch-competence of the obtained 
hiUB was set up in a quite different way from what I did. Instead of isolating single 
hiUBs and inducing them to branch in gel, they transferred the whole spheroid 
obtained at the end of step 7 of differentiation to Matrigel and treated it with branching 
inducing factors; they believed that the iUBs underwent initial elongation and 
bifurcation in the first 7 days of gel culture but that further branching morphogenesis 
was not observed. Spheroids obtained after step 7 of differentiation show multiple 
growing buds from all around their peripheries (figure 7.6.b). Transferring the whole 
spheroid to the branching inducing culture would make spotting and counting 
branching events confusing; it is hard to tell if there is any new bifurcation points or 
not in that model. In addition, other populations of cells, within the spheroids, could be 
supplying undefined additional factors that induce maturation and branching of the tip 
cells. After considering the difference in the way they evaluated the branch-
competence of the hiUB, the branching capacity of the hiUB that they showed was 
modest, if we were to consider the number of newly formed branches from each 
individual bud.  
In contrast, results obtained from miUBs were way more robust and even very close 
to what could be obtained from mouse embryonic UB, either in relation to their 
branching capacity or in their ability to induce nephron formation.  
Aim: 
I wanted to evaluate the Taguchi mouse protocol for obtaining branch-competent 
miUBs and organised renal organoids from mESCs. Having the mouse protocol 
working in the expected way would possibly imply the efficiency of the protocol but the 
insufficiency of its adaptation to hiPSCs.  
The availability of mouse embryonic kidneys would allow for comparing the obtained 
miUB to their embryonic counterparts but the limited availability of human embryonic 
tissue, and ethical considerations about their use, leads to extrapolating data from 
mouse to human which could be unreliable due to the inter-species difference. 
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7.6.1 Obtaining miUBs using the Taguchi protocol: 
E14 mESCs were maintained on the surface of gelatine-coated culture dishes and 
were tested for the pluripotency markers OCT3/4, Nanog and increased alkaline 
phosphatase activity (figure 7.8 a-c); to start differentiation cells were dissociated and 
cultured in U-bottom low attachment plates to allow them to aggregate and form 
embryoid bodies before starting the differentiation protocol. 
The seven steps of the differentiation protocol were applied to the embryoid bodies 
where the cells were first treated with Activin A for 1 day (step 1) to induce epiblast 
fate followed by 1.5 day of CHIR treatment (step 2), according to that protocol the 
duration of CHIR treatment has to be followed strictly to ensure obtaining AIM fate. A 
combination of RA, FGF9, and SB431542 was then added for 1 day (step 3) to obtain 
AIM mesoderm which was treated with RA, FGF9 and CHIR for 18 hrs (step 4) to 
derive CXCR4+/KIT+ WD progenitors (figure 7.8 a). 
After the end of step 4, the developed spheroids were dissociated and were FACS 
analysed for the co-expression of CXCR4 and KIT. An average population of 30% was 
positive for these two surface markers (n=3; figure 7.8 d and g). 
The positive population was sorted, and the recovered cells were re-aggregated then 
the differentiation was continued for further three days to induce maturation of the 
developed WD progenitors into E11.5 UBs. During these three days, the WD 
progenitors were first treated with RA, FGF9, CHIR for 1 day (step 5) then GDNF was 
added to the previous combination of growth factors for 1 day (step 6) and finally a 
combination of RA, CHIR and GDNF was used for 1 day (step 7). 
Similar to the human protocol, after step 5, the spheroids started to show outgrowing 
buds which increased in size and number after step 6 and 7. It is noteworthy that 
skipping the sorting step was possible, by shifting the spheroids from step 4 medium 
to step 5 medium directly, and spheroids still developed outgrowing buds (n= 4, in 
each repeat six different spheroids were included, all of them showed budding from 
their periphery without prior FACS); indeed spheroids that were shifted from step 4 to 
step 5 without sorting developed more buds compared to those seen in sorted re-
aggregates probably because sorting involves dissociation of the spheroids which 
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would cause the sorted re-aggregated cells to take longer time to assemble 
themselves into structures. 
Spheroids obtained at the end of the differentiation protocol (after step7) were 
examined for the expression of different UB markers and showed positivity to CDH1, 
PAX2, and GATA3 (n=5) suggesting successful induction of UB fate (figure 7.8 e, f). 
 
 
Figure 7.8. Differentiating mESCs into UBs using the mouse Taguchi protocol. a) 
Outline of the steps of the differentiation protocol. b, c) verification of the mESCs 
pluripotency by immunostaining for OCT3/4 and Nanog (b) or assessing alkaline 
phosphatase activity (c). d) FACS analysis of the cells after step 4, CXCR+/KIT+ cells 
were recovered and the differentiation protocol was continued. e, f) immunostaining of 
the developed spheroids at the end of differentiation showing positive staining for 
CDH1 and PAX2 (e) and for GATA3 (f). Scale bar is 100 μm. 
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 figure 7.8.g. Gating strategy for sorting KIT+/CXCR+ cells (Wolffian duct progenitors) 
after 6.25 days of applying the Taguchi protocol of differentiation to mESCs. The intact 
singlets represented 37.7% of the total analysed events. Three distinct populations 
were sorted from these intact singlets: KIT-/CXCR4- (double negative cells 25.4% of 
the intact singlets; 24,650/97,075), KIT+/CXCR4+ (cells with moderate positivity to both 
markers 28.2%; 27,387/97,075), and KIT++/CXCR++ (cells highly positive to both 
markers 21.4% of the intact singlets; 20,748/97,075). Cells from the three different 
groups were recovered and cultured separately, and the differentiation protocol was 
continued. At the end of the differentiation protocol, the KIT+/CXCR4+ and the 
KIT++/CXCR4++ cells both formed spheroids with budding UBs from all around. When 
UBs from the two groups were cultured in branching inducing mixture, they formed 
branched collecting trees. Thus, these two groups were considered as KIT+/CXCR+ 
(49.6% of the intact singlets) Wolffian duct progenitors. The spheroids formed from 
the KIT-/CXCR- cells did not show any outgrowing buds; these cells represented the 
negative population.  
7.6.2 Evaluating branch-competence in gel cultures: 
To evaluate the capacity of miUB to undergo iterative branching and form ramified 
inter-connected tree, the spheroids that developed outgrowing buds at the end of step 
7 differentiation were obtained and single buds were dissected from its periphery 
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(figure 7.8 a); the isolated buds were cultured suspended in Matrigel and treated with 
a combination GDNF, FGF1, CHIR and RA. The isolated miUBs showed branching 
capacity comparable to what was seen with isolated embryonic UBs. After 7 days in 
culture, the miUB, which started as single isolated bud, developed into a tree of 
branched tubules (n= 4, each repeat contained 8 different miUBs; a total of 32 miUBs 
were examined; 31/32 branched; figure 7.9 b,d). 
7.6.3 Testing the possibility of propagating miUBs in gel cultures: 
The ability of the obtained miUBs to branch in gel upon treatment with branching 
inducing factors has been reported in the original protocol, but it has never been 
investigated if these iUBs could be propagated and expanded for longer periods in gel 
cultures. 
Aim: 
Here, I wanted to examine how long could the miUBs keep their branching capacity in 
gel and to test if I can propagate them in culture for some passages. 
 Results: 
I extracted the branched tree after it has been cultured in the gel for seven days and 
dissected single tips from its periphery. The newly isolated miUBs were then cultured 
dipped in Matrigel and treated with the branching inducing mixture of growth factors. I 
was able to isolate as many as ten new miUBs from one branched miUB-tree, many 
more could even be dissected but that was enough for my purpose, and passaged 
them, individually, into new gel cultures, as second-generation miUBs (figure 7.9 d,e). 
Similar to the 1st generation miUB, originally obtained at the end of the differentiation 
protocol, the 2nd generation miUB underwent iterative branching forming a whole new 
branched tree after 7 days in culture (n=4, each repeat included 10 different 2nd 
generation miUBs all obtained from one 1st generation branched tree; a total of 40 2nd 
generation miUB were examined; 40/40 branched). The same process was repeated 
again with the branched 2nd generation miUBs which were extracted, cleaned from the 
surrounding Matrigel, and new tips were isolated from its periphery for passaging in 
gel culture (3rd generation miUBs). The isolated 3rd generation miUBs still maintained 
high capacity of branching and formed branching collecting system after 7 days of 
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culture under the treatment of branching inducing mixture (n=3, each repeat included 
10 different 3rd generation miUBs; a total of 30 2rd generation miUBs were examined; 
26/30 branched; figure 7.9 g,f).  
When stained for UB markers, the branched trees from the three different generations 
of miUB showed positive staining for the UB markers PAX2, CADH1, GATA3 and CK8 






Figure 7.9. Illustration of the gel passaging experiment. a) A spheroid obtained from 
the end of the differentiation protocol was dissected to isolate single UBs. The isolated 
miUBs were cultured in gel as 1st generation UBs. b, c) Show the isolated miUBs on 
day 0 (b) and day 7 (c) of gel culture. The ramified structure obtained in (c) was 
extracted from gel and single miUBs were isolated and passaged in the gel as 2nd 
generation miUBs, (d) shows day 0 and (e) shows day 7 of gel culture. The process 
was repeated, structures obtained in (e) were extracted from gel and single miUBs 
were dissected from the periphery and were cultures as 3rd generation miUBs. f, g) 
Show the 3rd generation miUBs on day 0 (f) and day 7 (g) of culture. Scale bar is 100 
μm. h) Graph shows the proportion of the isolated miUBs that branched and formed 
ramified trees in gel of the total examined miUBs; data are presented as mean, upper 
and lower limits of confidence interval. i) The table shows the 95% confidence interval 
(Wilson/Brown; see section 2.16) for obtaining branched tree from the three different 
generations of miUB. n= 32 for the 1st generation miUB group, 40 for the 2nd generation 
miUB group, and 30 for the 3rd generation miUB group. 
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Figure 7.10. Immunostaining results for the ramified trees obtained from the three 
different generations of miUB cultures a-c) show staining for CDH1, PAX2 and DAPI, 
d-f) show staining for GATA3 and CK8. Scale bar is 100 μm. 
7.6.4 Examining the ability of miUB to induce nephron formation and form 
organised renal tissue when mixed with embryonic MM: 
Next, I wanted to investigate if the obtained miUBs possess the functional capacity to 
induce nephrogenesis and form complex organised kidney structures arranged around 
a single collecting system. miUB was obtained by dissection from a spheroid at the 
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end of the differentiation protocol (after step 7), then aggregated with freshly isolated 
embryonic MM. Embryonic MM was obtained by microdissection of E11.5 metanephric 
rudiments to exclude UBs. To ensure that any branching collecting system is 
originating from the miUB, and not from embryonic UB cells that could be 
contaminating the MM cells, I first tried to label the miUBs with cell tracker red before 
mixing it with the MM, however, I noticed that the red label spread from the tagged 
iUB to the surrounding MM cells after 24 hrs of co-culture. As an alternative strategy 
to be sure no UB was being carried over with the MM, I used only kidney rudiments 
from which I was able to remove the embryonic UB intact. In addition, the collected 
MM was dissociated and passed through a cell strainer to ensure obtaining single 
cells. In this case, if any UB cells were not excluded during dissection, they would be 
dispersed into single cells and thus would be unlikely to result in a structure with single 
collecting system. 
The miUB was able to branch and induce nephron formation making an organised 
renal organoid very similar to Ganeva-style organoids that could be obtained by mixing 
embryonic MM with embryonic UB (Ganeva, Unbekandt and Davies, 2011); the 
developed nephrons appeared connected to the central collecting system (n=2; figure 
7.11).  
I next wanted to test if iUB cultured in a gel and then recovered from it could still 
maintain its ability to make realistic kidney structures when mixed with embryonic 
isolated MM; 1st generation branched iUBs were extracted from Matrigel, after 7 days 
of gel culture, single iUBs were isolated from the branched tree, cleaned as possible 
from the surrounding gel and were aggregated with freshly isolated embryonic MM 
cells. The gel-extracted iUBs maintained their ability to induce nephron formation and 
the re-aggregated cells formed renal organoids with single collecting system (n= 3). 
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Figure 7.11. Mouse iUBs (obtained by applying the Taguchi protocol to mESCs) 
induce nephron formation. a,b) Cell tracker red was used to label the isolated miUB 
before reaggregating it with embryonic MM, on day 0 (a) the red label was confined to 
the isolated miUB but on Day 1 (b) the whole reaggregated structure was stained with 
the dye. c, d) Organised kidney tissue constructed by co-culturing miUB and 
embryonic MM for 7 days. The constructed tissue showed condensed cap 
mesenchyme around the periphery of the tissue and formed glomeruli towards the 
centre. e) 4 days cultured miUB with embryonic MM stained for CDH1 and WT1. Scale 








7.7 Can miUB be reprogramed into Urothelium? 
During normal kidney development, after the outgrowth of the UB from the WD and its 
invasion into the MM, the UB sub-divides into proximal part that invaginates into the 
MM and undergoes branching morphogenesis to form the intra-renal collecting duct 
tree, and distal part, the stalk of the ureteric bud, that elongates without branching and 
develops into the epithelial layer of the definitive ureter (Bohnenpoll and Kispert, 
2014).  
The type of mesenchyme that surrounds the stalk part of the UB has a distinct 
developmental origin and distinct fate from that of the MM, which surrounds the tip 
part. The MM provides all signals necessary for inducing proliferation and branching 
of the UB tip which eventually form the intra-renal collecting duct tree, at the same 
time, it responds to inductive signals emanating from the growing tips and undergo 
mesenchymal to epithelial transition to form nephrons. While the mesenchyme 
surrounding the UB stalk, tail-bud derived mesenchyme which is characterised by the 
expression of TBX18, provides signals to elongate without branching and eventually 
differentiates into smooth muscle cells and fibroblasts which form the smooth muscle 
layer and the stromal layer surrounding the ureter (Airik et al., 2006; Brenner-
Anantharam et al., 2007; Bohnenpoll et al., 2013).  
Studies have shown that UB cells are multipotent cells that have the ability to 
differentiate towards extra-renal ureteric epithelium or intra-renal CD. The stalk part of 
the UB can branch and induce nephron formation when transplanted into the MM 
(Sweeney, Lindstrom and Davies, 2008), on the other side, isolated UB tips will stop 
branching, elongate and express the ureteric epithelium (urothelial) specific marker, 
Uroplakin, when transplanted into the ureteric mesenchyme (Bohnenpoll and Kispert, 
2014; Mills et al., 2017); these findings show that the type of mesenchyme controls 
the type of UB morphogenesis leading to either branching morphogenesis to form 
intra-renal collecting system, in the case of the proximal part of the UB, or ureteric 
morphogenesis, straight unbranched tube lined with highly specialised epithelium, in 
the case of the distal part of the UB.   
BMP4, a member of TGFβ-superfamily, has been shown to play an important role in 
ureteric morphogenesis and in inducing urothelial differentiation. It is normally 
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secreted by the peri-Wolffian mesenchyme, the type of mesenchyme that envelops 
the Wolffian duct, and by the TBX18+ mesenchyme surrounding the UB stalk. BMP4 
has been shown to inhibit UB outgrowth, budding, and branching morphogenesis. 
Genetic studies and in-vitro studies, performed on metanephric explants, showed that 
Bmp4 loss of function or inhibition leads to ectopic budding from the Wolffian duct or 
branching from the distal UB stalk and disruption of urothelial and smooth muscle 
differentiation (Miyazaki et al., 2000, 2003; Michos et al., 2007; Wang et al., 2009; 
Nishinakamura and Sakaguchi, 2014). In addition, exogenous BMP4 treatment has 
been shown to induce ureteral morphogenesis, to elongate unbranched and express 
the urothelial marker Uroplakin, in intra-renal UB tips, fated to undergo branching 
morphogenesis and form collecting tubules, in in-vitro cultures of metanephric kidney 
rudiments (Brenner-Anantharam et al., 2007).    
The recent modification that enabled the production of Mills-style renal organoids (see 
chapter 6 for more details) from mouse embryonic kidneys (equipped with a ureter-
like exit) was based on applying a local BMP4 source to re-program one of the ramified 
UB branches to acquire urothelial fate and serve as an exit while the rest of the tree 
induces nephrons forming an organised renal tissue (Mills et al., 2017). 
Aim: 
In the previous section, I showed that isolated miUB could be induced to branch and 
recapitulate branching morphogenesis, and are able to induce nephron formation if 
combined with MM. Whether the obtained iUB has the plasticity to develop into 
urothelium or not has not been investigated before. Here, I wanted to see if the iUBs 
could be reprogramed into urothelium and recapitulate ureteric morphogenesis if the 
surrounding environment changed, mimicking what happens during normal 
development. If this proved to be feasible, a ureter-like exit could be added to the 
current model of renal organoids obtained from mESCs following the same logic that 
was developed in Mills et al, 2017 and, in principle, it might be possible to transfer it 
to hiPSC-derived organoids.  
7.7.1 Results: 
To examine the ability of miUBs to acquire ureteric fate and express Uroplakin, mESCs 
were differentiated into miUB (following the 7 steps of differentiation), then single 
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miUBs were isolated and cultured in Matrigel for 7 days, under the treatment of 
branching inducing factors. Afterwards, the branched-iUB tree was extracted from the 
gel and 2nd generation iUBs were isolated from it, as previously described in section 
7.6.3, cultured suspended in Matrigel and treated with the branching inducing growth 
factors in presence of BMP4. The branching inducing growth factors were added to 
support the growth and prevent apoptosis of the isolated UBs, while BMP4 was added 
to these growth factors to test the ability to reprogram these structures into ureters that 
express Uroplakin. At the same time, a control group was cultured under the same 
conditions but in absence of BMP4.  
 
 
Figure 7.12. Reprograming miUB into extra-renal ureter like structure. mESCs were 
differentiated into miUBs by applying the Taguchi protocol of differentiation. the 
plasticity of the obtained miUB to obtain either extra-renal ureter like fate or intra-renal 
branched tree was examined by culturing isolated miUBs in gel in presence of 
branching inducing growth factors plus or minus BMP4. a) miUBs treated with BMP4 
stopped branching and grew thicker similar to what happens in the extra-renal stalk b) 
control miUB exposed to the same treatment minus BMP4 formed a branched tree. 
Scale bar is 100 μm. 
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The BMP4 treated miUBs grew thicker and stopped branching while the control iUBs 
branched as usual (n= 3, each repeat included 5 individual miUBs; a total of 15 miUBs 
were examined; figure 7.12). In addition, Uroplakin expression was highly upregulated 
in the treated group compared to the non-treated controls suggesting successful 
reprograming of miUBs into urothelium (n= 5; figure 7.13). This showed that miUB do 
possess the plasticity to be reprogramed into ureteric epithelium and indicated their 
close similarity to embryonic UBs as they can efficiently recapitulate the major 
functional abilities of the embryonic UB: branch and recapitulate branching 
morphogenesis, induce nephron formation and also can be reprogramed into 




Figure 7.13. a, b) BMP4-treated miUBs expressed the urothelial marker Uroplakin. c) 
Non-treated control stained negative for Uroplakin; UP: Uroplakin. Scale bar is 100 
μm. d) Graph illustrates the increase in Uroplakin mean fluorescence in response to 
BMP4 treatment; p value <0.0001; n= 5. 
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7.8 Discussion: 
I previously showed that results for obtaining UB fate using the Takasato protocol were 
variable; I also showed that when hiUBs obtained from that protocol were isolated and 
re-aggregated with sorted nephron progenitors they failed to branch or induce nephron 
formation. For these reasons, I wanted to further evaluate these structures and 
investigate their branching capacity in an MM free culture condition.  
I first determined that the combination of GDNF, FGF1, CHIR and RA was optimum 
for inducing robust branching in isolated embryonic UBs. Yuri et al showed in their 
study that treatment with GDNF, FGF1 and CHIR was enough to induce “extensive” 
branching in UBs isolated from mouse embryonic kidneys (Yuri et al, 2017). However, 
according to my results, in the absence of RA, the branching that was induced in 
response to this combination of growth factors was inconsistent, slower and limited 
compared to the treatment with the same plus RA. The importance of RA in 
maintaining RET expression in the UB tips has been highlighted in previous studies; it 
has been shown that supplying exogenous RA upregulates RET expression in 
metanephric kidney explants in a dose dependant manner and enhances branching 
morphogenesis (Moreau et al., 1998). Another study has shown that blocking RA 
receptors, via generating dominant-negative mouse models, abolishes RET 
expression in UBs and hence disturbs ureteric bud formation and branching 
morphogenesis (Rosselot et al., 2010). The limited and inconsistent branching of the 
isolated UBs when treated with GDNF, FGF1 and CHIR might be due to loss of RET 
expression in the absence of RA.  
I next showed that isolated hiUBs obtained from the Takasato protocol were able to 
form ramified structures with expression pattern characteristic to branched collecting 
tree in response to the treatment with GDNF, FGF1, CHIR and RA, as was optimised 
in embryonic UBs. Despite the variability in obtaining UB fate using this protocol, these 
data suggest that the obtained hiUBs are branch-competent. The branching process 
was, however, slower and the extent of branching was limited compared to mouse 
embryonic UBs. This could be seen as an interspecies difference. Generally, the 
human organogenesis period is much longer than that of the mouse. More specifically 
UB development in human starts at CS13 (28-32 days post ovulation), undergoes 1-2 
generations of branching by CS16 (37- 41 days post ovulation) and continues roughly 
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until weak 37 when nephrogenesis is completed (Lindström et al., 2018; Ryan et al., 
2018). This could by no way be compared to that of the mouse. The ramified hiUB tree 
showed expression of the specific UB markers CK8, CDH1, GATA3 and RET. 
In the previous chapter, I tried to construct organised renal tissue by mixing one of the 
hiUBs with nephron progenitors, but that was not successful. One possible explanation 
to that might be the absence of stromal renal progenitors from that re-aggregate. Data 
obtained here from mouse embryonic UBs suggested the importance of RA for proper 
branching of the isolated UBs and data from other studies also stressed on the 
importance of RA for RET expression as discussed earlier. RA has been shown to be 
produced in renal stromal cells by retinaldeyde dehydrogenase 2 and a model has 
been proposed where RA, secreted from renal stromal cells, signalling through RA 
receptors, in UB cells, regulates RET expression during both bud formation and 
branching morphogenesis (Rosselot et al., 2010). Based on this, it is likely that the 
absence of stromal cells from the re-combination experiment has led to unsuccessful 
experiment. This also fits with Taguchi and Nishinakamura’s results where they 
showed that mixing miUB with mouse nephron progenitors showed poor development 
unless stromal progenitors were added to the cultures. It is therefore expected that 
adding stromal progenitors at the re-aggregation step could improve the result. It is 
also likely that culturing hiUBs in the branching promoting mixture is inducing further 
maturation to these cells; it would be interesting to repeat the construction experiment 
using branched tubule, after an initial treatment with the branching inducing mixture, 
instead of hiUB that has freshly been isolated from the culture. 
I tried to reproduce the Taguchi and Nishinakamura protocol for obtaining hiUBs. I 
evaluated the differentiated cells at the middle of the differentiation and at the end of 
the differentiation protocol. Results of the FACS analysis at the middle of the 
differentiation suggested successful obtaining of WD progenitors (CXCR4+/KIT+ cells) 
and immunostaining at the end of the differentiation suggested successful obtaining 
of hiUBs (CDH1+/PAX2+/GATA3+). In addition, morphologically, the obtained 
spheroids showed multiple outgrowing buds at the end of the differentiation. However, 
sectioning of the spheroids is recommended for better staining and imaging as the 
obtained spheroids were very thick. This could help to confirm the expression of the 
UB markers, especially PAX2, the staining result of which was quite weak. Also, qPCR 
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would help to confirm and quantify the expression of these markers. When single buds 
were manually dissected from the periphery of the spheroids, at the end of the 
differentiation protocol, and cultured separately in branching inducing culture 
conditions they did not branch. 
Using the mouse version of the Taguchi and Nishinakamura protocol, I efficiently 
obtained branch-competent miUBs. The ability of these miUBs to branch was 
comparable to their embryonic counterpart; most importantly when those developed 
miUBs were mixed with embryonic MM they induced nephron formation in an 
organised renal structure. 
Additionally, I showed that miUBs could be propagated in gel for few passages. This 
could be a powerful tool for providing branched collecting trees that could serve as a 
model for studying different physiological aspects of the collecting duct cells; it would 
be interesting to examine if hiUBs could also be propagated in such a way.  
Embryonic UBs have the plasticity to acquire extra-renal urothelial fate if surrounded 
with peri-Wolffian mesenchyme or treated with exogenous BMP4 (Brenner-
Anantharam et al., 2007; Bohnenpoll and Kispert, 2014). A distinctive property that 
has been exploited to add a ureter-like exit to the organoids obtained from dissociated 
embryonic kidneys (Mills et al., 2017). Here, I showed that the obtained miUBs also 
possess plasticity to acquire urothelial fate and express UP. This implies that the 
current model of renal organoids obtained from mESCs could be further improved by 
locally treating one of the collecting tree branches with BMP4 and inducing it to a 











8 General discussion  
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Discussion: 
Protocols for directed differentiation of hiPSCs towards MM fate (Taguchi et al., 2014; 
Freedman et al., 2015; Morizane et al., 2015; Garreta et al., 2019), UB fate (Xia, Nivet, 
Sancho-Martinez, et al., 2013; Taguchi and Nishinakamura, 2017) or the simultaneous 
production for both of them (Takasato et al., 2013, 2015) have been established and 
have enabled the generation of renal organoids. The primary goal of this project was 
to evaluate the currently available model of renal organoids with respect to its 
efficiency, functional abilities and its suitability to detect nephrotoxicity, then to try to 
develop techniques to improve it. 
8.1 Evaluating renal organoids with respect to the efficiency in 
nephron formation and functional ability of the formed nephrons: 
I successfully reproduced the Takasato protocol for making renal organoids. I obtained 
renal tubules with gene expression patterns characteristic of the UB and the main 
renal cell types constituting the nephron. I then moved on to evaluate the functional 
ability of the obtained organoids. Kidney organoids are potential scaffolds for studying 
disease pathogenesis and developing new therapeutic options for them (Freedman et 
al., 2015; Gupta, Susa and Morizane, 2017; Harder et al., 2019). They also represent 
a possible model for studying drug interactions and testing the toxic potential of 
substrates in 3D tubular structures with complex multicellular components 
(Kandasamy et al., 2015; Bajaj et al., 2018) in addition to the increasing hope for their 
use in regenerative therapy (Kim, Nam and Yang, 2018; Combes et al., 2019; Garreta 
et al., 2019). Clearly, the potential use of organoids in any of these applications is 
conditioned by their functional capacity. Using fluorescent substrates, I reported that 
3D hiPSCs-derived renal organoids express functional anion and cation transporters, 
a finding that is of particular importance for the use of these organoids in studying drug 
interactions and nephrotoxicity screening purposes as they are involved in the 
pharmacokinetics of wide arrays of drugs (Nigam et al., 2015; Sanjay K. Nigam, 2015). 
Renal tubular function capacity of the organoid might be exploited to improve quality 
of the conventional dialysis methods if we were able to fabricate cell-based dialysis 
membranes that would be able to remove organic cations and anions (Narayanan et 
al., 2013; Pollock, 2013; Oxburgh et al., 2017; Masereeuw and Stamatialis, 2017). 
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8.2 Cryopreserving renal differentiated cells 
I developed and optimised a technique to cryopreserve and revive hiPSC-derived 
renal cells at two different differentiation points (12 days of differentiation and 18 days 
of differentiation); I showed that the revived cells possessed organic anion and cation 
transport-ability and were able to detect Cisplatin toxicity. The possibility of 
cryopreserving and successfully reviving renal differentiated cells has not been 
investigated before. Cryopreservation could be a useful tool for different applications 
of hiPSC-derived renal organoids as it shortens the time needed for obtaining 
organoids from 20 days to 9 days (or 3 days in the case of cryopreserving 18-day 
differentiated cells) in addition to saving the time and effort needed to maintain 
hiPSCs. Collectively the data suggest that cryopreserved renal cells could enable 
large scale production of renal organoids which could be employed for nephrotoxicity 
assays. Moreover, a recent study that evaluated variability between different renal 
organoids concluded that differences in technical parameters, between different runs 
of differentiation, is the biggest source of variability between renal organoids (Phipson 
et al., 2019). The ability to cryopreserve renal differentiated cells might help to 
minimise these variations. A cryopreserved stock of renal differentiated cells, that is 
obtained from the same differentiation runs, from which renal organoids are made on 
different occasions, to be used in downstream experiments and comparison purposes, 
could be a way to overcome run-to-run variability between organoids. 
8.3 Constructing and evaluating a fluorescent reporter system 
to screen for nephrotoxic compounds using renal organoids: 
Based on analysis of the transcriptomic data obtained from gentamicin treated renal 
differentiated cells, I identified HMOX1 as a promising reporter of nephrotoxicity. 
Findings from other recent studies supported this result; a study performed on HPTEC 
cells did multiplex gene expression analysis and revealed that HMOX1 induced the 
most significant response to increasing doses of the analysed drugs (Adler et al., 
2016). Similarly, another recent study, Bajaj et al presented HMOX1 as a more 
sensitive indicator of tubular toxicity in hPSC-derived organoids in comparison to the 
conventional marker KIM1 (Bajaj, A. David Rodrigues, et al., 2018).  An HMOX1-
fluorescent reporter-iPS cell line was constructed in my lab, based on my results. 
Working in collaboration with other lab members, I showed that organoids made from 
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the HMOX1-reporting-iPSCs can predict nephrotoxicity, at least when used with a 
range of concentrations and measurements done at more than one time point. We 
showed that the overall performance of the reporter cells was predictive for renal 
toxicity (see table 5.6 and the discussion of chapter 5 for more details). 
We have assessed the performance of the reporter cells in renal-differentiated 
organoids but we expect that it could be also used to screen for toxicity in other 
organoid models since HMOX1 is a global oxidative stress marker and hiPSCs could 
be differentiated into all specialised cell types in the human body. 
8.4 Steps towards improving the current model of renal 
organoids: 
The inherent ability of renal progenitors to self-organise was the base for making renal 
organoids from hiPSCs, first, by directing the differentiation of hiPSCs into renal 
progenitors, then, re-aggregating the obtained progenitors and allowing them to self-
organise into kidney tissue. However, relying solely on self-assembly lacks control 
over the spatial organisation of the cells and results in a quite chaotic tissue. 
Techniques for engineering an anatomically correct renal tissue from the disorganised 
organoid using dissociated mouse embryonic kidney cells have been developed 
sequentially (Ganeva, Unbekandt and Davies, 2011; Mills et al., 2017) (see 
introduction of chapter 6 for more details). These techniques rely on their first step on 
isolating UB cells from the disorganised tissue. I developed a technique for live-tagging 
and isolating UB structures from surrounding cells and structures. I showed that 
conjugating GDNF protein to a fluorophore successfully labelled UBs both in 
embryonic mouse kidney explants and hiPSC-derived renal tissue and thus enabled 
their isolation. GDNF/488 could be a useful tool for isolating correctly differentiated 
UBs from other cell fates in a mixed culture. While I developed this procedure to enable 
organising renal organoids following steps described in Ganeva et al., 2010, it could 
equally fit with other in-vitro approaches of engineering kidneys as populating 
decellularized scaffolds and 3D bioprinting strategies, both of which need a source of 
pure specialised cells (Kim et al., 2015; Montserrat, Garreta and Izpisua Belmonte, 
2016; Oxburgh et al., 2017; Hueso et al., 2019). 
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8.5 Comparing two different differentiation protocols with 
respect to their efficiency in producing branch-competent UBs: 
Although the Takasto original protocol described obtaining both UB and MM fate 
simultaneously  (Takasato et al., 2015), I reported a degree of variability in obtaining 
UB fate using this protocol which led me to evaluate a different protocol that aims to 
differentiate hiPSCs mainly into UB cells, the Taguchi and Nishinakamura 2017 
protocol, and compare between their efficiency in producing branch-competent UBs. I 
showed that hiUBs that were obtained from the Takasato protocol efficiently branched 
and formed ramified trees in response to the treatment with branching inducing factors. 
On the contrary, hiUB obtained from Taguchi and Nishinakamura protocol did not 
branch under the same culture conditions. Despite the variability seen in obtaining UB 
fate using Takasato protocol, the ability of the obtained UBs to branch and the pattern 
of expression seen in the branched structures suggest more mature structures 
compared to those obtained by the Taguchi and Nishinakamura protocol. In fact, the 
hiUB branching capacity that Taguchi and Nishinakamura have shown in their study 
was very limited and inconclusive.  
The branched collecting trees that I managed to generate from hiUBs could be used 
as a model for studying different physiological aspects of collecting ducts and for 
disease modelling. 
8.6 Current situation in renal organoids obtained from mESCs: 
I developed a technique to propagate miUBs, obtained by using the Taguchi and 
Nishinakamura mouse differentiation protocol, in gel cultures for three generations 
without loosing the expression of different UB markers. This amplification method of 
miUBs provides ramified branched collecting ducts on a large scale. A quite relevant 
result has been shown in 2002 using mouse embryonic UBs, but with a different 
experimental design. In that report, researchers cut one branched tree of embryonic 
UB into thirds and allowed each third to further branch (Steer et al., 2002). While that 
has been shown to amplify the obtained UB trees, starting each new generation by 
single tip structure allows for more robust amplification. Most importantly, there is the 
difference of applying this to tissue obtained from pluripotent cells rather than 
embryonic tissue. Encouragingly, when tips were isolated from the 1st generation 
ramified collecting tree, after its extraction from gel, were aggregated with dissected 
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embryonic MM it induced nephron formation and produced organised renal tissue. It 
is still to be evaluated if tips of the 2nd and 3rd generation branched tree would reserve 
this capacity or not.  
Additionally, I successfully reprogramed the obtained miUBs into urothelial fate with 
positive Uroplakin expression, a characteristic expression marker of the extra-renal 
ureter. In principle, this would enable the achievement of Mills-style renal organoids, 
equipped with a ureter-like exit, by inducing ureter-fate in one of the collecting duct 
branches of the re-aggregated organised organoid that we can now obtain from 
mESCs. 
8.7 Heterogeneity and variability of hiPSC-derived renal cells: 
Different protocols have been developed based on recapitulating steps of renal 
development in-vitro to form renal organoids. These protocols agree on the 
importance of WNT and FGF signalling pathways in deriving the differentiation of renal 
progenitors, however, they differ in their detailed combination of growth factors, the 
exact duration of treatment with each growth factor, and the duration of the whole 
differentiation protocol. In fact, some key findings of these studies are contradictory to 
one another. For instance, according to Taguchi and colleagues, 2014 and Taguchi 
and Nishinakamura, 2017 it is not possible to obtain NPs and UB progenitors 
simultaneously since they develop from different spatial origins. According to these 
two studies, NPS needs 5-7 days of CHIR treatment while the permissive time window 
of CHIR treatment for obtaining UBs is restricted to 1.5 days; longer treatments would 
result in the failure of obtaining UBs. In contrast to these two studies, Takasato and 
colleagues reported the simultaneous induction of UB progenitors and NPs by 
adjusting the CHIR treatment to 4 days of differentiation followed by 8 days of FGF9 
treatment. Garreta et al., 2019 described a protocol almost similar to the Takasato 
protocol, with fine-tuning to the extra-cellular environment to allow for better 
development and maturation of the obtained organoids, and reported the specific 
derivation of nephron progenitors but not UB cells.  
Since those studies were conducted in different laboratories and used different cell 
lines of hPSCs, mostly generated by different reprograming techniques, the 
discrepancy in the obtained data well reflects the heterogeneity of the genetic, 
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epigenetic and transcriptional features of the used cell lines (see section 1.4.3). 
Genetic heterogeneity could lead to discrepancy in the generated cell types upon 
differentiation, affect the functionality of the differentiated cells, or completely disrupt 
the differentiation capacity of the PSCs (Biendarra-Tiegs, Secreto and Nelson, 2019). 
In my study, I reported variability in obtaining UB fate (see section 3.3), in the 
percentage of the different nephron specific cell types compared to the total renal 
organoid (figure 3.13 a), and in the individual responses of organoids to nephrotoxic 
compounds (figure 5.4). Since my data were all obtained from a single cell line (AD3-
01), the variability suggests heterogeneity within one iPSC line (see section 1.4.3). It 
is important to determine differentiation protocols that are eiffeciently reproducible 
between different cell lines. Having used only one iPS cell line in this study, 
reproducing these results in other cell lines might necessitate modifications to the 
described techniques; it is also possible that obtaining some results might not be 
achievable.  
8.8 Species differences between human and mouse 
One major limitation to the field of kidney tissue engineering has always been the 
paucity of histological and molecular data about human embryogenesis; this has led 
to the construction of most of the currently available differentiation protocols based on 
extrapolated data from mouse embryogenesis to human. Although a lot of data are 
conserved between mammals, there are some distinct molecular features 
characteristic to each species. An example to this is the difference in SIX1 expression 
and function between human and mouse (O’Brien et al., 2016), the differences in the 
expression of the anchor genes that have recently been reported (genes expressed in 
mouse within the nephron lineage and are used to identify key cell types in mouse 
kidney)(Lindström et al., 2018 a), and other differences in regulatory features which 
might lead to a difference in the process of  nephrogenesis (Lindström et al., 2018 b). 
Even when ignoring the histological and the molecular differences, there are obvious 
anatomical discrepancies between mouse and human kidney including the difference 
in size, the duration of organogenesis, the timing at which nephrogenesis starts and 
ends and the UB branching starts and ends, and other features as lobe formation and 
organisation of the progenitor cells in the nephrogenic niche. In particular, the 
difference in timing and the duration of organogenesis makes transferring data, 
without actual defining parallel stages between the two different species,  from mouse 
 240 
to human more like a hit in the dark strategy. This discrepancy between mouse and 
human kidney development could explain why the Taguchi and Nishinakamura 
protocol achieved great results in mouse but not in human. Fortunately, recent studies 
aimed to tackle this problem by performing molecular and cellular characterisation of 
different stages of human kidney development through immunofluorescence staining, 
histologic analysis and transcriptomic profiling and contrasting the data to mouse 
kidney developmental stages (Lindström et al., 2018 a,b,c; Ryan et al., 2018). It is 
anticipated that this characterisation would enhance the field of kidney tissue 
engineering  
8.9 Future directions: 
My Initial trial to reconstruct an organised, Ganeva-style, renal organoid by re-
aggregating sorted nephron progenitors and isolated hiUB did not succeed. However, 
I expect that culturing hiUBs in branching inducing factors promote their maturation 
and further differentiation. It worth trying to give hiUB obtained by applying the 
Takasato protocol an initial induction of branch-promoting growth factors before re-
aggregating them with nephron progenitors. I expect a branched UB structure might 
be more able to induce nephron formation around its branched tips.  
It would be interesting to evaluate if hiUBs obtained from Takasato protocol can be 
reprogrammed into a urothelial fate (as I showed with miUB); initial results show that 
those hiUBs stop branching, in a ureter-like manner, when treated with BMP4 but 
further investigation is still needed to confirm the result and assess the expression of 
Uroplakin. We expect that if we surround hiUB with nephron progenitors and stromal 
progenitors we might obtain a properly organised kidney structure to which an exit 
could be added by applying local BMP4 signalling.  
The importance of renal stromal progenitors has been highlighted in different studies 
(Taguchi and Nishinakamura, 2017; Moreau et al., 1998; Rosselot et al., 2010). In the 
absence of stromal progenitors, the UB develops fewer and abnormal branches. 
Currently, there is no available protocol to specifically differentiate hiPSCs into renal 
stromal progenitors. It is expected that developing a protocol for obtaining stromal 
progenitors could positively impact the result of specified cell recombination and help 
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engineering an organised kidney organoid (Davies, 2017; Taguchi and 
Nishinakamura, 2017). 
The robustness of the Taguchi mouse protocol in achieving miUBs with characteristics 
very close to the embryonic UB, ability to induce nephron formation in an organised 
renal structure, and plasticity to acquire a urothelial fate suggests that further 
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Segment1 NEB builder primers: 
FP (segment1 FP NEB)  
AAGCTTGCATGCCTGCAGGTCGACTAGACGGGGCTGTAATCTGG 
RP ( labelled as ups RP Xbai) 
CGTGGTCAGCATGTGGCTG 





























































































FP (piggyback FP NEB) 
TCATATCCCCTATTTAACCCTAGAAAGATAGTCTG 

















FP (segment5 FP NEB) 
TTTCTAGGGTTAACAGGGTCTCTAGTGCTGTG 












































































































































































































































































GATA3 gene CDS: 
CTGATTGGTCCCTCCAGGCCCCGCCCCCGCTCGCCCCGCCCCTCTCGCTGGGGCG
CCTCGGAGCCGCGTGCCCTCCGCCCCGGGGTGCCCATTGCGCAGAGCGTGGCCTG
GAGACCCGCGAGCCGGGGAAGGTCGCCGTGGAGTCCCGACCAGAGGCCGGGGTT
GGGGTCGGTGCAGACCGAGGGCTGGTTTCCTTGACTGTGGGAGAAACGCCGGGA
GCCGGAGTAAGTAGGGCTCCGGGCGGGGCGAAAGGAAAAGTTGGGTCCCTAGA
GTGAAGACCGAGTTCTTTCTGTCCGTCTACACTGAGCGTACTCGGGGAATGAGTT
AGAGCCAGTCTCTTCCTCCCCTCCCCCCTTCTCATCCCTCACTGTTGCCACTCAAG
TCAAAAGCACACATTGATTACAAATATTAGGTCTGGAAAGGGCAGCTGCAACAG
CTGAAGCGTGTTCACTCTGGGGGCTTGAGAGCGCAGAAGGCTCGGGAAAGAGGT
GACAATGACAACAAAATTGACGCGGACGCTCCAGTCAAAGGCATCTCCCCTTTA
TCCGATGACTCACCCTCTTAGGAAGTCGGCCCGAGAGGCAAATCTCAAAATACCT
TGACATGAAACATTTTGTTTTTCTGATCAATTTAACGCGCACGTTTCCCCACATCG
ATGCGCTCTCCCAAACACCCTGCATTGGATCCTAATAATGATCCATGCGTGCCTA
TTTTTTAAAAGTCTGAAAAAGAAAATTCTGCCCATCGAAATGAACTTCATGAATG
GGGCAGGCTGGCTGCACCGGGACGGAATCGTCCACCCGACCCGAATGAATTGGC
AGGAGCCGCGGCCACATTTAAAGGGCCAGAGCGCGCGTTCCCTCCCGTCCGCCC
CCAAGCCCCGCGGGCCTCGCCCACCCTGCCCGCCGCCCCTCCGCCGGCGGCCGCC
CTCTGCGGCGCCCCTTTCCGGTCAGTGGAGGGGCGGGAGGAGGGGCGGGGGTGC
GCGGGGCGGGGGGAGAAGTCCTGGAGCGGGTTTGGGTTGCAGTTTCCTTGTGCC
GGGGATCCTGTCCCCTACTCGCCAGCGCCAGGCTCCTCCCCCCCGGCGCGGATGA
CACTAGAACCTCCTTAAGTTGCGTCGCGCCACAGCTGTCTGCGAACACTGAGCTG
CCTGGCGCCGTCTTGATACTTTCAGAAAGAATGCATTCCCTGTAAAAAAAAAAA
AAAAATACTGAGAGAGGGAGAGAGAGAGAGAAGAAGAGAGAGAGACGGAGGG
AGAGCGAGACAGAGCGAGCAACGCAATCTGACCGAGCAGGTCGTACGCCGCCG
CCTCCTCCTCCTCTCTGCTCTTCGCTACCCAGGTTGGTACTGGTGACTTTTTTTTTT
TTTAAGTTTGATTTTTTGCCCCCAACCACTTGGGAGGACCTAAATCAATTTTAAA
AACTCAACTCTCCTCTTTTGGAGGTTTTCTAGGGGCTGAGAGGACGGTCCCGGGA
CCGGTGTCCCCGAGGGAGGGACTTGCCCTCCAAGTCGTAACAGTCAGCCCTGGG
ACTTGCCCTCCAAGTTGCTCAGCCAGCCCCGGCTCCCGCGAGCCGGGCTGCAGGG
ACGTCCCCGAGAGCCCTGCGGGCTCCGCGGCCGTGTCCCCGCGCTCCCGTGCGGG
TCTCGGGTGCGCTGGGCGGGCGGGCGGCGCGAGGGGAGGTTGTGCCACTCCAGC
AACTCAGGGGCTCATCCAGGTCTCCCATTCTCTCCCTTGCAGGTGACCCGAGGAG
GGACTCCGCCTCCGAGCGGCTGAGGACCCCGGTGCAGAGGAGCCTGGCTCGCAG
AATTGCAGAGTCGTCGCCCCTTTTTACAACCTGGTCCCGTTTTATTCTGCCGTACC
CAGTTTTTGGATTTTTGTCTTCCCCTTCTTCTCTTTGCTAAACGACCCCTCCAAGAT
AATTTTTAAAAAACCTTCTCCTTTGCTCACCTTTGCTTCCCAGCCTTCCCATCCCC
CCACCGAAAGCAAATCATTCAACGACCCCCGACCCTCCGACGGCAGGAGCCCCC
CGACCTCCCAGGCGGACCGCCCTCCCTCCCCGCGCGCGGGTTCCGGGCCCGGCG
AGAGGGCGCGAGCACAGCCGAGGCCATGGAGGTGACGGCGGACCAGCCGCGCT
GGGTGAGCCACCACCACCCCGCCGTGCTCAACGGGCAGCACCCGGACACGCACC
ACCCGGGCCTCAGCCACTCCTACATGGACGCGGCGCAGTACCCGCTGCCGGAGG
AGGTGGATGTGCTTTTTAACATCGACGGTCAAGGCAACCACGTCCCGCCCTACTA
CGGAAACTCGGTCAGGGCCACGGTGCAGAGGTACCCTCCGACCCACCACGGTGA
 310 
GTGCGCCCGGGGTGCCGGGGCTCCCGCCGGCCGCTTCAGCCGTCCCGGCTCGGG
GAGGTCGGGAGGGACCTGAGGGCGGGGAGAGGTCAAGCGAAAGCCCCCATCTG
CCGTTCCTGGTTCATTTACAAAAAAATTGGGGCCCGGAAATGGGCGAGGAAGGC
CTCTGGCTCGTCGCGAGAGTGTGTTTTGAAAGAGTCGCAGCAGGCGCCTCTCCCG
GCTGGTGGCCCTGGGGCCTGGCGCTCACCTGGCGGGCGCCAGGCCGCAGCCCTC
CGTCTCTGCGCGGCTGCAGGTTTTGGGGTGGGGGGTCTCGGGATGTCCCCAGGCG
CGGGGTGCCCTGGCTCTGCCTCCGCGGGTCCGGGCTCTCTGGGCCCGGTAGCCGG
CGCCGGACAAGCACGGCTGGAACCCGGCTCTTCCAAAAAACCTGGCGTTCCCTG
TTACCCGCTAGCTCTTTCTAGGCGGGTGGGCGGGGTGGAGGGGGCCCTCTGCCAG
CGTCCCTCAATTCGCACATTTTCAGAAAGGCCCCAGAGACCTATTTATTCACACC
CTTCTCCTTGACCTTTTCCCAGAGCTAGTGCCTTTGGTTTTTAGACAGGTCTCTTA
CCTCCTGGCTTCAGGAATGGAATTCTGATGCTGAAGGGGTTTGGGCGGGGAAGA
CCCCTGTCTTAAGTTTGAGGGATCTGAGATTTCCCAGATTCCCGGCTGCACAGAA
TTTTCTTGCGTCTTTGCTTTCAAGTCGCCTCCTTGCCTGCAACTCTTGCCTTACTCT
GTCTCTGGGTACTGCCCTCCATTAGCCTCCCACCTAAGATGTAGGATACACCCCC
GTTTAAATAAAGGCAATTCCAGTACCACCTCTTTCCCCCTTTCACCTGGAGAAGT
TCAGGAGAGTTCTGAAATGTAAAAAAAGAAGACCAGGCCTGTGTAGTTTGAGGA
AAAAAGATCGAACACTTTCCAGCTCTAAGTTTGTTCCTAAAGAAGAAACAGGGG
TAAAACATCGGGCAGAAAAAGTGTGGGGCTTTCTGAGTCCAGCCAGACCGAATT
CTGCCCTGATTCCCCTACTCAGAGCCTGCCTTGACACGGATGACATAGCCCCTCC
GGCAGCAGGCGTCCTCTACCCTGCTGTCGCCAGGTTTTAAACAATCGTTTCTGCG
GATGGGGCGCCCTTTGCCCACGTTCTGTGCGGATCAGCAGTTAGGTGGAAATGCG
GTAGAGGCAGACTTAATATTATTTACTATACTACTTCCTGCATAATATGAATCTT
GACCCTTGGTGTTCAGAGAACTCTCTTTCCCTCTCCACTCCCCTCCCCTTCCTCTC
TCTTAAGATTTTAGTTTCAGTATTGTTCTTAATGGTTGAATCGAATGTCAAATGCT
GAGGCAGGTACTGGCTTTAAAGATCAAGAAGTGTGTGGATTTGCACTTGCTTTTT
AAATGTACCCCTCAGAGTGTATGAGTTACAGCTACCTTAAGATTGTGCGTTTTAA
ATGAAGGCTAATCAGACTCTGTGTCTGAGTCATCTTTCATTTAAAATATACACAT
CAACTGGAATTTTGTGTCTTAGGGGCTCAGGTGAAAATTCACCCATGGCACTGGT
GGGATCATAGCTTTATTGAGGGTGCATGGGGCTTACGTTATCTCCTTCTCCTTTAG
GATTTGGGAGGGTGAGAAAAGCAGAGAAAATGGCCATCCCAGGGTCCAGCCTTG
GGAACTTTCTCCAACAGCCCGAGCAATGAAAACGTCCCTGCAAATCCCATTTTAG
GCCTTTTGCGGGCAGCCTGGCCGTTTCTGAGCAAGCACTGGGTTAGGTTTCCGGA
AACTAACCCTGAAAGTCTCCTGACTTCTGTCCCAAGGCCTCTCCTTCCTGTATTTG
GTGCTGGGAGCTGGGCCTGACTCCAGGGTCGTTTTCTGGTGTGGAGCAGTTGTGT
GGCCGGGCTCCATCCTTCAGGCCTCCTCACTCACAGCCGGCTCTCTTATCAGGCT
GGCTGGGATTAAGTCCGAGTCAGGGAACTCAGGGCCATTGAAGGAAACCCATAA
ATCAAGTCAGGTTCTAGAGAGAGACCTTGGGGAATGTGATTTAGGCGGTGTATCT
GGAGAGGCCAAATAAGCAAAGGGGCCCTTCTCCCCCTCTGCAGCAACCTCTCGG
GTGTCAGCCACAGGCCCTTCATTCTGCTACATTTGATGGGACATCCCTGTGGGAG
AGATGGGTGAAGGATTCTGTCCCCAGCCTGACCCCCAGGTGTGCCAGGCAGGTA
CTCCGGGGACCGCCGGGAATTGAGAGTGGGCCTGAGCCCGGGCTTTTGCTGAAA
AGGAGGCCGATGCGAGGTAGAGATTCCCCAGGTGTCCCTGACGGCCTCCCAGGG
CCACACTCACCCTCCTTCTCTCTCCTGCCCTTTCCCCGTTGCCCCACAGGGAGCCA
GGTGTGCCGCCCGCCTCTGCTTCATGGATCCCTACCCTGGCTGGACGGCGGCAAA
GCCCTGGGCAGCCACCACACCGCCTCCCCCTGGAATCTCAGCCCCTTCTCCAAGA
CGTCCATCCACCACGGCTCCCCGGGGCCCCTCTCCGTCTACCCCCCGGCCTCGTC
CTCCTCCTTGTCGGGGGGCCACGCCAGCCCGCACCTCTTCACCTTCCCGCCCACC
CCGCCGAAGGACGTCTCCCCGGACCCATCGCTGTCCACCCCAGGCTCGGCCGGCT
CGGCCCGGCAGGACGAGAAAGAGTGCCTCAAGTACCAGGTGCCCCTGCCCGACA
 311 
GCATGAAGCTGGAGTCGTCCCACTCCCGTGGCAGCATGACCGCCCTGGGTGGAG
CCTCCTCGTCGACCCACCACCCCATCACCACCTACCCGCCCTACGTGCCCGAGTA
CAGCTCCGGACTCTTCCCCCCCAGCAGCCTGCTGGGCGGCTCCCCCACCGGCTTC
GGATGCAAGTCCAGGCCCAAGGCCCGGTCCAGCACAGGTAGGAGCCAGCTCTTC
CCTGGAGCCTTTTCTCCTCCCTCCTCCCCTTTTCCTCAATCCAGGGCCGCACCCAG
AGGGACCCCTCAGGGGAGCCGGGGTGTCCCAAAGCCTGCTGAGATGCCATTCTT
CCCATTCTTCCTGCCGGGAAGGCACTGCATGTCCTCCCATCCTAGCTCACGCCTG
GCCTCGGAAGCAGAGGGGAAGTGGGATCTGATTTAAAACCCCCCAATGAGCTGG
GATAGGAAAAAAGACAAACAAAAACAAAGTCATGCCCTCTTCTGCCTGTCGCAG
GACTTCTGGATTGGGCTGGTAACCTTTAGTCAGTTTCCAAGACCAAATGGAAGGC
CGAGGGAATAATTCTTGAGTGTTTCATGCTAAAACGAAACCTCCTCAAGCCTAAA
CAAACACAGGTCCCTCTATGACCCCTTTGGCCTCTGTCATTCTGACTGTTCCTCTC
GCTCAGCTCAAAGGGGACCACGCAGTGAGGACAGTCCTTTATTAGACGTGTAGA
CACAAAGTGTGTGTGCATGAGCCTGGCCAAAGCTGCACGCATATTCTCTGCGTGG
AAAAGGGGGCTCTCAGCTGAACTGGGAGAAAGCGGTGGCTTTGCATTGGGGAAG
CAGAGTTGAATGAAAATCAAATGTCGCCTGGCCCAGTTAGTTACCTGCAGCGTCT
CCTAGAGCTCTCAGTGCAGTCAGGGGCAGGAAACCGTATTAGGACATATTGCTT
GGCTGAGCTGCAGCCAGAGGAGGTAGAAAGGAACGGAAAAGTGCTCCAGGTGT
GTATCTCAGCTTCCTGTGCTCTGTTCCTTTCCAAAATGCAAACGCTGCCTAGCAGC
ACGCTGCATTTTTATTCAGTTGGTGTCATTACTTGCATGAAGAAAAACCCCACAC
AAAATACTTTGGCTTTAAAAATAAATCGATCTATCACCAATTCCATTTCTAAACA
AAGTAATTGAGTCAAAAGAGAGCTAGGGATTCTCTGATATTGATTTAACTGTATT
ATTAGACAGGGTTTGGTGAAGATTTTGATGTCTCCTTAGGCGTGTCCATTTCAGA
GTGGGCATCTCTTCTCTGATCGGCTCCAGGTATCTTGCCTCCGCTGTCTCTCTACA
GATCCTATATAGAAAGCAATCGTGAAAATCACTTGTCTTTTAGGGATGAGATGAG
CAGCCTTGAAACCGAGCTCCCAAAGCTCCGGTTTGAAAAACTTCAGAGGGAGTA
CTCTGGGAGCCCAGTGACCATGAGATCAGTTTTCAGGGTTTTTTTCCAGGGTGAC
ATTCACTCCGACTGCCTGAGCAGGACTGTCTCTATTTAGTTGATATGTTTTAGCTA
ATCCAATTATTTTCAGACTGCTGCACGCGACAGTTGCATTGTTTATCCTGAGCCA
GGAACTTTAATAGAGTCCGGATGCGGTTAGGCTGACAGAAGAACCCAGACCTGC
ATGTTCAGTACATGAAAGTAGGCAGGAGGGAGAGGGAGGCAGGCTAGCTGGTG
GAGTCAAAAAGAAAGCAAGAGGCCGGGAGAGCTGGAGGCACAAAGTGGCCACG
GTGCCTGGCAGGGGCTGGGCTTGGGGGTGGAGGGAAGGATTAAGAAGTGGGGT
GCAGCTTGACTCAGAAACACAGGCTGGGGAGCTGAATCGAAAGAGAGCAGACCT
ATGCATTTTGAGGTTGTGATGGGATTTCTTTTCTTTTTCTTTTTTTTTTAAAGTTCT
CTTTTCTGGTAAGGCTATGAGGTTGGGGAGAGCTCGTGGTATCTGAGGCCGGCGT
AGTGGTTTGTGCGGGGGGAGGGGACAGAGTGACTTTTCCAAGATACTCTGGTTTC
TTTACCCTCATTTCCGTGTTTGATTTCTCCCCCTCTTGTGCACACTTTCTGCCTTAA
GTTTAGTCTTTTCTTTCCTCTCATTTCTTTCCATAAGACTCTGAACATGGAGGGGA
GAAAGAGAGGGCCGTGGTTTCCCTAAGCCAGAGCTAGGAATACCGATACACCGA
TTTTGGTTTTTTTGGCGAGGAGGAGAGGAGGCCATTTCAATTTGGCCTTTTTACTT
CCTCCTTCTTAATTCCTTTCTCACAGTCGTGAAAACCAAGAACAGCACACCTGGC
AGGGGCGGCGAGCGAGCTGGGACTTTTGGGAGTGTGGAGGGGAAGTTTCGAGAA
GCCCCTCCTTTTGCAGGGGGTGGAGGTGGTGGGAATTCTTCAGGAGGGGATTCTC
TTGGTTTTAGTGGTTGCTCTCTCTCTCTCTCTCTCTCTTTTTTTTCCCCCTTTAACCT
CTTCTTTGCAAATGCATTTGCTGAAGGAGGACACAGAGAAGAGAGAGTTTTTGG
GGTTGTCGCTGGAAACGGTTGAAGTCGTGGTTAGGGCACCTATTGCTGTCTTAAC
GCCTGGGCTTTCGGGGCTGGGACGAAGCTTTTGCAAACAAAAGACAGAGTCTTT
GTGTCCAGGGCCGCTTCTTAGCTCCCCTGCCACCTTTCCAGTTGGGCATCTCCCTC
CACTGTCGTCTGATCGAGCTCCTGCCCTGCTCCCTACCCCCTCCCACAGCCTGGTT
 312 
TAAGGGTTTCAGGCCAAGGCGGAGCAAGAGGCATTTGCCAGCAGCTGTTGAATG
TCAAGAGGCCTCGCCGCTCTGTGGTTCTTGTCACCTAAGAGAGAGGTGTCTGCCT
GAGCAGCTCACAACAGGCAGGGGTGAGGAGAGGGGAGGAAAGAAGGCAGGAG
AGAGTCAGGGCCTCCATTAGGAAAACTGGCTGTTTGCTGAAGTCACAGACCAGA
GGCAGCAAGGAAAAAAGAAGAAGAAAAGCCCATAGGAGGCAATGGCAACCTTG
CCGAGTGAATCAAGACAGAAAATTACCCTAGTGTGCAGAACCTTGTTGAAGAGG
TAACCGTTGCTAGCTTTCAAGGTGTTTCTGAAAAGGAAGCTATCACCCTCCCCAC
CACCCTGCAAATGAGAGGAAATCAGACTGATCATGTCAGGCTGGGAGGTCCCCC
AGCACCAGGGTGCCCAGGAGCCGGGTGGCAACCACGCTCCCCGCCTCCAACCAC
AGCGGCCTCTCCTCACACTGCCCTCTGCCCAGTGCCCAAGTAGGGGAGGAGCCC
GAGGGGGTCCCCTGTCTGGGCAGGGTGGGGAGTGGGCCTGCAGTCCTAGCTGGG
ACAGGGCCAGTGCTGCCCCAGAAGGGGCTGACCCAGCAGCTACCAGGGACACAA
AAAGGCAGGCCTGCGGCCTGGCCTGGGCTGCAGCCGGTTACTCGCCCACTCACC
CTTCACTCTTTCCTTCCAGCCTCCCCCACATCCAGTCTGCCACATCCCTCAGGCTT
TTGACCCCAACTGAAAGGTGTCTGGGTGTGATTCAGGCCTGAGCCTTTTTCAAGA
ACTGAGAAGAGCCGTTGGGTACTTAGGAAGGCGCCTTTGGCATGCACTGCAGCG
TGTTTGTGTTTAATCTCAGGGGTTCTGGGGCACAGCAAAGGCTCTCTGGGGACCC
TAGGCTAAGAATCTTTTGGAATGTGGAGCAAAAAAAAAACCTCTCTTACATCCTC
ATTTTTTTTTTTTTTTTAAAAAACAAAGTAGACAAAAACTAGTGGGCACCATCCC
TGACTTTCAAGGGTGCAAGACCCTCTTCCATTTGCAAAAGTCTTTAACTTTCCTGA
AGAACTTACCCCTGGAGAGTATCACAGGCCCCCAAGTGTGAACCCCCCTAGTTCC
CTCCTACTTGATCTGGGGCTTTCCAAAGGCCCAATAGGTCCCATATCTGCCAAGG
CAGATTTTTCCTCCTTTTAGGGGAATCAAAATTCTCAAGCACCCTACTGGGTTCTC
TTCTTCTACCCCAGTGGTCCGGGCAGGTTGGAGGTCATTAATTACTCTCTTAAAA
CAAAACAGTCTTCAGAGCTCATTTTTCTTCCCTACCTACCCTCCGGGGTCCTCCTC
TGGGCCTCCCCTCTCTGGGGGACCAACTTGAGTTAAGCCTCCTGTTCCTGCAAGG
AAGGGGAGTCCTGGCTTTCTCTGGGCACCCAGAGAACTGGGCGCTAGAGACCCG
TGTGTCCCTGGGTCCCCCAAAACCAAGGAGATTCTCCTAGAAAGCATCTTTCTCT
TCCTCTTGCAAAGTTGAAATCAGTTAGCCAACTCCCCCATGTCTTGAAATGGTAA
TTTAAGGGATTCTTCCAAGGAGCTTTCTGGGTGGGTCTGGGTCGCTTTCCAGCCT
GGGCTGAGGGAGTGAATGCTGCTCAGACTTCCTACCGGCCTGGCTGGTTTTTCGT
TTATTTTGTTTGTTTGTGTTTTTGGGAAAAGAGAAACTGTAGGCAGGCCTTGGTTA
CTGAGCAGCCACCCCGCTTTGTTAACTTGCCTCTTCTCCTGATCTTCCTCTGATCG
GCTTCACTCTGTCCTCCCAAACCTTCCCTTTTCCTTTTTCCCTCCCTCCCCCTCTTC
CAGGTTCCCTGCCTAAAGTTTGCATTTCCCCCTTGCACCCCCTGGCTGGGGTCATA
CTTTAACTTCAGTCTCCGTAACAGCGGCTGGAAAGCTATGGAAACCCCTGCTGGG
TCCTAATCGCTTCCTTTCCAGCCAGGGACATTTGCAGTTTGATTGGAAGTAAAAT
CTAAAACCCTAGCTAGTGAAATCAATCAGCCGATTGATCAATCTATGCATCTATT
TATTATCTGTTCACCTATCTAGCCATTGATGAATCCTTCCTTTCCCCCATCCTAAT
CTTCATTATTTAATCAATCTCTATAGACAGACCCATGATGATAATGGGTCACCTTT
GTCTTCCTTTTTTTCCTTTGAGGGAAATGAATGGAATGTTTGCCTTTTGCCACCAT
CCAGGGCTCAGGATTTTCTCAGGGAAGTATTTGTAGCTGGAATCTGCATTCCTCC
TTGGTCCTGCCCGATCTTCTCCATCAAGTCGGGCAAGCCAAGAACAGGGTTCTGT
TGCAACGATGCATCTGCCCCTTCTGCGGGCGCCTCCGTGTGTGTCGGGGGAACGG
TCATGCCAGGACAGCATTCCCCAGCTCAACTTTGGAGCATCTTGGAAAGAGGTG
GGGGTGGACACGCTCCCCAAAAGAGGAGGGAGAAGGAAAAAAGTTCTCCATTTT
ACGTTTCTCCCCCAGTTCCAAATGCTGTCAGCTTTCCTGCGTGTTTTCCTTCCCTA
AGTGGCTTATCTGTGCTTTTGTTTCCAGAAGGCAGGGAGTGTGTGAACTGTGGGG
CAACCTCGACCCCACTGTGGCGGCGAGATGGCACGGGACACTACCTGTGCAACG
CCTGCGGGCTCTATCACAAAATGAACGGACAGAACCGGCCCCTCATTAAGCCCA
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AGCGAAGGCTGGTAAGTTCTCGGGAAGGGATGGATTCCATGCTGACCATTCTGG
GTTTCTCATTTCCTCTCTTCCGGAAGGACAGCTTTCTGCAGGAAATTGACAGGAT
AGCCTCCAATCGTGTCAGCTGGCTTGGGACAGTTTTTTTTTTTTTCCTTTTTCTTTC
TTTCTTTTCTTCTTCTTCTTTTTTTTTTTTTTTTTCAAATTTGATACACAGAACAGCT
CTTTTCCCCTCTTTTTCCCCATCCATGTTTCTTAAGTCGCTTGTGAACATTTTAAGG
AGACTGAATTCTTGGTTATCAAATCTGCAGTGTATTCCTGAATAGAATAATGGTA
TGAACAGGACCAGAGCAGCTGGTTTAAGTGCATTGATGAGCACCGTTTGACAGA
TAGAGACATTTAGTATGAGGATGGAATGTTCCAGAAACCATCCAGAATGGGTTC
CTGAAGTTGTGGCGTGTGGCTTCCCAGGAAGGATTACAGACTCAGTGCAATGGA
TGGATTTGTTATGCTAATGCTTCAAAATGGTTGGAGCTGATTAAATGAATTTCAG
AGGCTTCACCAGCAACCAGTGAGCCTAATGCCACTTTCCTCCTTTCTTGGTCTCA
GCCTTTGAGAACTTTCCACAGGCAATTCCTATGGGAAACGTCGTGTGAGTCCTCT
CATACCTGGCATTTGGTCTTCTTTTCTCTTTGAACTACTACCAGTAAGGTGATAGT
TTTTTCTCTCCTCTCTCATTATTCTTTTAAAAACTTTTTAAGCATGAGGGATCCTTG
AGAAAACCTGGCTCTGTCAAGCATTTATAAGGAAGACAACTTATAGGGGACATT
CATTTGCAAGCTCCTCTTTGGAAGTTTGAATAGTGAATGTATGTGACAGACAAAT
AACAACTCTAGCCACAGCTAAGAGATCAAAATGCTTTATGTGGTGCTGACATTCA
CCAAGTCGAGATGGGAGGAGGGGAATTTCCCCACGCAGATTAATGGATAAATTA
GCATCCATCAATTTCTAAGGAAGGAAAAAGAACACCTCTGTATTCTTTTTAAAGA
ATACTTTGCCCTCCCCATCAGATTGTAGTGCAACTCAACACCTTTCACATCCTATT
TTGAAGAAGGAAAAACTTTCTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTCA
CTCTGTCACCCAGGCTGGAGTGCAGTGGCACGATCTCGGCTCACTGCAACCTCCA
CCTCCCGGGTTCAAGCAATTCTCCTGTCTCAGCCTCCTGAATAGCTGGGAGTAGG
GACACCCGCCCCCACACCCGGCAAATTTTTGTATTTTCAGTAGAGACAGGGTTTC
GCCTTTTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCCACCGCCTCG
GCCTCCCAGAGTGCTGGGATTACAGGCATGAGCCACCGCTCCCAGCCAAAGAAG
GAAAACTTTCTAGGGATGGAAATGTCCACATGACTTTAATCTTTGACAATCCTGG
ATATCGAGGCTTTATTCTTTCTGATCTTTGCCCCCTTCTCCAACTTTCTCAACCTTC
CCCCACCTCTCCTCCAGCAGTTTGGTTTTTTTTTTTTTTTTTTTTTTTTTCCTTTCTC
TCATGTGCAAAGCTGACTTCCTAGGAAAAAGCTGCCGGATATCTGAGCACTGGA
GATAACTCATAAACAACAACTCAGCTTCCCCAACCTAAACACCAAGATGTTTGA
ACGTATCAGAACAAGAAGTGTTTGAAAAAAAAAAAAAAAAAAGGCTAGAGGTG
TTAGTGCAGAATGAATATGATCACACCACAAAAGAATGTTTTGAATCACTCAAA
AACCTGGCCTTAGTAAAAAAAAAAAAAAAAAAAGAGAGAGAGAGAGAGAGGA
AAAAAAAACAACAAACAAAAACCTTCTTGTTAAAATGTGTCTTGGTACCATTATA
GTTGTTTTTTTTGTTTTTTCTGTTTTTTTTCTAATAAAAGTAAAGAAGGAAAAAGA
GGGATTAAAAGTCTCAAGGCATGGGCTGATTGGTGAGCAAAAGTTTATTTGACA
TTTTCTTGGGTCTTCTTCCTCTGTCTGGTCAGATTGCAGAGGAGGATCGTAATTCC
ATTTTATGCAATTTTATCTCCACTCACCTTTCATAGGAAATCTCTAGAACTCTGAG
TAATAATTGCTTTGAATTTTAGAGTTCAATGACTGTCACATTTTCATCTCTCTTTT
CTTTCTTAATCATCTGTCTTTGGTGGTTTGATGTTTTTAGTTCTATAGAATTCATAA
GCTACAGGGAGGTAGAACACAGGACACATTCAGATTTCTTTTTCTTTCTTTCTTTC
TTTCTTTTTTTTTTTTAGCCCTGAGATGTATTTGACTTCTGAACACCTAGAACCCTT
TGTTTTCTTCTTTCCTGTATTCCCTGACCCTTTATTCCAGTTCCAGCTTGCTATTTT
TGTTTGATACATTTGCAGATTCACTGAAGACCACCCAGCCCATATATAGCTAGCT
CTTCTGTGAGATGTGTATTTAACCCTGAAAAAACTAATGCAAGAAATAGGAGAG
ATGACCGAAGGGAAGACTCATAGATTCTTTTCCCCCTGGCATTGCCAGGATTTTC
ATACATCTCACCACTAGTGAGAGGCTGAGCTGCTTGCTTTAATATACTGTACCTC
CTGCTAGTGACCCAAACAGTGTGGCTTTGAGAGACCCTAAGTTCCCATAAAGTTT
GTAGTACTGGAAGCATCTTCCTTTGCTTTTATTTAGATTGCTGTCAATAGACTGCA
 314 
AAAGATTACATGCTGTACCTTGTCATCTGGAGCTCTGACTTTACCAGTTGGCATT
ATATGCTTGTACTCTGTACATTCAGAATTGCTGGGCTAGGAAACCCAGGTGCCTG
AGTGATATTAATCTGCTATATCTGAGTAGCTCTTCTAAAAAAAAAAAACACTATA
GGAAGATAATAATCACATATAATTTAATTGTCAAAATCATTAAGCACTGGTTTTA
CGTAGTACTTTCTCCCAAAAAGTACACAAATGAAACAGTTGTTTAAGCATTAAAT
TACCATATTTCATAAAGGCAGTCGGGCAGAGGCATATGGGGTTAGATCAGCACT
CATGGACAATGTGAATTACATTCAAGATGGACAGCAAAAGACTCCCATCTTCTCC
CTTATGATAGGCCAGGGCAGTTTTTAGTTTCCAGTTCCTTAGAACACAGAAAAGA
AAGAATTTTTTTAAAAAGGTCATATATACTCTGTTATTTACATCCCACAGAAGCA
TATCTGTGAAACAATTTAGCAACTTTGAAAGAAAAAGGGTCACTCAGGTTAATTC
AAAATTGTCACTGGGTTCTCCATATCTGGCAGCTTCGGGTGTTGGCTTCAACTTTT
TGCTTGATAAAATATTGATATAAAACTGTACCAGAATCCCAGGCCGGGTGCGGT
GGCTCACTCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGTAGATCATGAG
GTCAGGAGATAGAGACCATCCTGGCTAACACAGGTGAAACCCCGTCTCTACTAA
AAATACAAAAAATTAGCTGGGGCGGTGGCGGGCGCCTGTAGTCTCCAGCTACTT
GGGAGGCTGAGGCAGGAGAATGGTGTGAACCCAGGAGGCGGAGCTTGCAGTGA
GCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTC
AGAAACAAAAGAAAACATAACAAAACAAAAAACAAAAAACAAAAAACAAAAC
TGTACCAGGATCCCTATAGTTCTTGTTCTGTGTTCTTATAACCATACCAGAATTTT
CTTCATCACAGACAGAGACTAAACTCTTTCTTCTCTTACCTTTCCTTTGATAATAT
TTTTGATCCAGGAATGGGGATAATTTTGCAGTTAAAATTTTCTTTTTATGATGGAA
GGTGAGGAGGAGAGAGAGGTTTATATTAGAAGTGACCCAACTCCATTTTCTTCCA
ATGGTTTTTTTCAGTTTTATTTTTTTAAAGCGTGAACAGAGAATAGTCACCTGATC
AATTTAAATATGTCAAAAAGTGAAAGAAAAAATCTCTCTTTTAAAGGAAATGAG
GGCAGTAACACAACCAAGGAATCAAAATTCAGGTTGAGGCTGACCTTTGACCTG
CAACTATGCTACTCCATGAACAGCAAGTAGGAAATGGCTGATTTCATGAAGGTG
GACTGGCATCAGAGGAGGCGAGGGATCCAGGGTTCCTGATGAGTGGCAACATTC
CTTGGTCTTTTGAGTTTGTTTGATTGGTGAATCAAATTTAGGTGACAGCCAGCTA
AAGAGAGTGAGGGTGGCTGTCTTGTGAATGGGAAGTGACCAAGCTTGAAAGCAC
AGACTGTGGTGGCTCACGCCTGTAATACCGGCACTTTGGGAGGCCGAGGCAGGT
GGATCACTTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATAGTAAAACCCT
GTCTCTACTAAAAATAGAAAAATTAGCCGGGCATGGTGGCAGGTGCTTATAAAT
CCCAGCTACTCGGGAGTGTGAGGCAGGAGAATTGCTTCAAGCCGTGAGGTGGAG
GTTGCAGTGAGCTGAGATCGCACCACTGCACTCCAGCCTGGGTGACAGAGCGAG
ACTCCATCTCAAAACGAGAAAAAAAGAAAGTGCAGGCTGTATAAATTTAGGAGG
TCTTGTTGACCTAGGATGTCCTACTTGGCGCTTCCTCAGGTGTGTCACCCATGTGT
ATGTGCCACACACTTGCACAGACATTCTTTGCAGAATTTGCTGTTGTGTTGGCAC
ACTGTTCTCTTTATAACTCAGCATTTCTTTATTTGCGATCCAGAGTGTTTTTGGTG
CTTGGCTTTGCGCCTCCTTTGCTGTGAATGCATCCTGATGGCTGGAGCCTGTTTGA
GGATGGATATTCTTGGGAGTTGTGTTTGAAAACAACCTCTTGTGGCCCTGGACTT
GGTGAAAAAGGCAACTGAAAGCCCAGTTCCAAAATGAGGCTGGCTAATTCAAAA
TTGCCACCCATAAAAATTAACCCTCTGGTGTACTTTGTGGGTTGAGGGTAGGAGG
CTAAGACTGCCAGGGAGGAGGCCCCGGCTTCCTGCTCCTACCGGGGAGCAGCAG
GTGAAACTCTGACCACGTTACTGCAATCCTGACATGCTCCAGTGGAGTGGCGACA
TTTTTCTTCTCGAGGCAGCTTTTGGGGATCTGTATTACTTTCATGTGGACCACTTG
CTAGTTTTGATTTCAATGATAATTTCTTCCTTCCTTTTTTTTTTTTTCAAGCCTGTC
TTCATAGTGATGACAACACATTTAACATTTGTTTTGATTTTACCCTCTCCTCTCTC
CCCACTCTCAGTCTGCAGCCAGGAGAGCAGGGACGTCCTGTGCGAACTGTCAGA
CCACCACAACCACACTCTGGAGGAGGAATGCCAATGGGGACCCTGTCTGCAATG
CCTGTGGGCTCTACTACAAGCTTCACAATGTAAGTGGACTGGGATCAGCAAGAA
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CAGGGCTCGCTTCCTGATGGTGACCAGCAAACAGCGTCACCACCACCCTCTCCAA
GTGAATCGCTCACCATGGGGGCAGATGACAGGTTCCAAATAATTGATGCAATAG
GACCTAGCTTGGAAAACTACTTTGTCTAGCATAGCCGTGCTGAGGCCGAGGGGG
CTCACAGCCTGGCAGCCACACAACCCCCTTGGTATGCATTGGACACTCCACATAC
CATGCAGCAATCCGATGTGCTGAGTGGGCCTGTGTGGTTTATAAGGAAAAAAAA
AAAATCTTCCTTTTGGAAAACAAAAAAAGCCACCGGTCCTATTTTGTTGTTTCCTT
ACATTTTAAACTCTTTGCAGAAAGAGAGAATGAAAGAGAAAGGTAAATAGAATT
GTAATGTGTGGCAGGGGGTCTGGAAACTAAGAGGACCCATTTGGTTACTGAGAG
GTAAAAAGTCTTGGCTAAATCTGTGCTACAAATTTGAAATGGATCCTCTGTATAA
AAGACATGGAAAAAAATGTCTGACAGATTTCGTCTGATGTCTTTGTCCGAACCAA
CTTTCACGTGCAGAGAGCTAGCTCCTGAGGAAGGTGGCTGGCCTGGGGGATGTT
ACCATACCAGGGAAAATAAACTGTCATTTTCTCCTTTTATATCATGTTAGCAGAG
CGGTAATTGCCAGTCACCTGAATTTAGTTGTGTCATTTCTGATCTTTCCATTTGGG
GTCCTCTCATTTTGTAATATATCTTAATCTTAAAAAATTTTTTTTTCAGTTTTTTTT
TTTTCCTGAAATCATTCTGGCTCAGAGGCCATGATTCTAGTGAGGCTTCAAGTTT
ACATTAACTCTAAAGACAAAAATGGTTATTTTGGTCTTTCTCTGTGTTGCTCTCTC
TCTCCTTCCTTTTTAGCTCTTTCTGATTCTCCTAAATTCTCTTGGCCAACCTGACTT
TGGCAAAGTCCGGGGCTGAACAGGGAGGAGACAGGGACTTTTGCTTGCGGCGGT
TCTGGCAATGAACTCATCTTACTCAGGAATACCTGGGAATTGGGGAGGAAGCTTT
TCTGGTTGGATTTTTTGAGTCATAAAGAACTTCTCAGGGTGACCCCAGCACCCTG
CTTCTTTTTCACTTCTTGGGAGCAAGTTGCTGTGATTCCGAGGAGCCCTGTACGCT
CATTCCCTGCCTGTGCCAACTCTCTCGCTGTGGCCCTGGTGCAGTGAATGAAACT
AGAGTCTTACTACGATCCCTTATTCTCCCTTAGGTCCTGGGACTGTGGTCTATATA
CATTTATCAGCAATTCAATCCAAGTTCTATTTTCACTTTGGGGAATTTGCTTGCTG
ACTACAGTAGAGATAGAGATTCGTGATTAAAATCTGGAAGGCTTGGGCTTATAA
GCTATTAGGTTATTAGCATTAGGGTTTATTAGCTATCCAGTCATCAGCACTGCCT
ATGAAATTATTTTTGGGCTGTAATTTATGGATTTCAAAGAACTTTCATGTTACTTG
ATTACATTTGAGCCTGAGATAGTCCCATGATGTAGACAGGGCAGAAATTATTTTT
ATTTCAGTTTTACTTGAGGGAGTTATGACTCAGAAAAGCAAGTCGCTTGCACAAG
GTAACGTGGCTGAGAAAGTATAAGAGTCAGGGCCCATTTCAGAGTCAGGAGGCT
TTCCTGGGAAGTTGGCAGTGTCAGAACTAAGAGGAGAACCAGGGGAAAGGGAA
TGCTCTCTTTTTTTAGAGTATAACAAAATTGTAACAAATTGTGTGTGTGTATATTT
CATCCCTATATTCGTGGAAGTATAGGAATTATAGGAGATTAACTAGCTATATGTT
TTTTTGAATAGTTAGCTGGGATGAGATATGATCTCACTTGTGTCTGATCACATAT
ATATATATTTCTGAAGAACATGAATTTCTCAAATCAAAGTAAAGCTGAGGAATCC
TCTCCATGGCTCACTTCTACCTCCTCAATCTTAATGAGCTTGGTCTTCATGGCTGG
GCTCCAGTGAATGGGAGACAGAAACTTCCTCATCCTCAAGAGTGGTTTTTCTGTC
TTCTCTGGTTTACCAGGAATTTGTAAAAGGAGGCGATTGATGTGTATTGAACAAT
AAGAGATAATAATCTATTAACATTGTCATCACGTTGCGTTTTGCTCTGCCCTTCCA
GACATCTCTACATGGATGCCATAAGCTCTTTCTTCTTATCTAGGTGTTGAGATAAC
TGCCTACCTCGGTATCAGCATCTCTCAGTGGTGTTGTGACTGGTTATCTGGGGTTG
TGTGGCTACTGGTGTAACTAGATATTATATTTAGATACCTGGCTATGTATAGCTA
GATATCGGCATCAGAGCTGTGTATCTGGACATTATCTTGGTGAAGATTTGATGTG
GGAGTAGATTCCTGTCATCTCTGTAGGCTGCATCTTTATCTTGATGATAACTTTGA
AGAAGGAACCTGGAGATGTTCCTCTGGCAGTGACCTTTCTGGGCTCTCCTGCCAT
CGGTCACGTTGCCTTCCTGGGCTTGGGGAAAATAAGGTCTCAGCTCCAGTGTGGG
GCTTTGTTTCCTTCTCCAGGTGACCTCTCCCAGCTCAGCTTCGGGAAGCTGGGTGT
TGGCTGCTCTCAGCAGGTTGGCCATTTGAATTCTTCCTTTCTTAGCTGTGATTTTC
TGGCTTTGGGAACAGACAGGTAAAACCCAGAGCCAAGGGTTCTCCACCCTTGAG
AACTGTGGCGGAAGGCGATGCTTTCAGCCCGGGAAGTCAGGAATGGCCAGGACA
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CTGACATTCACTCCTTGAGTCTGTTTGCCACCCTCCCCTGGGAACATGGCCAGAT
GTGGAGTTTGCTCTTCCGGGCAGATGTCTGCTGTTGGGGTTAATCTGCTTCTGCCT
CCCTGTGGGGAGTAACTTCTGTTTACTTTGTAAAGTTTCCTTTCTTGATTCTGGGC
CCCCAAAGCAAATGTATTTTTAAAGGCAAATGAGGTTTATTAAGAAGAGAGAAA
TGGCAGATGTCTCCGAGACTGAAGTCTCTTGATCTTGAGAGTAGGGTCTGGTCTC
TGTCTCTTTACTCTAGCACATTCTTGGTCTTTCCTTTTCAAGATGAGTGCCCTTTTG
TGCTTTGCACCCCATAGGTGGTTATTAAATACATGTTGATTGGTTGGTTGGCTGTT
TGTCTGGTTAGAAGTGGAGAGTCAGAGCTAGGTGGAAATAGCACTTGCAACCAT
TGCAGCTGCTGTTGGAATGACACAGGCAAGAGATCACTTTTGGGCCAGGCGCGG
TGGCTCATGCCTGCAATTCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACAA
TGTCGGGAGTTCGAGACCAGCCTGCCCAATATGGTGAAACCCCGTCTCTACTAAA
AATACAAAAATTAGCCAGGTGTGGTGGCAGGCGCCTCTAGTCCCAGCTACTCAG
GAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCC
GAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGCGGGAGACTTCGTCTCAAA
AAAAAAAAAAAAAAAAAAAAAAAGATCACCTTTAAGAAAGGCATGGTTTCATA
AAATACAACCCGGCTACATATAAATTCTAGCGGAAGATTTTATGGCACCTCTTAA
AGGCCAGGTAGAAGAGAGGCAACCGAAAGTTACTCAGTAGAACAGTACAGTCCT
CATTTCTTCAAGGCAGACAGCCTTAACCACCTAGAGGCTGATGGCCTGGGGAGT
ACTTTTCAAGTTCTGAAGCAGATTTGTCAAAGTAGCCAAAATGGCATTTCCCTCC
TGAAGATTCTTCACTACCTCGATTCTTATGAAATAGTCTAAGGAAGTTCTAAAGA
AATAAGACAAGTGAATTCTATTTTCGTTACCAGAGAAATACAATCGTACTAGACG
GGGCTGTAATCTGGTAACTGTATGTATTTTAGTTCTTCAGTCCCTGGGAAGGAGA
CAGGAGAAGGTGGGAGGGAGGAAGGGGCCAGCTGAAATGGAAACAGATCCCTG
ATCCGGGGCGGTCAGTGGAACCCTTCTTGGTGTGCGAGAGCCTGTGCATTTCAGA
GGCAGCAAAAAAGTAAAAAAAAAAAAAAAAAATTGATCTTTGTTTAGATTAACA
GACCCCTGACTATGAAGAAGGAAGGCATCCAGACCAGAAACCGAAAAATGTCTA
GCAAATCCAAAAAGTGCAAAAAAGTGCATGACTCACTGGAGGACTTCCCCAAGA
ACAGCTCGTTTAACCCGGCCGCCCTCTCCAGACACATGTCCTCCCTGAGCCACAT
CTCGCCCTTCAGCCACTCCAGCCACATGCTGACCACGCCCACGCCGATGCACCCG
CCATCCAGCCTGTCCTTTGGACCACACCACCCCTCCAGCATGGTCACCGCCATGG
GTTAGAGCCCTGCTCGATGCTCACAGGGCCCCCAGCGAGAGTCCCTGCAGTCCCT
TTCGACTTGCATTTTTGCAGGAGCAGTATCATGAAGCCTAAACGCGATGGATATA
TGTTTTTGAAGGCAGAAAGCAAAATTATGTTTGCCACTTTGCAAAGGAGCTCACT
GTGGTGTCTGTGTTCCAACCACTGAATCTGGACCCCATCTGTGAATAAGCCATTC
TGACTCATATCCCCTATTTAACAGGGTCTCTAGTGCTGTGAAAAAAAAAATGCTG
AACATTGCATATAACTTATATTGTAAGAAATACTGTACAATGACTTTATTGCATC
TGGGTAGCTGTAAGGCATGAAGGATGCCAAGAAGTTTAAGGAATATGGGAGAAA
TAGTGTGGAAATTAAGAAGAAACTAGGTCTGATATTCAAATGGACAAACTGCCA
GTTTTGTTTCCTTTCACTGGCCACAGTTGTTTGATGCATTAAAAGAAAATAAAAA
AAAGAAAAAAGAGAAAAGAAAAAAAAAGAAAAAAGTTGTAGGCGAATCATTTG
TTCAAAGCTGTTGGCCTCTGCAAAGGAAATACCAGTTCTGGGCAATCAGTGTTAC
CGTTCACCAGTTGCCATTGAGGGTTTCAGAGAGCCTTTTTCTAGGCCTACATGCTT
TGTGAACAAGTCCCTGTAATTGTTGTTTGTATGTATAATTCAAAGCACCAAAATA
AGAAAAGATGTAGATTTATTTCATCATATTATACAGACCGAACTGTTGTATAAAT
TTATTTACTGCTAGTCTTAAGAACTGCTTTCTTTCGTTTGTTTGTTTCAATATTTTC
CTTCTCTCTCAATTTTTGGTTGAATAAACTAGATTACATTCAGTTGGCCTAAGGTG
GTTGTGCTCGGAGGGTTTCTTGTTTCTTTTCCATTTTGTTTTTGGATGATATTTATT
AAATAGCTTCTAAGAGTCCGGCGGCATCTGTCTTGTCCCTATTCCTGCAGCCTGT
GCTGAGGGTAGCAGTGTATGAGCTACCAGCGTGCATGTCAGCGACCCTGGCCCG
ACAGGCCACGTCCTGCAATCGGCCCGGCTGCCTCTTCGCCCTGTCGTGTTCTGTG
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TTAGTGATCACTGCCTTTAATACAGTCTGTTGGAATAATATTATAAGCATAATAA
TAAAGTGAAAATATTTTAAAACTACAAAATGACATCGTATCCACGTGGTGGCCG
AGCTCTTCTAGAATCTGGTAGCTCTAGCTAATTTCAGAGAAAGGAGTTAAAAGA
AACAACTTAACAACCAGACATGTTAAGTTATTCACTAGGAACCGATGCTAACCCC
AGAGAGTCAACGTCTATTTTGGGGGGAGCTGGGAATATTTGGAGTTCTACATGCG
ACCTGGAGGAATTTATCCTGGGGCCGGGGTGACATCTGGGGTCCCCTAGTGAGT
GGCAGTGTGTCTTCCTGCTCTCCTCCTGCCCTCGAAGGAGGACTGGGAAGATTTC
CACGCTGAGATTCCCAGGCGCAAACTGCAGCTGATGCGTTCCTCGAGGTTCTCTT
TGAGATGGAAACGAGCCGGCTGCTCGTGTTCATTTCTGTTTTGCTTTTCTACTGTT
GAATGAATACCACCACAGTGAAGGGATTATTGGAATGTTTTCGAAACACAAAAT
AACCATTTTGTAACTTCTGCTGTATAGTTTTCTTTTCCTGTGGATGGAGTGTGTAA
CTACAGCACACATTTAAATGAAATCTCTGTTAATCGCCTCTGCACTATCTTAGCA
AATATTTTAAACCTAAAGCTAAATGTTGAAATAAAGGTGTAGAGCATTACTGAG
ATGCAAATGGAGCTCTCTCTGGCTCCTAATTAATGACCTACAACTCGACTGTTGT
TTCCAATTACTTTTGAAACACTGAAGGAAAGAATCACTGCTG 
 
